Few things cause more fear and apprehension

than a cancer diagnosis. But today—because
of early detection and a steady stream of new
and improved treatments—cancer increasingly
can be managed and even beaten. But patients
and their families are looking for more and bet-
ter treatments, and America’s biopharmaceuti-
cal research companies are responding.
Biopharmaceutical researchers are now work-
ing on 981 medicines for cancer. Many are
||ç|-lec| Weapors lo lç|l l|e d|sease, W|||e
some involve innovative research into using
existing medicines in new ways.
Researchers’ deep commitment to patients and
advancing science is at the core of the remark-
ao|e proçress rade |r lç|l|rç carcer. lr re-
cerl years We |ave seer s|çr|lcarl dec||res |r
cancer deaths. The number of cancer survivors
living in the United States has increased from
3 million in 1971 to nearly 12 million in 2008.
The increase in survivors is attributed in large
measure to earlier diagnosis and detection and
better treatments and follow-up care.
America’s biopharmaceutical research com-
panies are working on many new cutting-edge
approac|es lo lç|l carcer. T|ey |rc|ude:
· A red|c|re l|al |rlerleres W|l| l|e re-
tabolism of cancer cells by depriving them
of the energy provided by glucose.
· A red|c|re lor acule rye|o|d |eu|er|a
(AML) that inhibits cancer cells with a
mutation found in about a third of AML
sufferers.
· A l|erapy l|al uses rarolec|ro|oçy lo
target the delivery of medicines to cancer
cells, potentially overcoming some limita-
tions of existing treatments.
Despite recent progress, cancer remains the
second leading cause of death by disease
in the United States, exceeded only by heart
d|sease. lr 2012, sore 5ZZ,190 Arer|cars are
expecled lo d|e ol carcer÷rore l|ar 1,500
people a day. The hundreds of new medicines
to treat cancer now being developed are our
best hope for lessening the burden of cancer to
patients, their families and society.
More Than 900 Medicines and Vaccines in
Clinical Testing Offer New Hope in the Fight
Against Cancer
Medicines in Development
CANCER
PRESENTED BY AMERICA’S BIOPHARMACEUTICAL
RESEARCH COMPANIES
2
0
1
2

R
E
P
O
R
T
111
66
121
117
94
L
y
m
p
h
o
m
a
C
o
l
o
r
e
c
t
a
l

C
a
n
c
e
r
L
u
n
g

C
a
n
c
e
r
P
r
o
s
t
a
t
e

C
a
n
c
e
r
B
r
e
a
s
t

C
a
n
c
e
r
67
S
k
i
n

C
a
n
c
e
r
Medicines in Development
for Selected Cancer Types
More Than
1.6 million
New Cases
of Cancer
Are Expected
This Year
Medicines in Development Cancer 2012
2
¯¯For rore |rlorral|or aooul a spec|lc red|c|re |r l||s reporl, p|ease ca|| l|e le|ep|ore ruroer ||sled.
Lung Cancer
Liver Cancer
Leukemia
Kidney Cancer
Head/Neck Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Brain Cancer
Bladder Cancer 9
62
66
111
8
25
35
120
36
121
Multiple Myeloma
Lymphoma 117
57
Ovarian Cancer 63
Cancer-Related Conditions
Stomach Cancer
Solid Tumors
Skin Cancer
Sarcoma
Prostate Cancer
Pancreatic Cancer
94
58
21
67
280
23
38
Unspecified Cancer
Other Cancers 102
72
* Some medicines are listed in more than one category.
Medicines in Development for Cancer
*
Medicines in Development for Cancer
BLADDER CANCER
Product Name Sponsor Indication Development Status*
Abraxane
®
albumin-bound paclitaxel
Celgene
Summit, NJ
second-line bladder cancer
(see also breast, lung, ovarian,
pancreatic, skin)
P|ase ll
(908) 673-9000
AEZS-108 AEterna Zentaris
Basking Ridge, NJ
(see also ovarian, prostate, other) P|ase ll
(908) ê2ê-5128
BC-819
(gene therapy)
BioCancell Therapeutics
Jerusalem, Israel
(see also ovarian, pancreatic) P|ase ll
www.biocancell.com
EN3188
(mycobacterium cell wall-DNA
complex)
Endo Pharmaceuticals
Chadds Ford, PA
non-muscle invasive bladder cancer
(Fast Track)
P|ase lll
(ê10) 558-9800
Medicines in Development Cancer 2012
3
BLADDER CANCE
Product Name Sponsor Indication Development Status
EOquin
®
apaziquone
Allergan
Irvine, CA
Spectrum Pharmaceuticals
Irvine, CA
non-invasive bladder cancer
(Fast Track)
P|ase lll
(919) Z88-êZ00
Folotyn
®
pralatrexate
(Orphan Drug)
Allos Therapeutics
Westminster, CO
(see also breast, lung, lymphoma) P|ase ll
(303) 12ê-ê2ê2
icrucumab
(LY3012212/lVC-18F1)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
(see also breast, colorectal) P|ase ll
(800) 515-59Z9
tesetaxel Genta
Berkeley Heights, NJ
second-line bladder cancer
(see also breast, prostate, skin,
stomach)
P|ase ll
(908) 286-9800
v81-815 Viventia Biotechnologies
Mississauga, Canada
(see also head/neck) P|ase ll
(905) 3ê2-29Z3
BRAIN CANCER
Product Name Sponsor Indication Development Status
8l9 l-131 rAo United Therapeutics
Silver Spring, MD
(see also sarcoma, other) P|ase l
(301) 608-9292
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also breast, colorectal, lung,
lymphoma, ovarian, prostate, skin,
other)
P|ase l
(81Z) 93Z-ê100
AC180
(pan-HER inhibitor)
Ambit Biosciences
San Diego, CA
glioma
(see also breast, lung)
P|ase l
(858) 331-2100
AEE788 Novartis Pharmaceuticals
East Hanover, NJ
glioblastoma P|ase l/ll
(888) 669-6682
afatinib
(8l8w2992)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
glioblastoma
(see also breast, head/neck, lung)
P|ase l/ll
(800) 213-012Z
APN301
(c|11.18 rAo/|rler|eu||r-2
fusion protein)
Apeiron Biologics
Vienna, Austria
neuroblastoma in children
(see also skin)
P|ase ll corp|eled
www.apeiron-biologics.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
4
BRAIN CANCER
Product Name Sponsor Indication Development Status
AR-67 Arno Therapeutics
Flemington, NJ
glioblastoma
(see also leukemia, solid tumors)
P|ase ll
(862) 703-7170
ARC-100 Archer Biosciences
New York, NY
glioblastoma (recurrent)
(see also breast, prostate, skin)
--------------------------------------------------
neuroblastoma
(combination therapy)
--------------------------------------------------
medulloblastoma
(combination therapy)
P|ase ll
(ê1ê) Z1Z-9090
-------------------------------------------
P|ase l/ll
(ê1ê) Z1Z-9090
-------------------------------------------
P|ase l
(ê1ê) Z1Z-9090
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
glioblastoma
(see also leukemia, lung, lymphoma,
prostate, stomach)
P|ase ll
(ê10) 108-0301
Avastin
®
bevacizumab
Genentech
South San Francisco, CA
lrsl-||re ç||oo|aslora ru|l|lorre
(see also breast, colorectal, lung,
ovarian, other)
P|ase lll
(800) ê2ê-3553
Azedra™
rela|odooerzy|çuar|d|re l-131
(Orphan Drug)
Vo|ecu|ar lrs|ç|ls P|arraceul|ca|s
Cambridge, MA
neuroblastoma (pediatric)
(Fast Track), paraganglioma,
pheochromocytoma (Fast Track)
P|ase ll
(ê1Z) 192-5551
bafetinib CytRx
Los Angeles, CA
second-line brain cancer
(see also leukemia, prostate)
P|ase l
(310) 82ê-5ê18
BKM120
(Pl3K |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
glioblastoma
(see also breast, lung, other)
P|ase l/ll
(888) 669-6682
c|11.18 rAo
(Orphan Drug)
United Therapeutics
Silver Spring, MD
neuroblastoma (children) P|ase lll
(301) 608-9292
cilengitide
(Orphan Drug)
EMD Serono
Rockland, MA
newly-diagnosed glioblastoma
(combination therapy)
(see also prostate)
P|ase lll
(800) 283-8088
cintredekin besudotox
(Orphan Drug)
lN3Y3 T|erapeul|cs
Phoenix, AZ
glioma (adolescents and children)
(Fast Track)
P|ase l
(602) 910-2617
Cotara
®
monoclonal antibody TNT-1
(Orphan Drug)
Peregrine Pharmaceuticals
Tusr|n, 0/
recurrent glioblastoma
(Fast Track)
P|ase ll
(Z11) 508-ê000
CPP-1X
(elorr|l||re)
Cancer Prevention Pharmaceuticals
Tuoson, /Z
neuroblastoma P|ase l
(520) 908-ZZZ1
Medicines in Development for Cancer
Medicines in Development Cancer 2012
5
BRAIN CANCER
Product Name Sponsor Indication Development Status
crenolanib
(CP-8ê8-59ê)
AROG Pharmaceuticals
0a||as, TX
glioma (adults)
(see also stomach)
--------------------------------------------------
glioma (pediatric)
P|ase ll
(211) 591-0002
-------------------------------------------
P|ase l
(211) 591-0002
DCVax
®
-Brain
brain cancer vaccine
(Orphan Drug)
Northwest Biotherapeutics
Bethesda, MD
glioblastoma P|ase ll
(210) 19Z-9021
EZ050 Eisai
Woodcliff Lake, NJ
second-line glioblastoma
(see also head/neck, liver, skin,
solid tumors, stomach)
P|ase l/ll
(888) 122-1Z13
E7080
(lenvatinib)
Eisai
Woodcliff Lake, NJ
glioma
(see also skin, other)
P|ase ll
(888) 122-1Z13
EPO-806
(patupilone)
Novartis Pharmaceuticals
East Hanover, NJ
brain metastases from lung cancer
(see also prostate)
P|ase ll
(888) 669-6682
G-100 prophage cancer vaccine
(vitespen)
(Orphan Drug)
Agenus
Lexington, MA
newly-diagnosed glioma P|ase ll
(Z81) êZ1-1100
G-200 prophage cancer vaccine
(vitespen)
(Orphan Drug)
Agenus
Lexington, MA
recurrent glioma P|ase ll
(Z81) êZ1-1100
GliAtak™
gene therapy
(Orphan Drug)
Advantagene
Auburndale, MA
glioma
--------------------------------------------------
brain cancer (children)
P|ase ll
(ê1Z) 91ê-5115
-------------------------------------------
P|ase l
(ê1Z) 91ê-5115
GMB-Vax
dendritic cell cancer vaccine
Activartis Biotech
Vienna, Austria
lrsl-||re ç||oo|aslora P|ase ll
www.activartis.com
0RN1005
(LRP directed peptide-drug
conjugate)
Geron
Menlo Park, CA
brain metastases
--------------------------------------------------
glioma
P|ase ll
(ê50) 1Z3-ZZ00
-------------------------------------------
P|ase l corp|eled
(ê50) 1Z3-ZZ00
03K211813ê
(BRaf protein kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
brain metastases from melanoma
(see also lung, skin)
P|ase ll
(888) 825-5219
Hycamtin
®
topotecan
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
metastatic brain cancer P|ase lll
(888) 825-5219
Medicines in Development for Cancer
Medicines in Development Cancer 2012
6
Medicines in Development for Cancer
BRAIN CANCER
Product Name Sponsor Indication Development Status
lCT-10Z
(dendritic cell vaccine)
(Orphan Drug)
lrruroCe||u|ar T|erapeul|cs
Woodland Hills, CA
glioblastoma P|ase ll
(818) 992-2907
Levulan
®
PDT
aminolevulinic acid
DUSA Pharmaceuticals
Wilmington, MA
P|ase ll
(9Z8) ê5Z-Z500
lonafarnib Merck
Whitehouse Station, NJ
glioblastoma P|ase l
(800) 672-6372
Lucanix
®
belagenpumatucel-L
NovaRx
San Diego, CA
glioma
(see also lung)
P|ase l
(858) 522-8ê00
macitentan Actelion Pharmaceuticals US
South San Francisco, CA
glioblastoma (combination therapy) P|ase l
(ê50) ê21-ê900
VE0l-5Z5
(anti-PDGFR-alpha mAb)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
glioblastoma
(see also lung)
P|ase ll
(800) 236-9933
(301) 398-0000
mibefradil
(T-type calcium channel
inhibitor)
(Orphan Drug)
Tau Therapeutics
Charlottesville, VA
glioblastoma P|ase l
(131) 9Z1-ê9ê9
rolexalr çado||r|ur Pharmacyclics
Sunnyvale, CA
glioblastoma (combination therapy) P|ase ll
(108) ZZ1-0330
nimotuzumab
(Orphan Drug)
YM Biosciences USA
Lehigh Valley, PA
metastatic brain cancer,
recurrent glioma (pediatric)
(see also breast, prostate)
P|ase ll
(ê10) 5ê0-0ê00
olaratumab
(LY3012207)
Eli Lilly
Indianapolis, IN
lrC|ore 3yslers
Bridgewater, NJ
glioblastoma
(see also ovarian)
P|ase ll
(800) 515-59Z9
Opaxio™
paclitaxel poliglumex
Cell Therapeutics
Seattle, WA
glioma, glioblastoma
(see also lung, ovarian, stomach,
other)
P|ase ll
(800) 215-2355
perifosine AEterna Zentaris
Basking Ridge, NJ
refractory metastatic glioma
(see also colorectal, kidney,
leukemia, lung, lymphoma, multiple
myeloma, sarcoma, solid tumors,
stomach)
P|ase ll
(908) ê2ê-5128
Medicines in Development Cancer 2012
7
Medicines in Development for Cancer
BRAIN CANCER
Product Name Sponsor Indication Development Status
PLX3397
(CSF-1R kinase inhibitor)
Plexxikon
Berkeley, CA
recurrent glioblastoma
(see also leukemia, lymphoma,
solid tumors)
P|ase ll
(510) ê1Z-1000
Po|y-lCLC
(Orphan Drug)
Oncovir
Washington, DC
anaplastic astrocytoma (adolescents
and children), glioblastoma
(adolescents and children)
P|ase ll
www.oncovir.com
PX-866 Oncothyreon
Seattle, WA
second-line glioblastoma
(see also head/neck, lung, prostate)
P|ase ll
(206) 801-2100
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
glioma
(see also colorectal, head/neck, lung,
ovarian, pancreatic, sarcoma,
skin, solid tumors)
P|ase l/ll
(103) êZ0-Z3ZZ
rindopepimut
(Orphan Drug)
Celldex Therapeutics
Needham, MA
lrsl-||re ç||oo|aslora
(Fast Track)
--------------------------------------------------
second-line glioblastoma
(Fast Track)
P|ase lll
(Z81) 133-0ZZ1
-------------------------------------------
P|ase ll
(Z81) 133-0ZZ1
SB-313-xTZ Sangamo Biosciences
Richmond, CA
glioblastoma P|ase l
(510) 9Z0-ê000
SBG Biotec Pharmacon
Tromsø, horuay
neuroblastoma (pediatric) P|ase l/ll corp|eled
www.biotec.no
SL-701
(brain cancer vaccine)
Stemline Therapeutics
New York, NY
glioma (adults)
--------------------------------------------------
glioma (children)
P|ase l/ll
(212) 831-1111
-------------------------------------------
P|ase l/ll
(212) 831-1111
SPRYCEL
®
dasatinib
Bristol-Myers Squibb
Princeton, NJ
glioblastoma
(see also breast, pancreatic,
prostate, other)
in clinical trials
(800) 332-205ê
Tarceva
®
erlotinib
(Orphan Drug)
Genentech
South San Francisco, CA
03l P|arraceul|ca|s
Farmingdale, NY
late-stage brain metastases,
recurrent ependymoma (children),
glioblastoma
(see also breast, head/neck,
leukemia, liver, lung, other)
P|ase ll
(800) ê2ê-3553
(631) 962-0600
terameprocol Erimos Pharmaceuticals
lousron, TX
glioma (intravenous)
(see also cervical, head/neck,
solid tumors, other)
P|ase l/ll
(Z13) 511-2000
TGF-ß R1 inhibitor
(LY215Z299)
Eli Lilly
Indianapolis, IN
(see also liver) P|ase ll
(800) 515-59Z9
Medicines in Development Cancer 2012
8
BRAIN CANCER
Product Name Sponsor Indication Development Status
TH-302 Threshold Pharmaceuticals
South San Francisco, CA
astrocytoma
(see also leukemia, multiple
myeloma, pancreatic, sarcoma)
P|ase ll
(ê50) 1Z1-8200
Toca 511/Toca FC
(cytosine deaminase gene
therapy)
Tocagen
San Diego, CA
glioblastoma P|ase l/ll
(858) 112-8100
trans-sodium crocetinate (TSC)
(Orphan Drug)
Diffusion Pharmaceuticals
Charlottesville, VA
gliobastoma P|ase l/ll
(131) 220-0Z18
Tvl-8ra|r-1
(cellular immunotherapy
vaccine)
TVAX Biomedical
Lenexa, KS
glioma P|ase ll
(913) 192-2221
VAL-083 Del Mar Pharmaceuticals
Vancouver, Canada
çrade lv ra||çrarl ç||ora P|ase l/ll
(ê01) ê29-5989
VB-111 VBL Therapeutics
Or Yehuda, Israel
glioblastoma
(see also other)
P|ase l/ll
www.vblrx.com
Xeloda
®
capecitabine
Genentech
South San Francisco, CA
newly-diagnosed glioma
(adolescents and children)
(see also colorectal, liver, stomach)
P|ase l
(800) ê2ê-3553
Zelboraf
®
vemurafenib
Genentech
South San Francisco, CA
Plexxikon
Berkeley, CA
brain metastases
(see also colorectal, other)
P|ase ll
(800) ê2ê-3553
BREAST CANCER
Product Name Sponsor Indication Development Status
18F-luorol|yr|d|re Merck
Whitehouse Station, NJ
breast cancer (diagnosis) P|ase ll
(800) 672-6372
Abraxane
®
albumin-bound paclitaxel
Celgene
Summit, NJ
lrsl-||re relaslal|c oreasl carcer
(see also bladder, lung, ovarian,
pancreatic, skin)
P|ase ll
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, colorectal, lung,
lymphoma, ovarian, prostate, skin,
other)
P|ase ll
(81Z) 93Z-ê100
AC180
(pan-HER inhibitor)
Ambit Biosciences
San Diego, CA
(see also brain, lung) P|ase l
(858) 331-2100
Medicines in Development for Cancer
Medicines in Development Cancer 2012
9
BREAST CANCER
Product Name Sponsor Indication Development Status
acolbifene
(1l|-çereral|or 3ERV)
EndoCeutics
Quebec, Canada
P|ase ll
(118) ê53-0033
AE37 peptide vaccine Antigen Express
Worcester, MA
(see also ovarian) P|ase ll
(508) 852-8Z83
afatinib
(8l8w2992)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
second-line metastatic breast cancer
(see also brain, head/neck, lung)
--------------------------------------------------
lrsl-||re oreasl carcer
P|ase lll
(800) 213-012Z
-------------------------------------------
P|ase ll
(800) 213-012Z
alrox|lere ASCEND Therapeutics
Herndon, VA
breast cancer (prevention) P|ase ll
(Z03) 1Z1-1Z11
$ÀQLWRU
®
everolimus
Novartis Pharmaceuticals
East Hanover, NJ
HER2-positive breast cancer
(see also kidney, lymphoma)
P|ase lll
(888) 669-6682
AFP1ê1 Kirax
Bonita Springs, FL
P|ase ll
(239) 111-5100
amrubicin Celgene
Summit, NJ
late-stage breast cancer
(see also lung)
P|ase l/ll
(908) 673-9000
ARC-100 Archer Biosciences
New York, NY
(see also brain, prostate, skin) P|ase ll
(ê1ê) Z1Z-9090
ARRY-380
(HER2 inhibitor)
Array BioPharma
Boulder, CO
P|ase l
(8ZZ) ê33-213ê
AUY922
(Hsp90 inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
breast cancer (monotherapy)
(see also colorectal, lung, multiple
myeloma, stomach)
--------------------------------------------------
breast cancer (combination therapy)
P|ase ll
(888) 669-6682
-------------------------------------------
P|ase l/ll
(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012
10
BREAST CANCER
Product Name Sponsor Indication Development Status
Avastin
®
bevacizumab
Genentech
South San Francisco, CA
adjuvant HER2-negative breast can-
cer, adjuvant HER2-positive breast
cancer, adjuvant triple negative
breast cancer
(see also brain, colorectal, lung,
ovarian, other)
P|ase lll
(800) ê2ê-3553
AZD8931
(erbB kinase inhibitor)
AstraZeneca
Wilmington, DE
advanced breast cancer
(combination therapy)
(see also solid tumors)
P|ase ll
(800) 236-9933
8AY 8ê-5011
(lonaprisan)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
metastatic breast cancer P|ase ll corp|eled
(888) 812-293Z
8ll8 2021 8|oçer ldec
Cambridge, MA
(see also stomach) P|ase ll corp|eled
(617) 679-2000
BKM120
(Pl3K |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
second-line breast cancer
(see also brain, lung, other)
P|ase l/ll
(888) 669-6682
breast cancer vaccine
(dendritic cell vaccine)
0uarlur lrruro|oç|cs
Tamµa, FL
P|ase l/ll
(8êê) 213-1591
brostallicin Cell Therapeutics
Seattle, WA
triple-negative breast cancer P|ase l
(800) 215-2355
BTSCAN Molecular Targeting Technologies
West Chester, PA
breast cancer (diagnosis) P|ase l
(610) 738-7938
BZL-101 Bionovo
Emeryville, CA
P|ase l
(510) ê01-2000
cabozantinib
(XL181)
Exelixis
South San Francisco, CA
(see also kidney, lung, ovarian,
prostate, other)
P|ase ll
(ê50) 83Z-Z000
cancer vaccine MabVax Therapeutics
San Diego, CA
(see also sarcoma) P|ase l
(858) 259-9105
CDX-011
(glembatumumab vedotin)
Celldex Therapeutics
Needham, MA
breast cancer (Fast Track)
(see also skin)
P|ase ll
(Z81) 133-0ZZ1
CV-301
(cancer vaccine)
8N lrruroT|erapeul|cs
Mountain View, CA
metastatic breast cancer P|ase ll
(ê50) ê81-1êê0
D-1MT NewLink Genetics
Ames, IA
second-line metastatic breast cancer
(see also solid tumors)
P|ase l/ll
(515) 29ê-5555
Medicines in Development for Cancer
Medicines in Development Cancer 2012
11
BREAST CANCER
Product Name Sponsor Indication Development Status
dalotuzumab
(VK-0ê1ê)
Merck
Whitehouse Station, NJ
second-line breast cancer
(combination therapy)
(see also lung, pancreatic, other)
--------------------------------------------------
lrsl-||re oreasl carcer
P|ase ll
(800) 672-6372
-------------------------------------------
P|ase l
(800) 672-6372
DPX-0907 lrrurovacc|re
Halifax, Canada
(see also ovarian, prostate) P|ase l
(902) 192-1819
eniluracil Adherex Technologies
Pson. Tr|ang|e Park, h0
metastatic breast cancer
(combination therapy)
P|ase ll
(919) ê3ê-1530
entinostat Syndax Pharmaceuticals
Waltham, MA
(see also colorectal, kidney,
leukemia, lung, lymphoma)
P|ase ll
(Z81) 119-1100
etirinotecan pegol
(NKTR-102)
Nektar Therapeutics
San Francisco, CA
metastatic breast cancer
(see also colorectal, ovarian,
solid tumors)
P|ase lll
(855) 182-ê58Z
EZN-2208
(PE0-3N38, lrlecar peço|)
Enzon Pharmaceuticals
Piscataway, NJ
metastatic breast cancer
(see also colorectal, solid tumors)
P|ase ll
(9Z3) 980-1500
Faslodex
®
fulvestrant
AstraZeneca
Wilmington, DE
lrsl-||re advarced oreasl carcer P|ase lll
(800) 236-9933
folate binding protein (E39)
vaccine
Galena Biopharma
Lake Oswego, OR
(see also ovarian, other) P|ase l
(855) 855-1253
Folotyn®
pralatrexate
Allos Therapeutics
Westminster, CO
(see also bladder, lung, lymphoma) P|ase ll
(303) 12ê-ê2ê2
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
(see also colorectal, leukemia, liver,
lung, multiple myeloma, pancreatic,
prostate, skin, stomach)
P|ase ll
(Z81) 2Z1-8200
ganitumab
(AV0 1Z9)
Amgen
Tnousano Daks, 0/
combination therapy
(see also colorectal, lung, pancreatic,
sarcoma)
P|ase ll
(800) ZZ2-ê13ê
GDC-0980
(Pl3 ||rase/rT0R dua|
inhibitor)
Genentech
South San Francisco, CA
hormone receptor-positive breast
cancer
(see also lymphoma, solid tumors)
P|ase ll
(800) ê2ê-3553
03K2302021A
(wT1 arl|çer-spec|lc carcer
immunotherapeutic)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
neoadjuvant breast cancer P|ase l/ll
(888) 825-5219
GVAX
®
Breast
cancer vaccine
BioSante Pharmaceuticals
Lincolnshire, IL
P|ase l
(81Z) 1Z8-0500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
12
BREAST CANCER
Product Name Sponsor Indication Development Status
lER2 arl|çer-spec|lc carcer
immunotherapeutic
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
P|ase ll
(888) 825-5219
icrucumab
(LY3012212/lVC-18F1)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
metastatic breast cancer
(see also bladder, colorectal)
P|ase ll
(800) 515-59Z9
imetelstat Geron
Menlo Park, CA
metastatic breast cancer
(combination therapy)
(see also leukemia, lung,
multiple myeloma)
P|ase ll
(ê50) 1Z3-ZZ00
lVT-1012 |rrurol|erapeul|c
vaccine
lrrurolope
Doylestown, PA
(see also ovarian) P|ase l
(215) 253-1180
indibulin
(Zl0-301)
Zl0PlARV 0rco|oçy
New York, NY
late-stage breast cancer P|ase l/ll
(ê1ê) 211-0Z00
iniparib
(83l-201)
3arol u3
Bridgewater, NJ
neoadjuvant breast cancer
(see also lung, ovarian)
P|ase ll
(800) 981-2191
Kw-2150 Kyowa Hakko Kirin Pharma
Princeton, NJ
lrsl-||re oreasl carcer, secord-||re
breast cancer
P|ase l/ll
(609) 919-1100
LFA102
(anti-prolactin receptor anti-
body)
Novartis Pharmaceuticals
East Hanover, NJ
XOMA
Berkeley, CA
(see also prostate) P|ase l
(888) 669-6682
L0K9Z1
(wNT s|çra||rç pal|Way
inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
(see also skin) P|ase l
(888) 669-6682
linifanib Abbott Laboratories
Abbott Park, IL
breast cancer (combination therapy)
(see also colorectal, kidney, liver,
lung)
P|ase ll
(81Z) 93Z-ê100
liposome encapsulated
paclitaxel (LEP-ETU)
lrsys T|erapeul|cs
Phoenix, AZ
P|ase ll
(602) 910-2617
litronesib
(LY2523355)
Eli Lilly
Indianapolis, IN
metastatic breast cancer
(see also lung)
P|ase ll
(800) 515-59Z9
L0R-2010 Lorus Therapeutics
Toronro, 0anaoa
metastatic breast cancer
(see also colorectal, kidney,
leukemia, prostate)
P|ase ll
(11ê) Z98-1200
Lymphoseek
®
Tc-99m tilmanocept
Navidea Pharmaceuticals
Dublin, OH
breast cancer (diagnosis)
(see also head/neck, skin)
application submitted
(ê11) Z93-Z500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
13
BREAST CANCER
Product Name Sponsor Indication Development Status
maraciclatide GE Healthcare
Waukesha, WI
breast cancer (diagnosis) in clinical trials
www.gehealthcare.com
VK-0Z52
(notch signaling pathway
inhibitor)
Merck
Whitehouse Station, NJ
early-stage breast cancer,
late-stage breast cancer
(see also other)
P|ase l
(800) 672-6372
MK-2206
(c-akt inhibitor)
Merck
Whitehouse Station, NJ
HER2-positive breast cancer
(see also other)
P|ase l
(800) 672-6372
MM-111 Merrimack Pharmaceuticals
Cambridge, MA
breast cancer (combination therapy) P|ase l/ll
(ê1Z) 111-1000
MM-302
(anti-HER2 antibody
doxorubicin conjugate)
Merrimack Pharmaceuticals
Cambridge, MA
P|ase l
(ê1Z) 111-1000
motesanib Amgen
Tnousano Daks, 0/
(see also colorectal, lung, other) P|ase l/ll
(800) ZZ2-ê13ê
MVA-BN
®
HER2
(HER-2/neu-based MVA
vaccine)
8N lrruroT|erapeul|cs
Mountain View, CA
P|ase l
(ê50) ê81-1êê0
Myocet™
doxorubicin liposomal
Sopherion Therapeutics
Princeton, NJ
lrsl-||re oreasl carcer
(combination therapy) (Fast Track)
P|ase lll
(609) 986-2020
NeuVax™
carcer vacc|re EZ5
Galena Biopharma
Lake Oswego, OR
early-stage breast cancer
(prevention of relapse)
(see also prostate)
P|ase lll
(855) 855-1253
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also colorectal, head/neck,
kidney, leukemia, liver, lung, multiple
myeloma, ovarian, other)
P|ase lll
(888) 812-293Z
nimotuzumab YM Biosciences USA
Lehigh Valley, PA
(see also brain, prostate) P|ase l
(ê10) 5ê0-0ê00
NK-012 Nippon Kayaku
Tokyo, Jaµan
(see also lung) P|ase ll
www.nipponkayaku.co.jp
OBP-301 Oncolys Biopharma
Tokyo, Jaµan
(see also head/neck, liver, lung) P|ase l
www.oncolys.com
00X-12Z OncoGenex Pharmaceuticals
Bothell, WA
(see also lung, ovarian) P|ase l
(125) ê8ê-1500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
14
BREAST CANCER
Product Name Sponsor Indication Development Status
onartuzumab Genentech
South San Francisco, CA
metastatic breast cancer
(combination therapy)
(see also colorectal, lung)
P|ase ll
(800) ê2ê-3553
OPT-822/OPT-821 Optimer Biotechnology
San Diego, CA
P|ase ll/lll
(858) 909-0Z3ê
PB-272 (neratinib) Puma Biotechnology
Los Angeles, CA
second-line breast cancer,
neoadjuvant breast cancer
P|ase ll
(121) 218-ê500
pertuzumab Genentech
South San Francisco, CA
lrsl-||re relaslal|c oreasl carcer
--------------------------------------------------
second-line late-stage breast cancer
application submitted
(800) ê2ê-3553
-------------------------------------------
P|ase ll
(800) ê2ê-3553
pertuzumab companion
diagnostic
(lER2 Fl3l p|arr0x¹)
Dako
Glostrup, Denmark
Genentech
South San Francisco, CA
breast cancer (diagnostic) P|ase lll
www.dako.com
(800) ê2ê-3553
pertuzumab companion
diagnostic
(HercepTest™)
Dako
Glostrup, Denmark
Genentech
South San Francisco, CA
breast cancer (diagnosis) P|ase lll
www.dako.com
(800) ê2ê-3553
pixantrone Cell Therapeutics
Seattle, WA
breast cancer (Fast Track)
(see also lymphoma)
P|ase ll
(800) 215-2355
PTC299 PTC Therapeutics
$ourn P|a|nle|o, hJ
(see also solid tumors, other) P|ase l/ll
(908) 222-7000
Quinamed
®
aroralde
Cephalon
Frazer, PA
(see also ovarian, prostate) P|ase ll
(ê10) 311-0200
ramucirumab
(lVC-11218)
Eli Lilly
Indianapolis, IN
lrC|ore 3yslers
Bridgewater, NJ
metastatic breast cancer
(see also colorectal, stomach)
P|ase lll
(800) 515-59Z9
Reximmune-C
®
personalized cancer vaccine
Epeius Biotechnologies
San Marino, CA
P|ase l/ll
(ê2ê) 111-êê95
Rexin-G
®
Epeius Biotechnologies
San Marino, CA
metastatic breast cancer
(see also pancreatic, sarcoma)
P|ase l/ll
(ê2ê) 111-êê95
Medicines in Development for Cancer
Medicines in Development Cancer 2012
15
BREAST CANCER
Product Name Sponsor Indication Development Status
ridaforolimus ARlA0 P|arraceul|ca|s
Cambridge, MA
Merck
Whitehouse Station, NJ
metastatic breast cancer
(see also kidney, lung, prostate,
sarcoma, other)
P|ase ll
(800) 672-6372
rucaparib Clovis Oncology
Boulder, CO
(see also ovarian) P|ase ll
(303) ê25-5000
sagopilone Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also ovarian, prostate) P|ase ll corp|eled
(888) 812-293Z
sarar|ur 3V-153 |ex|drorar
injection
EUSA Pharma
Langhorne, PA
(see also multiple myeloma, prostate,
sarcoma, other)
P|ase ll
(800) 833-3533
3AR215108
(XL11Z)
(ora| Pl3K |r||o|lor)
3arol u3
Bridgewater, NJ
Exelixis
South San Francisco, CA
(see also other) P|ase ll
(800) 981-2191
(ê50) 83Z-Z000
3AR215109
(XLZê5)
(Pl3K/rT0R |r||o|lor)
3arol u3
Bridgewater, NJ
Exelixis
South San Francisco, CA
(see also lymphoma) P|ase ll
(800) 981-2191
(ê50) 83Z-Z000
3AR25ê212
(MM-121)
(anti-ErbB3 mAb)
Merrimack Pharmaceuticals
Cambridge, MA
3arol u3
Bridgewater, NJ
(see also lung, ovarian) P|ase ll
(800) 981-2191
SF1 (sonodynamic therapy) SonneMed
Boston, MA
advanced breast cancer P|ase l/ll
www.sonnemed.com
SPRYCEL
®
dasatinib
Bristol-Myers Squibb
Princeton, NJ
(see also brain, pancreatic, prostate,
other)
in clinical trials
(800) 332-205ê
3R 1ê231 3Rl lrlerral|ora|
Menlo Park, CA
P|ase ll
(ê50) 859-2000
Tarceva
®
erlotinib
Genentech
South San Francisco, CA
03l P|arraceul|ca|s
Farmingdale, NY
(see also brain, head/neck, leukemia,
liver, lung, other)
P|ase ll
(800) ê2ê-3553
(631) 962-0600
tesetaxel Genta
Berkeley Heights, NJ
lrsl-||re oreasl carcer
(see also bladder, prostate, skin,
stomach)
P|ase ll
(908) 286-9800
Medicines in Development for Cancer
Medicines in Development Cancer 2012
16
BREAST CANCER
Product Name Sponsor Indication Development Status
ThermoDox
®
doxorubicin liposomal
Celsion
Lawrenceville, NJ
recurrent breast cancer
(see also colorectal, liver)
P|ase l/ll
(609) 896-9100
tigatuzumab
(arl|-0R5 arl|oody)
Daiichi Sankyo
Parsippany, NJ
(see also colorectal, liver, lymphoma,
ovarian, pancreatic)
P|ase ll
(9Z3) 911-2ê00
tivozanib
(A3P1130/Av-951)
Astellas Pharma US
0eerle|o, lL
AVEO Pharmaceuticals
Cambridge, MA
breast cancer (combination therapy)
(see also colorectal, kidney)
P|ase l/ll
(800) ê95-1321
(ê1Z) 299-5000
TKl258
(dovitinib)
Novartis Pharmaceuticals
East Hanover, NJ
metastatic breast cancer
(see also kidney, multiple myeloma,
prostate, skin, other)
P|ase ll
(888) 669-6682
trabectedin Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
metastatic breast cancer
(see also ovarian, prostate, sarcoma)
P|ase lll
(800) 81Z-528ê
trastuzumab-DM1
(R03502)
Genentech
South San Francisco, CA
P|ase lll
(800) ê2ê-3553
trastuzumab-DM1
companion diagnostic
(HercepTest™)
Dako
Glostrup, Denmark
Genentech
South San Francisco, CA
breast cancer (diagnosis) P|ase lll
www.dako.com
(800) ê2ê-3553
trastuzumab-DM1
companion diagnostic
(lER2 Fl3l p|arr0x¹)
Dako
Glostrup, Denmark
Genentech
South San Francisco, CA
breast cancer (diagnosis) P|ase lll
www.dako.com
(800) ê2ê-3553
TRC 105
(ENG protein inhibitor)
TRACON Pharmaceuticals
San Diego, CA
(see also ovarian, prostate, other) P|ase l/ll
(858) 550-0Z80
trebananib
(AMG386)
Amgen
Tnousano Daks, 0/
(see also colorectal, kidney, liver,
ovarian, stomach, other)
P|ase ll
(800) ZZ2-ê13ê
Tykerb
®
lapatinib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
|rlarralory oreasl carcer
(see also colorectal, head/neck,
stomach)
--------------------------------------------------
adjuvarl oreasl carcer, lrsl-||re
metastatic breast cancer
--------------------------------------------------
neoadjuvant breast cancer
application submitted
(888) 825-5219
-------------------------------------------
P|ase lll
(888) 825-5219
-------------------------------------------
P|ase ll
(888) 825-5219
upamostat
(wX-êZ1)
w||ex
Munich, Germany
P|ase ll
www.wilex.de
Medicines in Development for Cancer
Medicines in Development Cancer 2012
17
BREAST CANCER
Product Name Sponsor Indication Development Status
varlitinib ASLAN Pharmaceuticals
Singapore
P|ase ll
www.aslanpharma.com
VeriStrat
®
companion diagnostic test
E0FR-TKl
Biodesix
Boulder, CO
advanced breast cancer
(diagnosis-outcome test in
HER2-overexpressing tumors)
P|ase lll
(303) 11Z-0500
YV155
(sepantronium)
Astellas Pharma US
0eerle|o, lL
(see also lymphoma) P|ase ll
(800) ê95-1321
Zolinza
®
vorinostat
Merck
Whitehouse Station, NJ
(see also leukemia, lung, lymphoma,
multiple myeloma, other)
P|ase ll
(800) 672-6273
Zytiga
®
abiraterone
Janssen Biotech
Horsham, PA
second-line metastatic breast cancer
(see also prostate)
P|ase ll
(800) 52ê-ZZ3ê
CERVICAL CANCER
Product Name Sponsor Indication Development Status
ADXS-HPV Advaxis
Princeton, NJ
cervical cancer, cervical
intraepithelial neoplasia
P|ase ll
(ê09) 152-9813
PV-00101 PharmaMar
Madrid, Spain
(see also sarcoma, other) P|ase ll
www.pharmamar.com
PV701
(replication-competent oncolytic
virus)
we||slal 8|o|oç|cs
Gaithersburg, MD
(see also colorectal) P|ase ll
(210) ê83-2500
terameprocol Erimos Pharmaceuticals
lousron, TX
cervical intraepithelial neoplasia
(intravaginal)
(see also brain, head/neck, solid
tumors, other)
P|ase ll
(Z13) 511-2000
v503
(HPV virus-like particle (VLP)
vaccine)
Merck
Whitehouse Station, NJ
prevention of cervical cancer,
prevention of vulvovaginal cancer
P|ase lll
(800) 672-6372
v505
(HPV vaccine)
Merck
Whitehouse Station, NJ
prevention of cervical cancer P|ase ll corp|eled
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012
18
CERVICAL CANCER
Product Name Sponsor Indication Development Status
verpasep caltespen
(cancer vaccine)
Akela Pharma
/usr|n, TX
cervical intraepithelial neoplasia P|ase l corp|eled
(512) 831-0119
VGX-3100
(DNA cancer vaccine)
lrov|o P|arraceul|ca|s
Blue Bell, PA
cervical intraepithelial neoplasia P|ase ll
(8ZZ) 11ê-ê81ê
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, breast, lung,
lymphoma, ovarian, prostate, skin,
other)
P|ase ll
(81Z) 93Z-ê100
Aptocine™
la|aporlr
Light Sciences Oncology
Bellevue, WA
metastatic colorectal cancer P|ase lll
(125) 95Z-8900
AUY922
(Hsp90 inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
second-line colorectal cancer
(combination therapy)
(see also breast, lung, multiple
myeloma, stomach)
P|ase l
(888) 669-6682
Avastin
®
bevacizumab
Genentech
South San Francisco, CA
metastatic colorectal cancer
(treatment beyond progression)
(see also brain, breast, lung, ovarian,
other)
P|ase lll
(800) ê2ê-3553
AVX701
(CEA cancer immunotherapy)
AlphaVax
Pson. Tr|ang|e Park, h0
colorectal cancer prevention in
patients with advanced or metastatic
CEA-expressing malignancies
P|ase l/ll
(919) 595-0100
belinostat Spectrum Pharmaceuticals
Henderson, NV
colorectal cancer (combination
therapy)
(see also leukemia, liver, lung,
lymphoma, ovarian, other)
P|ase l/ll
(Z02) 835-ê300
brivanib
(VEGFR/FGFR kinase inhibitor)
Bristol-Myers Squibb
Princeton, NJ
metastatic colorectal cancer
(see also liver, sarcoma)
P|ase ll
(800) 332-205ê
CPX-1
(|r|rolecar/loxur|d|re)
Celator Pharmaceuticals
Princeton, NJ
P|ase ll corp|eled
(ê09) 213-0123
CT-011 CureTech
Yavne, Israel
lrsl-||re relaslal|c co|orecla| carcer
(combination therapy)
(see also leukemia, lymphoma)
P|ase ll
www.curetechbio.com
E7820 Eisai
Woodcliff Lake, NJ
P|ase ll
(888) 122-1Z13
Medicines in Development for Cancer
Medicines in Development Cancer 2012
19
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
efatutazone Daiichi Sankyo
Parsippany, NJ
metastatic colorectal cancer
(see also lung, other)
P|ase ll
(9Z3) 911-2ê00
EGEN-001 EGEN
Huntsville, AL
(see also ovarian, other) P|ase l/ll
(25ê) 512-00ZZ
EGFR antagonist
companion diagnostic
0lA0EN
Valencia, CA
colorectal cancer (diagnosis) application submitted
www.qiagen.com
encapsulated cell therapy
(macrobeads)
Roços|r lrsl|lule
New York, NY
refractory metastatic colorectal
cancer
(see also pancreatic, prostate)
P|ase ll
(212) Z1ê-15êê
entinostat Syndax Pharmaceuticals
Waltham, MA
metastatic colorectal cancer
(combination therapy)
(see also breast, kidney, leukemia,
lung, lymphoma)
P|ase ll
(Z81) 119-1100
ERBITUX
®
cetuximab
Bristol-Myers Squibb
Princeton, NJ
Eli Lilly
Indianapolis, IN
lrsl-||re co|orecla| carcer
(see also stomach)
in clinical trials
(800) 332-205ê
(800) 515-59Z9
etirinotecan pegol
(NKTR-102)
Nektar Therapeutics
San Francisco, CA
second-line colorectal cancer
(see also breast, ovarian, solid
tumors)
P|ase ll/lll
(855) 182-ê58Z
EZN-2208
(PE0-3N38, lrlecar peço|)
Enzon Pharmaceuticals
Piscataway, NJ
metastatic colorectal cancer
(see also breast, solid tumors)
P|ase ll
(9Z3) 980-1500
FANG™ Vaccine
autologous tumor cell vaccine
Gradalis
0arro||ron, TX
(see also ovarian, skin) P|ase ll
(211) 112-8100
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
refractory, metastatic colorectal
cancer
(see also breast, leukemia, liver,
lung, multiple myeloma, pancreatic,
prostate, skin, stomach)
P|ase ll
(Z81) 2Z1-8200
ganitumab
(AV0 1Z9)
Amgen
Tnousano Daks, 0/
second-line metastatic colorectal
cancer (combination therapy)
(see also breast, lung, pancreatic,
sarcoma)
P|ase ll
(800) ZZ2-ê13ê
0l-1000
(cancer vaccine)
0|ooelrrure
Louisville, CO
(see also lung, pancreatic) P|ase ll
(303) ê25-2Z00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
20
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
GM-CT-01 Galectin Therapeutics
Newton, MA
colorectal cancer
(combination therapy)
P|ase ll
(ê1Z) 559-0033
03-êê21
(monoclonal antibody)
Gilead Sciences
Foster City, CA
(see also pancreatic) P|ase ll
(800) 115-3235
GVAX
®
Colorectal
cancer vaccine
BioSante Pharmaceuticals
Lincolnshire, IL
P|ase l
(81Z) 1Z8-0500
icrucumab
(LY3012212/lVC-18F1)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
(see also bladder, breast) P|ase ll
(800) 515-59Z9
lV0-2055
(TLR9 agonist)
ldera P|arraceul|ca|s
Cambridge, MA
(see also head/neck, lung) P|ase l
(ê1Z) êZ9-5000
Imprime PGG
®
Biothera
Eagan, MN
(see also leukemia, lung, skin) P|ase lll
(ê51) êZ5-0300
JX-591
(pexastimogene devacirepvec)
Jennerex Biotherapeutics
San Francisco, CA
(see also liver) P|ase l/ll
(115) 281-888ê
KRN-330 Kyowa Hakko Kirin Pharma
Princeton, NJ
colorectal cancer
(combination therapy)
--------------------------------------------------
colorectal cancer (monotherapy)
P|ase l/ll
(609) 919-1100
-------------------------------------------
P|ase l
(609) 919-1100
|aoeluzurao l-131
(lVVu-111)
lrrurored|cs
Morris Plains, NJ
P|ase ll
(9Z3) ê05-8200
labetuzumab-SN-38
(lVVu-130)
lrrurored|cs
Morris Plains, NJ
P|ase l
(9Z3) ê05-8200
LGX818
(RAF inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
metastatic colorectal cancer
(see also skin)
P|ase l
(888) 669-6682
linifanib Abbott Laboratories
Abbott Park, IL
second-line colorectal cancer
(see also breast, kidney, liver, lung)
P|ase ll
(81Z) 93Z-ê100
L0R-2010 Lorus Therapeutics
Toronro, 0anaoa
metastatic colorectal cancer
(see also breast, kidney, leukemia,
prostate)
P|ase ll
(11ê) Z98-1200
motesanib Amgen
Tnousano Daks, 0/
(see also breast, lung, other) P|ase l
(800) ZZ2-ê13ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
21
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
metastatic colorectal cancer
(see also breast, head/neck, kidney,
leukemia, liver, lung, multiple
myeloma, ovarian, other)
P|ase ll
(888) 812-293Z
NPC-1C
(ensituximab)
Neogenix Oncology
Rockville, MD
metastatic colorectal cancer
(see also pancreatic)
P|ase l
(301) 917-6893
onartuzumab Genentech
South San Francisco, CA
(see also breast, lung) P|ase ll
(800) ê2ê-3553
OncoVAX
®
acl|ve spec|lc |rrurol|erapy
Vaccinogen
Frederick, MD
(Fast Track) P|ase l/ll
(301) êê8-8100
perifosine AEterna Zentaris
Basking Ridge, NJ
refractory metastatic colorectal
cancer (combination therapy)
(Fast Track)
(see also brain, kidney, leukemia,
lung, lymphoma, multiple myeloma,
sarcoma, solid tumors, stomach)
P|ase lll
(908) ê2ê-5128
PHY906 PhytoCeutica
heu laven, 0T
(see also liver, pancreatic,
cancer-related)
P|ase l/ll
(203) ZZZ-31ê2
picoplatin Ponaird Pharmaceuticals
Seattle, WA
(see also lung, ovarian, prostate) P|ase ll
(206) 281-7001
polyclonal antibody stimulator Cancer Advances
Durham, NC
(see also pancreatic, stomach) P|ase ll
(919) 361-2162
PV701
(replication-competent oncolytic
virus)
we||slal 8|o|oç|cs
Gaithersburg, MD
(see also cervical) P|ase ll
(210) ê83-2500
ramucirumab
(lVC-11218)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
(see also breast, stomach) P|ase lll
(800) 515-59Z9
regorafenib Bayer HealthCare Pharmaceuticals
Wayne, NJ
metastatic colorectal cancer
(Fast Track)
(see also kidney, lung, solid tumors,
stomach)
P|ase lll
(888) 812-283Z
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
(see also brain, head/neck, lung,
ovarian, pancreatic, sarcoma,
skin, solid tumors)
P|ase l
(103) êZ0-Z3ZZ
Medicines in Development for Cancer
Medicines in Development Cancer 2012
22
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
RG7160
(EGFR inhibitor)
Roche
Nutley, NJ
second-line metastatic colorectal
cancer (combination therapy)
P|ase ll
(9Z3) 235-5000
R0Z111
(EGFL7 inhibitor)
Genentech
South San Francisco, CA
(see also lung) P|ase ll
(800) ê2ê-3553
RIGScan™
luror-spec|lc, rad|o-|aoe|ed
monoclonal antibody targeting
agent
Navidea Biopharmaceuticals
Dublin, OH
metastatic colorectal cancer
(diagnosis)
application submitted
(800) 793-0079
robatumumab Merck
Whitehouse Station, NJ
(see also sarcoma, solid tumors) P|ase ll corp|eled
(800) 672-6372
3yr001 Symphogen
Lyngby, Denmark
metastatic colorectal cancer P|ase ll
www.symphogen.com
TAS-102 Taiho Pharma U.S.A.
Princeton, NJ
P|ase l
(ê09) Z50-5300
telatinib ACT Biotech
San Francisco, CA
(see also stomach) P|ase l
(115) 230-3900
TF2
(pretargeted radioimmuno-
therapy)
lrrurored|cs
Morris Plains, NJ
colorectal cancer P|ase l
(9Z3) ê05-8200
ThermoDox
®
doxorubicin liposomal
Celsion
Lawrenceville, NJ
adjuvant inoperable/unresectable,
metastatic colorectal cancer
(see also breast, liver)
P|ase ll
(609) 896-9100
tigatuzumab
(arl|-0R5 arl|oody)
Daiichi Sankyo
Parsippany, NJ
(see also breast, liver, lymphoma,
ovarian, pancreatic)
P|ase l
(9Z3) 911-2ê00
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
(see also kidney, liver, lung,
pancreatic, sarcoma, other)
P|ase l/ll
(Z81) 991-0300
(9Z3) 911-2ê00
tivozanib
(A3P1130/Av-951)
Astellas Pharma US
0eerle|o, lL
AVEO Pharmaceuticals
Cambridge, MA
colorectal cancer
(combination therapy)
(see also breast, kidney)
P|ase ll
(800) ê95-1321
(ê1Z) 299-5000
trebananib
(AMG386)
Amgen
Tnousano Daks, 0/
(see also breast, kidney, liver,
ovarian, stomach, other)
P|ase ll
(800) ZZ2-ê13ê
Tykerb
®
lapatinib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
metastatic colorectal cancer
(see also breast, head/neck,
stomach)
P|ase ll
(888) 825-5219
Medicines in Development for Cancer
Medicines in Development Cancer 2012
23
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
Vectibix
®
panitumumab
Amgen
Tnousano Daks, 0/
lrsl-||re ard secord-||re co|orecla|
cancer
(see also head/neck)
application submitted
(800) ZZ2-ê13ê
Xeloda
®
capecitabine
Genentech
South San Francisco, CA
lrsl-||re ard secord-||re relaslal|c
colorectal cancer
(combination therapy)
(see also brain, liver, stomach)
application submitted
(800) ê2ê-3553
Zaltrap™
al|oercepl
Regeneron Pharmaceuticals
Tarryroun, hY
3arol u3
Bridgewater, NJ
second-line metastatic colorectal
cancer
(see also prostate)
application submitted
(911) 315-Z100
(800) 981-2191
Zelboraf
®
vemurafenib
Genentech
South San Francisco, CA
Plexxikon
Berkeley, CA
(see also brain, other) P|ase l
(800) ê2ê-3553
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
ACE-011
(dalantercept)
Acceleron Pharma
Cambridge, MA
(see also multiple myeloma) P|ase ll
(ê1Z) ê19-9200
afatinib
(8l8w2992)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
second-line head/neck cancer
(see also breast, brain, lung)
P|ase ll
(800) 213-012Z
AP531ê Access Pharmaceuticals
0a||as, TX
P|ase ll
(211) 905-5100
EZ050 Eisai
Woodcliff Lake, NJ
(see also brain, liver, skin, solid
tumors, stomach)
P|ase l/ll
(888) 122-1Z13
foretinib
(GSK1363089)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also kidney, liver, lung) P|ase ll corp|eled
(888) 825-5219
GL-0810
(Orphan Drug)
Gliknik
Baltimore, MD
P|ase l
www.gliknik.com
GL-0817
(Orphan Drug)
Gliknik
Baltimore, MD
(see also multiple myeloma) P|ase l
www.gliknik.com
HF-10 Takara Bio
Shiga, Japan
P|ase l
www.takara-bio.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
24
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
lV0-2055
(TLR9 agonist)
ldera P|arraceul|ca|s
Cambridge, MA
second-line head and neck cancer
(combination therapy)
(see also colorectal, lung)
P|ase ll
(ê1Z) êZ9-5000
lRX-2 lRX T|erapeul|cs
New York, NY
(Fast Track) P|ase ll
(212) 582-1199
Lymphoseek
®
Tc-99m tilmanocept
Navidea Pharmaceuticals
Dublin, OH
head and neck cancer (diagnosis)
(see also breast, skin)
P|ase lll
(ê11) Z93-Z500
Multikine
®
leukocyte interleukin
(Orphan Drug)
CEL-3Cl
Vienna, VA
lrsl-||re |ead ard rec| carcer P|ase lll
(Z03) 50ê-91ê0
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also breast, colorectal, kidney,
leukemia, liver, lung, multiple
myeloma, ovarian, other)
P|ase ll
(888) 812-293Z
OBP-301 Oncolys Biopharma
Tokyo, Jaµan
(see also breast, liver, lung) P|ase l
www.oncolys.com
PX-866 Oncothyreon
Seattle, WA
head and neck cancer (combination
therapy)
(see also brain, lung, prostate)
P|ase ll
(206) 801-2100
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
metastatic head and neck cancer
(combination therapy)
(see also brain, colorectal, lung,
ovarian, pancreatic, sarcoma, skin,
solid tumors)
P|ase lll
(103) êZ0-Z3ZZ
R0Z59Z
(EGFR antagonist)
Genentech
South San Francisco, CA
P|ase ll
(800) ê2ê-3553
seliciclib
(CYC202)
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
nasopharyngeal cancer
(see also solid tumors)
P|ase ll
(908) 51Z-Z330
Tarceva
®
erlotinib
Genentech
South San Francisco, CA
03l P|arraceul|ca|s
Farmingdale, NY
lrsl-||re |ead/rec| carcer
(combination therapy)
(see also brain, breast, leukemia,
liver, lung, other)
P|ase ll
(800) ê2ê-3553
(631) 962-0600
TAS-106 Taiho Pharma U.S.A.
Princeton, NJ
P|ase ll
(ê09) Z50-5300
Medicines in Development for Cancer
Medicines in Development Cancer 2012
25
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
terameprocol Erimos Pharmaceuticals
lousron, TX
head and neck cancer (intratumoral)
(see also brain, cervical, solid
tumors, other)
P|ase l
(Z13) 511-2000
TNFerade™
golnerminogene pradenovec
GenVec
Gaithersburg, MD
(see also prostate, skin, stomach) P|ase l/ll corp|eled
(8ZZ) 913-ê832
Tykerb
®
lapatinib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
head and neck squamous cell
carcinoma (resectable disease)
(see also breast, colorectal, stomach)
P|ase lll
(888) 825-5219
v81-815
(Orphan Drug)
Viventia Biotechnologies
Mississauga, Canada
(Fast Track)
(see also bladder)
P|ase ll
(905) 3ê2-29Z3
Vectibix
®
panitumumab
Amgen
Tnousano Daks, 0/
lrsl-||re |ead ard rec| carcer
(see also colorectal)
--------------------------------------------------
second-line head and neck cancer
P|ase lll
(800) ZZ2-ê13ê
-------------------------------------------
P|ase ll
(800) ZZ2-ê13ê
KIDNEY CANCER
Product Name Sponsor Indication Development Status
$ÀQLWRU
®
everolimus
Novartis Pharmaceuticals
East Hanover, NJ
hepatocellular carcinoma
(see also breast, lymphoma)
P|ase ll
(888) 669-6682
AGS-003
(personalized dendritic cell
vaccine)
Argos Therapeutics
Durham, NC
renal cancer (combination therapy)
(Fast Track)
--------------------------------------------------
metastatic renal cancer
(monotherapy)
P|ase ll
(919) 287-6300
-------------------------------------------
P|ase ll
(919) 287-6300
AMG 172 Amgen
Tnousano Daks, 0/
P|ase l
(800) ZZ2-ê13ê
anti-PD1
(8V3-93ê558)
Bristol-Myers Squibb
Princeton, NJ
renal cell carcinoma
(see also lung, skin)
P|ase ll
(800) 332-205ê
8NC105 Bionomics
Tneoarron, /usrra||a
P|ase ll
www.bionomics.com.au
cabozantinib
(XL181)
Exelixis
South San Francisco, CA
renal cell carcinoma
(see also breast, lung, ovarian,
prostate, other)
P|ase l
(ê50) 83Z-Z000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
26
KIDNEY CANCER
Product Name Sponsor Indication Development Status
CVX 060
(PF-0185ê881)
(Ang2 antagonist)
Plzer
New York, NY
renal cell carcinoma
(see also solid tumors)
P|ase ll
(8ê0) Z32-515ê
CYT107
(interleukin-7)
Cytheris
Rockville, MD
(see also skin) P|ase l
(301) 231-0151
entinostat Syndax Pharmaceuticals
Waltham, MA
(see also breast, colorectal,
leukemia, lung, lymphoma)
P|ase l/ll
(Z81) 119-1100
foretinib
(GSK1363089)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also head/neck, liver, lung) P|ase ll
(888) 825-5219
lVA901
(cancer vaccine)
immatics biotechnologies
Tueo|ngen, Sermany
renal cancer P|ase lll
www.immatics.com
Inlyta
®
axitinib
(Orphan Drug)
Plzer
New York, NY
advanced renal cell carcinoma in
treatment-naive patients
(see also liver, other)
P|ase lll
(8ê0) Z32-515ê
Istodax
®
romidepsin
Celgene
Summit, NJ
renal cancer
(see also pancreatic, prostate, other)
P|ase ll
(908) 673-9000
L8l589
(panobinostat)
Novartis Pharmaceuticals
East Hanover, NJ
renal cancer
(see also leukemia, multiple
myeloma, prostate, solid tumors)
P|ase ll
(888) 669-6682
linifanib Abbott Laboratories
Abbott Park, IL
renal cancer
(see also breast, colorectal, liver,
lung)
P|ase ll
(81Z) 93Z-ê100
L0R-2010
(Orphan Drug)
Lorus Therapeutics
Toronro, 0anaoa
metastatic renal cancer
(see also breast, colorectal,
leukemia, prostate)
P|ase ll
(11ê) Z98-1200
naptumomab estafenatox Active Biotech
Lund, Sweden
(see also lung, pancreatic) P|ase l corp|eled
www.activebiotech.com
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
renal cell carcinoma
(adjuvant therapy)
(see also breast, colorectal,
head/neck, leukemia, liver, lung,
multiple myeloma, ovarian, other)
P|ase lll
(888) 812-293Z
Oncophage
®
vitespen
(Orphan Drug)
Agenus
Lexington, MA
renal cell carcinoma (Fast Track) P|ase ll
(Z81) êZ1-1100
03l-02Z
(TORC1/TORC2 inhibitor)
03l P|arraceul|ca|s
Farmingdale, NY
renal cancer
(see also lymphoma)
P|ase ll
(631) 962-0600
Medicines in Development for Cancer
Medicines in Development Cancer 2012
27
KIDNEY CANCER
Product Name Sponsor Indication Development Status
perifosine AEterna Zentaris
Basking Ridge, NJ
metastatic renal cancer
(see also brain, colorectal, leukemia,
lung, lymphoma, multiple myeloma,
sarcoma, solid tumors, stomach)
P|ase ll
(908) ê2ê-5128
Redectane
®
ç|rerlux|rao l-121
companion diagnostic
w||ex
Munich, Germany
renal cancer (diagnosis) P|ase lll corp|eled
www.wilex.de
regorafenib Bayer HealthCare Pharmaceuticals
Wayne, NJ
renal cancer
(see also colorectal, lung,
solid tumors, stomach)
P|ase ll
(888) 812-283Z
Rencarex
®
girentuximab
(Orphan Drug)
w||ex
Munich, Germany
clear cell renal cell carcinoma
(Fast Track)
P|ase lll
www.wilex.de
ridaforolimus ARlA0 P|arraceul|ca|s
Cambridge, MA
Merck
Whitehouse Station, NJ
(see also breast, lung, prostate,
sarcoma, other)
P|ase l
(800) 672-6372
30N-Z5
(vorsetuzumab mafodotin)
Seattle Genetics
Bothell, WA
renal cancer
(see also lymphoma)
P|ase l
(125) 52Z-1000
Sutent
®
sunitinib
(Orphan Drug)
Plzer
New York, NY
renal cell carcinoma
(adjuvant therapy)
P|ase lll
(8ê0) Z32-515ê
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
(see also colorectal, liver, lung,
pancreatic, sarcoma, other)
P|ase ll
(Z81) 991-0300
(9Z3) 911-2ê00
tivozanib
(A3P1130/Av-951)
Astellas Pharma US
0eerle|o, lL
AVEO Pharmaceuticals
Cambridge, MA
lrsl-||re rera| carcer
(see also breast, colorectal)
--------------------------------------------------
renal cancer
(combination therapy)
P|ase lll
(800) ê95-1321
(ê1Z) 299-5000
-------------------------------------------
P|ase l
(800) ê95-1321
(ê1Z) 299-5000
TKl258
(dovitinib)
Novartis Pharmaceuticals
East Hanover, NJ
(see also breast, multiple myeloma,
prostate, skin, other)
P|ase lll
(888) 669-6682
Torisel
®
temsirolimus
(Orphan Drug)
Plzer
New York, NY
renal cell carcinoma P|ase lll
(8ê0) Z32-515ê
trebananib
(AMG386)
Amgen
Tnousano Daks, 0/
renal cancer
(see also breast, colorectal, liver,
ovarian, stomach, other)
P|ase ll
(800) ZZ2-ê13ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
28
KIDNEY CANCER
Product Name Sponsor Indication Development Status
Tvl-K|drey-1
(cellular immunotherapy
vaccine)
TVAX Biomedical
Lenexa, KS
renal cell carcinoma P|ase ll corp|eled
(913) 192-2221
veglin
(VEGF antisense)
VasGene Therapeutics
Los Angeles, CA
(see also lung, skin) P|ase l
(323) 221-7818
Votrient™
pazopanib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also ovarian, other) P|ase lll
(888) 825-5219
LEUKEMIA
Product Name Sponsor Indication Development Status
A8l0-0501
(TALL101)
Abiogen Pharma
Pisa, Italy
chronic myeloid leukemia (CML) P|ase ll
www.abiogen.it
AC220
(quizartinib)
Ambit Biosciences
San Diego, CA
Astellas Pharma US
0eerle|o, lL
second-line and third-line acute
myeloid leukemia (AML)
(monotherapy)
(see also solid tumors)
--------------------------------------------------
acute lymphocytic leukemia (ALL)
(coro|ral|or l|erapy), lrsl-||re AVL
P|ase ll
(858) 331-2100
(800) ê95-1321
-------------------------------------------
P|ase l
(858) 331-2100
(800) ê95-1321
AC130
(JAK2 inhibitor)
Ambit Biosciences
San Diego, CA
P|ase l
(858) 331-2100
Adcetris™
brentuximab vedotin
Millennium Pharmaceuticals
Cambridge, MA
Seattle Genetics
Bothell, WA
(see also lymphoma) P|ase ll
(800) 390-5êê3
(125) 52Z-1000
AE03515ê
(XlAP |r||o|lor)
Aegera Therapeutics
Montreal, Canada
AML
(see also lymphoma)
--------------------------------------------------
chronic lymphocytic leukemia (CLL)
P|ase ll
(511) 288-5532
-------------------------------------------
P|ase l/ll
(511) 288-5532
AFX-9151 Afecta Pharmaceuticals
Irvine, CA
in clinical trials
(919) 253-1ê88
Medicines in Development for Cancer
Medicines in Development Cancer 2012
29
LEUKEMIA
Product Name Sponsor Indication Development Status
A03-005 Argos Therapeutics
Durham, NC
CLL P|ase l/ll
(919) 287-6300
AL0-151 Aldagen
Durham, NC
P|ase l
(919) 181-25Z1
ALXN6000
(samalizumab)
Alexion Pharmaceuticals
0nesn|re, 0T
CLL
(see also multiple myeloma)
P|ase l/ll corp|eled
(203) 2Z2-259ê
aminopterin Syntrix Biosystems
Auburn, WA
ALL P|ase ll corp|eled
(253) 833-8009
anti-CD22/CD19 mAb-toxin
conjugate
Abiogen Pharma
Pisa, Italy
ALL P|ase l
www.abiogen.com
AR-12 Arno Therapeutics
Flemington, NJ
CLL
(see also lymphoma, multiple
myeloma)
P|ase l/ll
(862) 703-7170
AR-67 Arno Therapeutics
Flemington, NJ
myelodysplastic syndromes
(see also brain, solid tumors)
P|ase ll
(862) 703-7170
Arranon
®
nelarabine
(Orphan Drug)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
lrsl-||re ALL
(see also lymphoma)
--------------------------------------------------
second-line ALL
P|ase lll
(888) 669-6682
-------------------------------------------
P|ase l/ll
(888) 669-6682
ARRY-520
(KSP inhibitor)
Array BioPharma
Boulder, CO
AML
(see also multiple myeloma,
solid tumors)
P|ase ll
(8ZZ) ê33-213ê
Arzerra
®
ofatumumab
(Orphan Drug)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
lrsl-||re CLL (coro|ral|or l|erapy)
(see also lymphoma)
P|ase lll
(888) 825-5219
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
CLL
(see also brain, lung, lymphoma,
prostate, stomach)
P|ase ll
(ê10) 108-0301
AT-10ê/0eo|o-1113 Ascenta Therapeutics
Malvern, PA
Debiopharm
Lausanne, Switzerland
AML
(see also lymphoma)
P|ase l
(ê10) 108-0301
www.debiopharm.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
30
LEUKEMIA
Product Name Sponsor Indication Development Status
ATZ519
(CDK inhibitor)
Astex Pharmaceuticals
Dublin, CA
CLL
(see also lymphoma, multiple
myeloma, solid tumors)
P|ase ll
(925) 5ê0-0100
AT9283
(aurora/Jak2 inhibitor)
(Orphan Drug)
Astex Pharmaceuticals
Dublin, CA
AML
(see also lymphoma, multiple
myeloma, solid tumors)
P|ase l/ll
(925) 5ê0-0100
AVL-292
(Btk inhibitor)
Celgene
Summit, NJ
second-line CLL
(combination therapy)
(see a|so |yrp|ora, urspec|led)
P|ase l
(908) 673-9000
AZD1208
(Pim kinase inhibitor)
AstraZeneca
Wilmington, DE
AML P|ase l
(800) 236-9933
bafetinib
(Orphan Drug)
CytRx
Los Angeles, CA
second-line CLL
(see also brain, prostate)
--------------------------------------------------
ALL, CML
P|ase ll
(310) 82ê-5ê18
-------------------------------------------
P|ase l
(310) 82ê-5ê18
Bcl-2 inhibitor
(ABT-199/GDC-0199)
Abbott Laboratories
Abbott Park, IL
Genentech
South San Francisco, CA
CLL
(see also lymphoma)
P|ase l
(81Z) 93Z-ê100
(800) ê2ê-3553
belinostat Spectrum Pharmaceuticals
Henderson, NV
AML
(see also colorectal, liver, lung,
lymphoma, ovarian, other)
P|ase l/ll
(Z02) 835-ê300
8l-811283
(aurora kinase B inhibitor)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
AML
(see also solid tumors)
P|ase l/ll
(800) 213-012Z
8l-83ê82ê 8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
CLL P|ase l
(800) 213-012Z
bosutinib Plzer
New York, NY
previously treated CML application submitted
(8ê0) Z32-515ê
cenersen
(Orphan Drug)
Eleos
Omaha, NE
AML P|ase ll corp|eled
(102) 393-3031
Ceplene
®
histamine dihydrochloride
injection
(Orphan Drug)
EpiCept
Tarryroun, hY
AML application submitted
(911) ê0ê-3500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
31
LEUKEMIA
Product Name Sponsor Indication Development Status
CLL immunotherapeutic vaccine MaxCyte
Gaithersburg, MD
CLL P|ase l/ll
(301) 911-1Z00
Clolar
®
clofarabine injection
(Orphan Drug)
Genzyme
Cambridge, MA
AML (adults) P|ase lll
(ê1Z) 252-Z500
CNDO-109
(tumor activated NK cells)
Coronado Biosciences
Burlington, MA
AML P|ase l
(781) 238-6621
CPX-351
(cytarabine/daunorubicin)
(Orphan Drug)
Celator Pharmaceuticals
Princeton, NJ
AML P|ase ll
(ê09) 213-0123
CT-011 CureTech
Yavne, Israel
second-line AML
(combination therapy)
(see also colorectal, lymphoma)
P|ase ll
www.curetechbio.com
CwP232291 Jw P|arraceul|ca|
Seoul, South Korea
AML P|ase l
Dacogen
®
decitabine
Eisai
Woodcliff Lake, NJ
AML
--------------------------------------------------
pediatric AML
application submitted
(888) 122-1Z13
-------------------------------------------
P|ase ll
(888) 122-1Z13
danusertib Nerviano Medical Sciences
Nerviano, Italy
CML P|ase ll
www.nervianoms.com
DCC-2036 Deciphera Pharmaceuticals
Lawrence, KS
ALL, CML
--------------------------------------------------
AML
P|ase l/ll
(Z85) 830-2100
-------------------------------------------
P|ase l
(Z85) 830-2100
0C03-1501A Genentech
South San Francisco, CA
CLL
(see also lymphoma)
P|ase l
(800) ê2ê-3553
DCDT-2980S Genentech
South San Francisco, CA
recurrent CLL
(see also lymphoma)
P|ase l
(800) ê2ê-3553
Elacyt™
elacytarabine
(Orphan Drug)
Clavis Pharma
Oslo, Norway
late-stage AML
(Fast Track)
--------------------------------------------------
early-stage AML
P|ase lll
www.clavispharma.com
-------------------------------------------
P|ase ll
www.clavispharma.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
32
LEUKEMIA
Product Name Sponsor Indication Development Status
elesclomol Synta Pharmaceuticals
Lexington, MA
AML
(see also lung, ovarian)
P|ase l
(Z81) 2Z1-8200
entinostat Syndax Pharmaceuticals
Waltham, MA
(see also breast, colorectal, kidney,
lung, lymphoma)
P|ase ll
(Z81) 119-1100
epratuzumab
(Orphan Drug)
lrrurored|cs
Morris Plains, NJ
UCB
Atlanta, GA
ALL in children (combination therapy)
(see also lymphoma)
P|ase ll
(9Z3) ê05-8200
forodesine
(Orphan Drug)
BioCryst Pharmaceuticals
Durham, NC
CLL
(see also lymphoma)
P|ase ll
(919) 859-1302
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
ALL, AML, CML
(see also breast, colorectal, liver,
lung, multiple myeloma, pancreatic,
prostate, skin, stomach)
--------------------------------------------------
myelodysplastic syndromes
P|ase l/ll
(Z81) 2Z1-8200
-------------------------------------------
P|ase l
(Z81) 2Z1-8200
GNKG-168 38l 8|olec|
Tokyo, Jaµan
CLL P|ase l
www.sbibiotech.jp
GRNVAC1
(dendritic cell vaccine)
Argos Therapeutics
Durham, NC
Geron
Menlo Park, CA
AML
(see also prostate)
P|ase ll
(ê50) 1Z3-ZZ00
GS-1101
(Pl3K de|la |r||o|lor)
Gilead Sciences
Foster City, CA
second-line CLL
(see also lymphoma)
P|ase lll
(800) 115-3235
GSK2110183
(protein kinase B inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also multiple myeloma) P|ase ll
(888) 825-5219
03K21305Z9A
(wT1 arl|çer-spec|lc carcer
immunotherapeutic)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
AML P|ase ll
(888) 825-5219
GVAX
®
Leukemia
cancer vaccine
(Orphan Drug)
BioSante Pharmaceuticals
Lincolnshire, IL
AML, CML P|ase ll
(81Z) 1Z8-0500
luV195-Ac-225
(||rluzurao Ac-225)
Actinium Pharmaceuticals
Newark, NJ
AML P|ase l
(9Z3) 311-ê500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
33
LEUKEMIA
Product Name Sponsor Indication Development Status
luV195-8|-213
(lintuzumab Bi-213)
Actinium Pharmaceuticals
Newark, NJ
AML P|ase l/ll
(9Z3) 311-ê500
luV195/r0e|
(lintuzumab-gelonin conjugate)
Targa Therapeutics
San Diego, CA
AML, CML, myelodysplastic
syndromes
P|ase l
(858) 183-êê00
ibrutinib
(PCl-32Zê5)
Janssen Biotech
Horsham, PA
Pharmacyclics
Sunnyvale, CA
CLL
(see also lymphoma, multiple
myeloma)
P|ase l/ll
(800) 52ê-ZZ3ê
(108) ZZ1-0330
imatinib sublingual Kedem Pharmaceuticals
Mesa, AZ
CML in clinical trials
(ê01) 321-1211
imetelstat Geron
Menlo Park, CA
CLL
(see also breast, lung, multiple
myeloma)
P|ase l/ll
(ê50) 1Z3-ZZ00
Imprime PGG
®
Biothera
Eagan, MN
CLL
(see also colorectal, lung, skin)
P|ase l/ll
(ê51) êZ5-0300
lNN0-305
(wT-1 vacc|re)
CytRx
Los Angeles, CA
AML, myelodysplastic syndromes
(see also solid tumors)
P|ase l
(310) 82ê-5ê18
inotuzumab ozogamicin Plzer
New York, NY
ALL
(see also lymphoma)
P|ase l
(8ê0) Z32-515ê
l3F35
(recombinant
immunotherapeutic vaccine)
Memgen
San Diego, CA
CLL (monotherapy)
(see also lymphoma)
--------------------------------------------------
refractory metastatic CLL
(combination therapy)
P|ase ll
(858) 521-5100
-------------------------------------------
P|ase l
(858) 521-5100
JNJ-2ê181585
(quisinostat)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
myelodysplastic syndromes,
metastatic leukemia
(see also lymphoma)
P|ase l
(800) 81Z-528ê
JVRS-100
(lipid-DNA complex vaccine)
Colby Pharmaceutical
San Jose, CA
P|ase l
(ê50) 333-3152
KX2-391 Kinex Pharmaceuticals
Buffalo, NY
AML in the elderly
(see also prostate)
P|ase l
(716) 898-8626
Medicines in Development for Cancer
Medicines in Development Cancer 2012
34
LEUKEMIA
Product Name Sponsor Indication Development Status
L8l589
(panobinostat)
Novartis Pharmaceuticals
East Hanover, NJ
ALL, AML, myelodysplastic
syndromes
(see also kidney, multiple myeloma,
prostate, solid tumors)
P|ase ll
(888) 669-6682
L0E225
(erismodegib)
Novartis Pharmaceuticals
East Hanover, NJ
CML (combination therapy)
(see also pancreatic, solid tumors,
skin)
P|ase l
(888) 669-6682
lestaurtinib
(Orphan Drug)
Cephalon
Frazer, PA
AML P|ase ll
(ê10) 311-0200
leukemia DNA vaccine lrov|o P|arraceul|ca|s
Blue Bell, PA
University of Southampton
Southampton, United Kingdom
AML, CML P|ase ll
(8ZZ) 11ê-ê81ê
L0Z10
(activated T-cells)
Lentigen
Gaithersburg, MD
University of Pennsylvania
Philadelphia, PA
ALL, B-cell prolymphocytic leukemia,
CLL
(see also lymphoma)
P|ase l
(301) 52Z-1200
L0R-2010
(Orphan Drug)
Lorus Therapeutics
Toronro, 0anaoa
AML (combination therapy)
(see also breast, colorectal, kidney,
prostate)
--------------------------------------------------
CML, myelodysplastic syndromes
P|ase ll
(11ê) Z98-1200
-------------------------------------------
P|ase l
(11ê) Z98-1Z01
lurbinectedin PharmaMar
Madrid, Spain
(see also solid tumors) P|ase l
www.pharmamar.com
Marqibo
®
vincristine liposomal
(Orphan Drug)
Talon Therapeutics
San Mateo, CA
relapsed or refractory Philadelphia
chromosome-negative ALL
(Fast Track)
(see also lymphoma, skin, other)
--------------------------------------------------
ALL in the elderly (Fast Track)
application submitted
(ê50) 588-ê101
-------------------------------------------
P|ase lll
(ê50) 588-ê101
milatuzumab lrrurored|cs
Morris Plains, NJ
CLL (monotherapy)
(see also lymphoma, multiple
myeloma)
P|ase l/ll
(9Z3) ê05-8200
VK-Z95ê
(dinaciclib)
(Orphan Drug)
Merck
Whitehouse Station, NJ
CLL
(see also lymphoma)
P|ase ll
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012
35
LEUKEMIA
Product Name Sponsor Indication Development Status
VK-8212 Merck
Whitehouse Station, NJ
AML
(see also solid tumors)
P|ase l
(800) 672-6372
mocetinostat
(MGCD0103, HDAC inhibitor)
MethylGene
Montreal, Canada
CLL
(see also lymphoma, solid tumors)
P|ase ll corp|eled
(511) 33Z-3333
Mozobil
®
plerixafor
Genzyme
Cambridge, MA
AML P|ase l
(ê1Z) 252-Z500
navitoclax
(ABT-263)
Abbott Laboratories
Abbott Park, IL
lrsl-||re CLL (coro|ral|or l|erapy)
(see also lung, lymphoma)
--------------------------------------------------
CLL, lymphoid leukemia
P|ase ll
(81Z) 93Z-ê100
-------------------------------------------
P|ase l
(81Z) 93Z-ê100
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
AML, myelodysplastic syndromes
(see also breast, colorectal,
head/neck, kidney, liver, lung,
multiple myeloma, ovarian, other)
P|ase l/ll
(888) 812-293Z
obatoclax
(Orphan Drug)
Cephalon
Frazer, PA
CLL
(see also lung, lymphoma, multiple
myeloma)
P|ase l/ll corp|eled
(ê10) 311-0200
obinutuzumab
(0A101/R0Z159)
8|oçer ldec
Weston, MA
Genentech
South San Francisco, CA
lrsl-||re CLL (coro|ral|or l|erapy)
(see also lymphoma)
P|ase lll
(Z81) 1ê1-2000
(800) ê2ê-3553
Omapro™
omacetaxine
(Orphan Drug)
Cephalon
Frazer, PA
second-line CML
(see also solid tumors)
--------------------------------------------------
AML, myelodysplastic syndromes
application submitted
(ê10) 311-0200
-------------------------------------------
P|ase ll
(ê10) 311-0200
0N 013105 Onconova Therapeutics
Newtown, PA
ALL
(see also lymphoma)
P|ase l
(2êZ) Z59-3ê80
oral azacitidine
(Orphan Drug)
Celgene
Summit, NJ
myelodysplastic syndromes
(Fast Track)
(see also lung, lymphoma,
solid tumors)
--------------------------------------------------
AML, CML
P|ase ll
(908) 673-9000
-------------------------------------------
P|ase l
(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
36
LEUKEMIA
Product Name Sponsor Indication Development Status
oral clofaribine Genzyme
Cambridge, MA
myelodysplastic syndromes P|ase l
(ê1Z) 252-Z500
0vl-123
(Orphan Drug)
0rcov|sla lrroval|ve T|erap|es
$an /nron|o, TX
TdT-positive leukemia P|ase l
(210) 677-6000
0X|1503 OXiGENE
South San Francisco, CA
AML, myelodysplastic syndromes P|ase l
(ê50) ê35-Z000
perifosine AEterna Zentaris
Basking Ridge, NJ
refractory metastatic CLL
(see also brain, colorectal, kidney,
lung, lymphoma, multiple myeloma,
sarcoma, solid tumors, stomach)
P|ase ll
(908) ê2ê-5128
PKC112
(midostaurin)
Novartis Pharmaceuticals
East Hanover, NJ
AML P|ase lll
(888) 669-6682
PLX3397
(CSF-1R kinase inhibitor)
Plexxikon
Berkeley, CA
recurrent or refractory AML
(see also brain, lymphoma,
solid tumors)
P|ase l/ll
(510) ê1Z-1000
ponatinib
(Orphan Drug)
ARlA0 P|arraceul|ca|s
Cambridge, MA
Philadelphia-positive ALL, CML
--------------------------------------------------
AML
P|ase ll
(ê1Z) 191-0100
-------------------------------------------
P|ase l
(ê1Z) 191-0100
PR101 Proacta
La Jolla, CA
AML P|ase l/ll
(858) ê12-038ê
Revlimid
®
lenalidomide
(Orphan Drug)
Celgene
Summit, NJ
CLL, myelodysplastic syndromes
(see also lymphoma)
P|ase lll
(908) 673-9000
rigosertib
(Orphan Drug)
Onconova Therapeutics
Newtown, PA
myelodysplastic syndromes
(intravenous)
(see also lymphoma, ovarian,
pancreatic)
--------------------------------------------------
CLL
--------------------------------------------------
AML
--------------------------------------------------
myelodysplastic syndromes (oral)
P|ase lll
(2êZ) Z59-3ê80
-------------------------------------------
P|ase ll
(2êZ) Z59-3ê80
-------------------------------------------
P|ase l/ll
(2êZ) Z59-3ê80
-------------------------------------------
P|ase l
(2êZ) Z59-3ê80
Medicines in Development for Cancer
Medicines in Development Cancer 2012
37
LEUKEMIA
Product Name Sponsor Indication Development Status
sapacitabine
(CYC682)
(Orphan Drug)
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
lrsl-||re AVL
(see also lung, solid tumors)
--------------------------------------------------
CLL (combination therapy),
myelodysplastic syndromes
P|ase lll
(908) 51Z-Z330
-------------------------------------------
P|ase ll
(908) 51Z-Z330
SB989
(pracinostat)
3¯8l0
Oakland, CA
myelodysplastic syndromes
(see also solid tumors, other)
P|ase l
(ê50) Z30-28ê0
381518
(pacritinib)
3¯8l0
Oakland, CA
myelodysplastic syndromes
--------------------------------------------------
myeloid leukemia
P|ase ll
(ê50) Z30-28ê0
-------------------------------------------
P|ase l/ll
(ê50) Z30-28ê0
SF1126
(Orphan Drug)
Semafore Pharmaceuticals
Indianapolis, IN
CLL
(see also multiple myeloma,
solid tumors)
P|ase l
(31Z) 8Zê-30Z5
30l110
(DNMT inhibitor)
Astex Pharmaceuticals
Dublin, CA
AML, myelodysplastic syndromes P|ase l/ll
(925) 5ê0-0100
3L-101
(recombinant fusion protein)
(Orphan Drug)
Stemline Therapeutics
New York, NY
AML, myelodysplastic syndromes P|ase l/ll
(ê1ê) 502-2310
tamibarotene
(Orphan Drug)
CytRx
Los Angeles, CA
acute promyelocytic leukemia (APL)
(Fast Track)
(see also lung)
--------------------------------------------------
APL (combination therapy)
P|ase ll
(310) 82ê-5ê18
-------------------------------------------
P|ase l
(310) 82ê-5ê18
Tarceva
®
erlotinib
Genentech
South San Francisco, CA
03l 0rco|oçy
Farmingdale, NY
myelodysplastic syndromes
(see also brain, breast, head/neck,
liver, lung, other)
P|ase ll
(800) ê2ê-3553
(631) 962-0600
Tasigna
®
nilotinib
(Orphan Drug)
Novartis Pharmaceuticals
East Hanover, NJ
CML (adolescents and children),
ALL (adolescents and children)
(see also skin, stomach)
P|ase ll
(888) 669-6682
Temodar
®
temozolomide
Merck
Whitehouse Station, NJ
AML
(see also lung)
P|ase ll
(800) 672-6372
TH-302 Threshold Pharmaceuticals
South San Francisco, CA
(see also brain, multiple myeloma,
pancreatic, sarcoma)
P|ase l
(ê50) 1Z1-8200
thiarabine Access Pharmaceuticals
0a||as, TX
(see also lymphoma) P|ase l/ll
(215) 901-5100
Medicines in Development for Cancer
Medicines in Development Cancer 2012
38
LEUKEMIA
Product Name Sponsor Indication Development Status
TL-32711
(birinapant)
TetraLogic Pharmaceuticals
Malvern, PA
AML
(see also solid tumors)
P|ase l/ll
(610) 889-9900
tosedostat
(Orphan Drug)
Chroma Therapeutics
Oxon, United Kingdom
AML P|ase ll
www.chromatherapeutics.com
trametinib GlaxoSmithKline
Pson. Tr|ang|e Park, h0
relapsed or refractory leukemia
(see also brain, lung, lymphoma,
multiple myeloma, pancreatic, skin)
P|ase lll
(888) 825-5219
Treanda
®
bendamustine
Cephalon
Frazer, PA
ALL in children, AML in children
(see also lymphoma, multiple
myeloma)
P|ase l/ll
(ê10) 311-0200
treosulfan Medac
Wedel, Germany
ALL, AML, myelodysplastic
syndromes
P|ase ll
www.medac.de
TRU-016
(humanized anti-CD37
therapeutic)
Emergent BioSolutions
Rockville, MD
CLL
(see also lymphoma)
P|ase ll
(301) Z95-1800
Velcade
®
bortezomib
Millennium Pharmaceuticals
Cambridge, MA
second-line T-cell prolymphocytic
leukemia
(see also lymphoma, other,
cancer-related)
P|ase ll
(800) 390-5êê3
veltuzumab
(Orphan Drug)
lrrurored|cs
Morris Plains, NJ
CLL
(see also lymphoma)
P|ase l/ll
(9Z3) ê05-8200
Vidaza
®
azacitidine
(Orphan Drug)
Celgene
Summit, NJ
AML in the elderly
(see also lymphoma)
P|ase lll
(908) 673-9000
vosaroxin
(Orphan Drug)
Sunesis Pharmaceuticals
South San Francisco, CA
second-line AML
(Fast Track)
(see also ovarian)
--------------------------------------------------
AML in the elderly
P|ase lll
(ê50) 2êê-3Z39
-------------------------------------------
P|ase ll
(ê50) 2êê-3Z39
XmAb
®
5574
(MOR208, anti-CD19 mAb)
MorphoSys
Planegg, Germany
Xencor
Monrovia, CA
recurrent CLL P|ase l
www.morphosys.com
(ê2ê) 305-5900
Zolinza
®
vorinostat
Merck
Whitehouse Station, NJ
AML, myelodysplastic syndromes
(see also breast, lung, lymphoma,
multiple myeloma, other)
P|ase ll
(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012
39
LIVER CANCER
Product Name Sponsor Indication Development Status
ALN-VSP Alnylam Pharmaceuticals
Cambridge, MA
P|ase l
(ê1Z) 551-8200
bavituximab Peregrine Pharmaceuticals
Tusr|n, 0/
(see also lung, pancreatic) P|ase l/ll
(Z15) 508-ê000
BAY 86-9766
(MEK inhibitor)
Ardea Biosciences
San Diego, CA
Bayer HealthCare Pharmaceuticals
Wayne, NJ
lrsl-||re ||ver carcer
(combination therapy)
(see also pancreatic)
P|ase ll
(888) 812-293Z
belinostat Spectrum Pharmaceuticals
Henderson, NV
inoperable/unresectable liver cancer
(see also colorectal, leukemia, lung,
lymphoma, ovarian, other)
P|ase l/ll
(Z02) 835-ê300
8ll8 022 8|oçer ldec
Cambridge, MA
(see also lung) P|ase l corp|eled
(617) 679-2000
brivanib
(VEGFR/FGFR kinase inhibitor)
Bristol-Myers Squibb
Princeton, NJ
lrsl-||re ||ver carcer,
liver cancer (TACE)
(see also colorectal, sarcoma)
P|ase lll
(800) 332-205ê
cixutumumab
(LY301221Z/lVC-A12)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
(see also lung) P|ase ll
(800) 515-59Z9
darinaparsin
(Zl0-101)
Zl0PlARV 0rco|oçy
New York, NY
(see also lymphoma, multiple
myeloma, solid tumors)
P|ase ll
(ê1ê) 211-0Z00
DC Bead
®
doxorubicin-eluting beads
Bayer HealthCare Pharmaceuticals
Wayne, NJ
Biocompatibles
Surrey, United Kingdom
P|ase ll
(888) 812-293Z
EZ050 Eisai
Woodcliff Lake, NJ
(see also brain, head/neck, skin,
solid tumors, stomach)
P|ase l/ll
(888) 122-1Z13
foretinib
(GSK1363089)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also head/neck, kidney, lung) P|ase l
(888) 825-5219
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
(see also breast, colorectal,
leukemia, lung, multiple myeloma,
pancreatic, prostate, skin, stomach)
P|ase ll
(Z81) 2Z1-8200
Inlyta
®
axitinib
Plzer
New York, NY
(see also kidney, other) P|ase ll
(8ê0) Z32-515ê
irinotecan eluting beads 8|ocorpal|o|es lrlerral|ora|
Surrey, United Kingdom
liver metastases from colorectal
cancer
P|ase ll
www.biocompatibles.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
40
LIVER CANCER
Product Name Sponsor Indication Development Status
JX-591
(pexastimogene devacirepvec)
(Orphan Drug)
Jennerex Biotherapeutics
San Francisco, CA
(see also colorectal) P|ase ll
(115) 281-888ê
lansoprazole
(Orphan Drug)
Apricus Biosciences
San Diego, CA
lrsl-||re ||ver carcer P|ase ll
(858) 220-8011
linifanib Abbott Laboratories
Abbott Park, IL
lrsl-||re ||ver carcer (rorol|erapy)
(see also breast, colorectal, kidney,
lung)
P|ase lll
(81Z) 93Z-ê100
mapatumumab Human Genome Sciences
Rockville, MD
liver cancer (combination therapy)
(see also lung, multiple myeloma)
P|ase ll
(301) 309-8501
MB07133
(HepDirect HepB inhibitor)
Ligand Pharmaceuticals
La Jolla, CA
inoperable/unresectable liver cancer P|ase l/ll corp|eled
(858) 550-Z500
melphalan drug delivery system Delcath Systems
New York, NY
inoperable/unresectable liver cancer application submitted
(212) 189-2100
ruparloslal (Pl-88) Progen Pharmaceuticals
Queensland, Australia
liver cancer (Fast Track)
(see also skin)
P|ase lll
www.progen.com.au
Nexavar
®
sorafenib
(Orphan Drug)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
heptocellular carcinoma
(adjuvant therapy)
(see also breast, colorectal,
head/neck, kidney, leukemia, lung,
multiple myeloma, ovarian, other)
P|ase lll
(888) 812-293Z
NV-1020 Catherex
Philadelphia, PA
P|ase l/ll corp|eled
OBP-301 Oncolys Biopharma
Tokyo, Jaµan
(see also breast, head/neck, lung) P|ase l
www.oncolys.com
PEG arginine deiminase
(A0l-PE0 20)
Polaris Pharmaceuticals
San Diego, CA
hepatocellular carcinoma
(see also prostate, skin, other)
P|ase lll
(858) 152-êê88
PHY906 PhytoCeutica
heu laven, 0T
(see also colorectal, pancreatic,
cancer-related)
P|ase l/ll corp|eled
(203) ZZZ-31ê2
PV-10
(rose bengal sodium)
(Orphan Drug)
Provectus Pharmaceuticals
rnoxv|||e, Th
liver cancer, liver metastases
(see also skin)
P|ase l
(8êê) 591-5999
RG7686 Roche
Nutley, NJ
metastatic liver cancer
(combination therapy)
P|ase ll
(9Z3) 235-5000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
41
LIVER CANCER
Product Name Sponsor Indication Development Status
Tarceva
®
erlotinib
Genentech
South San Francisco, CA
03l P|arraceul|ca|s
Farmingdale, NY
lrsl-||re |roperao|e/urreseclao|e ||ver
cancer (combination therapy)
(see also brain, breast, head/neck,
leukemia, lung, other)
--------------------------------------------------
second-line liver cancer
(combination therapy)
P|ase lll
(800) ê2ê-3553
(631) 962-0600
-------------------------------------------
P|ase ll
(800) ê2ê-3553
(631) 962-0600
TGF-ß R1 inhibitor
(LY215Z299)
Eli Lilly
Indianapolis, IN
(see also brain) P|ase ll
(800) 515-59Z9
ThermoDox
®
doxorubicin liposomal
(Orphan Drug)
Celsion
Lawrenceville, NJ
lrsl-||re |roperao|e/urreseclao|e ||ver
cancer (Fast Track)
(see also breast, colorectal)
P|ase lll
(609) 896-9100
tigatuzumab
(arl|-0R5 arl|oody)
Daiichi Sankyo
Parsippany, NJ
(see also breast, colorectal,
lymphoma, ovarian, pancreatic)
P|ase ll
(9Z3) 911-2ê00
tivantinib (ARQ 197) ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
second-line liver cancer
(see also colorectal, kidney, lung,
pancreatic, sarcoma, other)
--------------------------------------------------
liver cancer (combination therapy)
P|ase ll
(Z81) 991-0300
(9Z3) 911-2ê00
------------------------------------------
P|ase l
(Z81) 991-0300
(9Z3) 911-2ê00
trebananib
(AMG386)
Amgen
Tnousano Daks, 0/
(see also breast, colorectal, kidney,
ovarian, stomach, other)
P|ase ll
(800) ZZ2-ê13ê
Xeloda
®
capecitabine
Genentech
South San Francisco, CA
biliary cancer (combination therapy)
(see also brain, colorectal, stomach)
P|ase ll
(800) ê2ê-3553
Zadaxin
®
thymalfasin alfa 1
(Orphan Drug)
SciClone Pharmaceuticals
Foster City, CA
(see also skin) P|ase ll/lll
(ê50) 358-315ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
42
LUNG CANCER
Product Name Sponsor Indication Development Status
Abraxane
®
albumin-bound paclitaxel
Celgene
Summit, NJ
lrsl-||re ror-sra||-ce|| |urç carcer
(NSCLC)
(see also bladder, breast, ovarian,
pancreatic, skin)
application submitted
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
NSCLC
(see also brain, breast, colorectal,
lymphoma, ovarian, prostate, skin,
other)
P|ase ll
(81Z) 93Z-ê100
AC180
(pan-HER inhibitor)
Ambit Biosciences
San Diego, CA
NCSLC
(see also brain, breast)
P|ase l
(858) 331-2100
Actimid
®
pomalidomide
Celgene
Summit, NJ
small-cell lung cancer (SCLC)
(see also lymphoma, multiple
myeloma, pancreatic)
P|ase l/ll
(908) 673-9000
afatinib
(8l8w2992)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
lrsl-||re N3CLC
(see also brain, breast, head/neck)
--------------------------------------------------
second-line NSCLC (Fast Track)
P|ase lll
(800) 213-012Z
-------------------------------------------
P|ase ll/lll
(800) 213-012Z
Alimta
®
pemetrexed
Eli Lilly
Indianapolis, IN
lrsl-||re ard ra|rlerarce N3CLC P|ase lll
(800) 515-59Z9
AMG888/U3-1287
(anti-HER3 antibody)
Amgen
Tnousano Daks, 0/
Daiichi Sankyo
Parsippany, NJ
NSCLC P|ase ll
(800) ZZ2-ê13ê
(9Z3) 911-2ê00
amrubicin
(Orphan Drug)
Celgene
Summit, NJ
SCLC (Fast Track)
(see also breast)
--------------------------------------------------
lrsl-||re 3CLC
P|ase lll
(908) 673-9000
-------------------------------------------
P|ase ll
(908) 673-9000
amuvatinib
(VP1Z0)
Astex Pharmaceuticals
Dublin, CA
SCLC (combination therapy)
(see also lymphoma)
P|ase ll
(925) 5ê0-0100
anti-PD1
(8V3-93ê558)
Bristol-Myers Squibb
Princeton, NJ
(see also kidney, skin) P|ase ll
(800) 332-205ê
AP26113 ARlA0 P|arraceul|ca|s
Cambridge, MA
NSCLC P|ase l
(ê1Z) 191-0100
apricoxib
(TG01)
Tragara Pharmaceuticals
San Diego, CA
second-line NSCLC
(combination therapy)
(see also pancreatic)
P|ase ll
(858) 350-ê900
Medicines in Development for Cancer
Medicines in Development Cancer 2012
43
LUNG CANCER
Product Name Sponsor Indication Development Status
astuprotimut-R
(VA0E-A3 arl|çer-spec|lc
cancer immunotherapeutic)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
adjuvant NSCLC
(see also skin)
P|ase lll
(888) 825-5219
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
NSCLC (combination therapy),
SCLC (combination therapy)
(see also brain, leukemia, lymphoma,
prostate, stomach)
P|ase ll
(ê10) 108-0301
AUY922
(Hsp90 inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
third-line NSCLC
(see also breast, colorectal, multiple
myeloma, stomach)
--------------------------------------------------
second-line late-stage NSCLC
(combination therapy)
P|ase ll
(888) 669-6682
-------------------------------------------
P|ase l/ll
(888) 669-6682
Avastin
®
bevacizumab
Genentech
South San Francisco, CA
adjuvant NSCLC
(see also brain, breast, colorectal,
ovarian, other)
P|ase lll
(800) ê2ê-3553
bavituximab Peregrine Pharmaceuticals
Tusr|n, 0/
lrsl-||re N3CLC,
second-line NSCLC
(see also liver, pancreatic)
P|ase ll
(Z15) 508-ê000
belinostat Spectrum Pharmaceuticals
Henderson, NV
mesothelioma
(see also colorectal, leukemia, liver,
lymphoma, ovarian, other)
--------------------------------------------------
NSCLC
--------------------------------------------------
SCLC
P|ase ll corp|eled
(Z02) 835-ê300
-------------------------------------------
P|ase l/ll
(Z02) 835-ê300
-------------------------------------------
P|ase l
(Z02) 835-ê300
8ll8 022 8|oçer ldec
Cambridge, MA
NSCLC
(see also liver)
P|ase l corp|eled
(617) 679-2000
BKM120
(Pl3K |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
late-stage NSCLC
(see also brain, breast, other)
P|ase ll
(888) 669-6682
cabozantinib
(XL181)
Exelixis
South San Francisco, CA
NSCLC
(see also breast, kidney, ovarian,
prostate, other)
P|ase l/ll
(ê50) 83Z-Z000
C8P-501
(peptide mimetic)
CanBas
Shizouka, Japan
mesothelioma (combination therapy),
lrsl-||re N3CLC (coro|ral|or
therapy)
(see also solid tumors)
P|ase ll
www.canbas.co.jp
Medicines in Development for Cancer
Medicines in Development Cancer 2012
44
LUNG CANCER
Product Name Sponsor Indication Development Status
CC-223
(mTOR inhibitor)
Celgene
Summit, NJ
NSCLC
(see also lymphoma, multiple
myeloma)
P|ase l
(908) 673-9000
CEP-9722
(PARP inhibitor)
Cephalon
Frazer, PA
NSCLC (combination therapy)
(see also lymphoma)
P|ase ll
(ê10) 311-0200
Chk1 inhibitor
(LY2603618)
Eli Lilly
Indianapolis, IN
NSCLC
(see also pancreatic)
P|ase ll
(800) 515-59Z9
cixutumumab
(LY301221Z/lVC-A12)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
NSCLC
(see also liver)
P|ase ll
(800) 515-59Z9
CLR1101-l-121 Novelos Therapeutics
Madison, WI
NSCLC (diagnosis) P|ase l/ll
(ê08) 111-8120
CLR1101-l-131 Novelos Therapeutics
Madison, WI
NSCLC (diagnosis) P|ase l/ll
(ê08) 111-8120
CO-1686
(EGFR inhibitor)
Clovis Oncology
Boulder, CO
second-line NSCLC P|ase l/ll
(303) ê25-5000
custirsen
(OGX-001/TV-1011)
OncoGenex Pharmaceuticals
Bothell, WA
Teva Pharmaceuticals
T|kva, lsrae|
lrsl-||re N3CLC
(see also prostate)
P|ase ll
(125) ê8ê-1500
dacomitinib
(PF-00299801)
Plzer
New York, NY
NSCLC
(see also solid tumors)
P|ase lll
(8ê0) Z32-515ê
dalotuzumab
(VK-0ê1ê)
Merck
Whitehouse Station, NJ
recurrent NSCLC (combination
therapy)
(see also breast, pancreatic, other)
P|ase ll
(800) 672-6372
EC20
(technetium Tc-99m etarfolatide)
Endocyte
West Lafayette, IN
NSCLC (diagnosis)
(see also ovarian)
P|ase ll
www.endocyte.com
EC115
(vintafolide)
Endocyte
West Lafayette, IN
Merck
Whitehouse Station, NJ
NSCLC
(see also ovarian)
P|ase ll
www.endocyte.com
(800) 672-6372
efatutazone Daiichi Sankyo
Parsippany, NJ
NSCLC
(see also colorectal, other)
P|ase ll
(9Z3) 911-2ê00
elesclomol Synta Pharmaceuticals
Lexington, MA
NSCLC
(see also leukemia, ovarian)
P|ase l/ll
(Z81) 2Z1-8200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
45
LUNG CANCER
Product Name Sponsor Indication Development Status
emepepimut-S EMD Serono
Rockland, MA
Oncothyreon
Seattle, WA
NSCLC (Fast Track)
(see also prostate)
P|ase lll
(800) 283-8088
entinostat Syndax Pharmaceuticals
Waltham, MA
NSCLC (combination therapy)
(see also breast, colorectal, kidney,
leukemia, lymphoma)
P|ase ll
(Z81) 119-1100
lc|aluzurao
(AV-299)
AVEO Pharmaceuticals
Cambridge, MA
NSCLC (combination therapy)
(see also solid tumors)
P|ase ll
(ê1Z) 299-5000
Folotyn
®
pralatrexate
Allos Therapeutics
Westminster, CO
NSCLC
(see also bladder, breast, lymphoma)
P|ase ll
(303) 12ê-ê2ê2
foretinib
(GSK1363089)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
NSCLC
(see also head/neck, kidney, liver)
P|ase l/ll
(888) 825-5219
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
second-line NSCLC (combination
therapy)
(see also breast, colorectal,
leukemia, liver, multiple myeloma,
pancreatic, prostate, skin, stomach)
--------------------------------------------------
SCLC
P|ase ll/lll
(Z81) 2Z1-8200
-------------------------------------------
P|ase ll
(Z81) 2Z1-8200
ganitumab
(AV0 1Z9)
Amgen
Tnousano Daks, 0/
lrsl-||re 3CLC (coro|ral|or l|erapy)
(see also breast, colorectal,
pancreatic, sarcoma)
P|ase l/ll
(800) ZZ2-ê13ê
0l-1000
(cancer vaccine)
0|ooelrrure
Louisville, CO
NSCLC
(see also colorectal, pancreatic)
P|ase l
(303) ê25-2Z00
Gleevec
®
imatinib
Novartis Pharmaceuticals
East Hanover, NJ
NSCLC (combination therapy)
(see also prostate, skin, other)
P|ase ll
(888) 669-6682
03K211813ê
(BRaf protein kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
BRAF mutation-positive disease
NSCLC
(see also brain, skin)
P|ase ll
(888) 825-5219
Halaven
®
eribulin
Eisai
Woodcliff Lake, NJ
NSCLC
(see also prostate, sarcoma)
P|ase lll
(888) 122-1Z13
HS-110
(cancer vaccine)
Heat Biologics
Chapel Hill, NC
late-stage NSCLC (combination
therapy)
P|ase l
(919) 210-Z133
Medicines in Development for Cancer
Medicines in Development Cancer 2012
46
LUNG CANCER
Product Name Sponsor Indication Development Status
HyperAcute
®
Lung
lung cancer immunotherapy
NewLink Genetics
Ames, IA
metastatic NSCLC P|ase ll
(515) 29ê-5555
l0V-2101
(multi-epitope cancer vaccine)
Biotech Synergy
San Diego, CA
NSCLC P|ase ll
(858) 159-êê89
imetelstat Geron
Menlo Park, CA
late-stage NSCLC
(see also breast, leukemia,
multiple myeloma)
P|ase ll
(ê50) 1Z3-ZZ00
lV0-2055
(TLR9 agonist)
ldera P|arraceul|ca|s
Cambridge, MA
(see also colorectal, head/neck) P|ase l
(ê1Z) êZ9-5000
Imprime PGG
®
Biothera
Eagan, MN
NSCLC
(see also colorectal, leukemia, skin)
P|ase ll
(ê51) êZ5-0300
iniparib
(83l-201)
3arol u3
Bridgewater, NJ
squamous NSCLC
(see also breast, ovarian)
--------------------------------------------------
non-squamous NSCLC
P|ase lll
(800) 981-2191
-------------------------------------------
P|ase ll
(800) 981-2191
Iressa
®
çell|r|o
AstraZeneca
Wilmington, DE
lrsl-||re E0FR rulal|or-pos|l|ve
NSCLC
P|ase lll
(800) 236-9933
l3l3-ElF1E
Rx
ls|s P|arraceul|ca|s
Carlsbad, CA
late-stage NSCLC (combination
therapy)
(see also prostate)
P|ase ll
(800) êZ9-1Z1Z
JNJ-2ê8511ê5
(Hdm2 inhibitor)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
NSCLC
(see also prostate, solid tumors)
P|ase l
(800) 81Z-528ê
Karenitecin
®
8NP1350
BioNumerik Pharmaceuticals
$an /nron|o, TX
NSCLC
(see also ovarian, solid tumors)
P|ase ll
(210) ê11-1Z01
KD019
(33Kl |r||o|lor)
Kadmon Pharmaceuticals
Warrendale, PA
late-stage NSCLC P|ase lll
(Z21) ZZ8-ê100
KD032
(ras/mTOR inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
NSCLC
(see also pancreatic)
P|ase ll corp|eled
(Z21) ZZ8-ê100
linifanib Abbott Laboratories
Abbott Park, IL
NSCLC
(see also breast, colorectal, kidney,
liver)
P|ase ll
(81Z) 93Z-ê100
litronesib
(LY2523355)
Eli Lilly
Indianapolis, IN
NSCLC
(see also breast)
P|ase ll
(800) 515-59Z9
Medicines in Development for Cancer
Medicines in Development Cancer 2012
47
LUNG CANCER
Product Name Sponsor Indication Development Status
lorvotuzumab mertansine
(lV0N901)
(Orphan Drug)
lrruro0er
Waltham, MA
SCLC
(see also multiple myeloma)
P|ase ll
(Z81) 895-0ê00
Lucanix
®
belagenpumatucel-L
NovaRx
San Diego, CA
NSCLC (Fast Track)
(see also brain)
P|ase lll
(858) 522-8ê00
mapatumumab Human Genome Sciences
Rockville, MD
NSCLC (combination therapy)
(see also liver, multiple myeloma)
P|ase ll
(301) 309-8501
VE0l-5Z5
(anti-PDGFR-alpha mAb)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
NSCLC
(see also brain)
P|ase ll
(800) 236-9933
(301) 398-0000
V0C02ê5
(multi-kinase inhibitor)
MethylGene
Montreal, Canada
NSCLC (combination therapy) P|ase l/ll
(511) 33Z-3333
MORAb-003
(farletuzumab)
Eisai
Woodcliff Lake, NJ
NSCLC
(see also ovarian)
P|ase ll
(888) 122-1Z13
MORAb-009
(amatuximab)
Eisai
Woodcliff Lake, NJ
mesothelioma P|ase ll
(888) 122-1Z13
motesanib Amgen
Tnousano Daks, 0/
NSCLC
(see also breast, colorectal, other)
P|ase lll
(800) ZZ2-ê13ê
naptumomab estafenatox Active Biotech
Lund, Sweden
NSCLC (Fast Track)
(see also kidney, pancreatic)
P|ase l corp|eled
www.activebiotech.com
navitoclax
(ABT-263)
Abbott Laboratories
Abbott Park, IL
NSCLC, SCLC
(see also leukemia, lymphoma)
P|ase ll
(81Z) 93Z-ê100
necitumumab
(lVC-11F8)
Bristol-Myers Squibb
Princeton, NJ
Eli Lilly
Indianapolis, IN
lrC|ore 3yslers
Bridgewater, NJ
NSCLC P|ase lll
(800) 332-205ê
(800) 515-59Z9
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
NSCLC
(see also breast, colorectal,
head/neck, kidney, leukemia, liver,
multiple myeloma, ovarian, other)
P|ase lll
(888) 812-293Z
Medicines in Development for Cancer
Medicines in Development Cancer 2012
48
LUNG CANCER
Product Name Sponsor Indication Development Status
NGR-hTNF
(Orphan Drug)
MolMed
Milan, Italy
second-line mesothelioma P|ase lll
www.molmed.com
NK-012 Nippon Kayaku
Tokyo, Jaµan
SCLC
(see also breast)
P|ase ll
www.nipponkayaku.co.jp
NTX-010 Neotropix
Malvern, PA
SCLC
(see also other)
P|ase ll
www.neotropix.com
obatoclax Cephalon
Frazer, PA
lrsl-||re 3CLC
(see also leukemia, lymphoma,
multiple myeloma)
P|ase ll
(ê10) 311-0200
OBP-301 Oncolys Biopharma
Tokyo, Jaµan
mesothelioma
(see also breast, head/neck, liver)
P|ase l
www.oncolys.com
00X-12Z OncoGenex Pharmaceuticals
Bothell, WA
NSCLC
(see also breast, ovarian)
P|ase l
(125) ê8ê-1500
ombrabulin
(AVE8062)
3arol u3
Bridgewater, NJ
lrsl-||re N3CLC
(see also ovarian, sarcoma)
P|ase ll
(800) 981-2191
onartuzumab Genentech
South San Francisco, CA
metastatic NSCLC
(see also breast, colorectal)
P|ase lll
(800) ê2ê-3553
Oncoprex™
(TUSC2/FUS1 gene therapy)
Genprex
/usr|n, TX
NSCLC P|ase l
(512) 59Z-5900
Opaxio™
paclitaxel poliglumex
Cell Therapeutics
Seattle, WA
NSCLC
(see also brain, ovarian, stomach,
other)
P|ase lll
(800) 215-2355
oral azacitidine Celgene
Summit, NJ
NSCLC
(see also leukemia, lymphoma,
solid tumors)
P|ase l
(908) 673-9000
03l-90ê
(l0F-1R/1R lyros|rase ||rase
inhibitor)
03l P|arraceul|ca|s
Farmingdale, NY
NSCLC
(see also ovarian, other)
P|ase ll
(631) 962-0600
P2015 Bryan Oncor
Somerville, MA
NSCLC, SCLC P|ase l corp|eled
palifosfamide
(Zl0-201)
Zl0PlARV 0rco|oçy
New York, NY
SCLC
(see also sarcoma, solid tumors)
P|ase l
(ê1ê) 211-0Z00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
49
LUNG CANCER
Product Name Sponsor Indication Development Status
pegdinetanib
(VEGFR-2 adnectin)
(8V3-811203)
Bristol-Myers Squibb
Princeton, NJ
NSCLC P|ase ll
(800) 332-205ê
perifosine AEterna Zentaris
Basking Ridge, NJ
NSCLC
(see also brain, colorectal, kidney,
leukemia, lymphoma, multiple
myeloma, sarcoma, solid tumors,
stomach)
P|ase l/ll
(908) ê2ê-5128
picoplatin
(Orphan Drug)
Ponaird Pharmaceuticals
Seattle, WA
second-line SCLC
(Fast Track)
(see also colorectal, ovarian,
prostate)
P|ase ll
(206) 281-7001
plinabulin
(NPl-2358)
Nereus Pharmaceuticals
San Diego, CA
NSCLC P|ase ll
(858) 58Z-1090
PRAVE arl|çer-spec|lc carcer
immunotherapeutic
(recombinant)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
NSCLC
(see also skin)
P|ase l
(888) 825-5319
PT107
(allogeneic tumor cell vaccine)
Pique Therapeutics
Durham, NC
NSCLC P|ase ll
(919) 80ê-1395
PX-866 Oncothyreon
Seattle, WA
NSCLC (combination therapy)
(see also brain, head/neck, prostate)
P|ase ll
(206) 801-2100
ranpirnase Tamir Biotechnology
Monmouth Junction, NJ
NSCLC P|ase ll
(732) 823-1003
regorafenib Bayer HealthCare Pharmaceuticals
Wayne, NJ
NSCLC
(see also colorectal, kidney,
solid tumors, stomach)
P|ase l
(888) 812-283Z
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
NSCLC (combination therapy)
(see also brain, colorectal,
head/neck, ovarian, pancreatic,
sarcoma, skin, solid tumors)
P|ase ll
(103) êZ0-Z3ZZ
retaspimycin lrlr|ly P|arraceul|ca|s
Cambridge, MA
NSCLC P|ase ll
(ê1Z) 153-1000
R0Z111
(EGFL7 inhibitor)
Genentech
South San Francisco, CA
NSCLC
(see also colorectal)
P|ase ll
(800) ê2ê-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012
50
LUNG CANCER
Product Name Sponsor Indication Development Status
R0Z599
(antibody drug conjugate)
Genentech
South San Francisco, CA
NSCLC
(see also ovarian)
P|ase l
(800) ê2ê-3553
ridaforolimus ARlA0 P|arraceul|ca|s
Cambridge, MA
Merck
Whitehouse Station, NJ
NSCLC
(see also breast, kidney, prostate,
sarcoma, other)
P|ase ll
(800) 672-6372
sapacitabine
(CYC682)
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
NSCLC
(see also leukemia, solid tumors)
P|ase ll
(908) 51Z-Z330
3AR25ê212 (VV-121)
(anti-ErbB3 mAb)
Merrimack Pharmaceuticals
Cambridge, MA
3arol u3
Bridgewater, NJ
NSCLC
(see also breast, ovarian)
P|ase ll
(800) 981-2191
talactoferrin alfa (oral)
(Orphan Drug)
Agennix
Princeton, NJ
NSCLC
(Fast Track)
P|ase lll
(ê09) 521-1000
tamibarotene CytRx
Los Angeles, CA
NSCLC
(see also leukemia)
P|ase ll
(310) 82ê-5ê18
Tarceva
®
erlotinib
Genentech
South San Francisco, CA
03l P|arraceul|ca|s
Farmingdale, NY
adjuvant NSCLC
(see also brain, breast, head/neck,
leukemia, liver, other)
P|ase lll
(800) ê2ê-3553
(631) 962-0600
Tavocept
®
dimesna
BioNumerik Pharmaceuticals
$an /nron|o, TX
(see also cancer-related) P|ase lll
(210) ê11-1Z01
Tc-99m ethylenedicysteine
glucosamine
(EC-G)
Cell Point
Centennial, CO
NSCLC (diagnosis) P|ase ll/lll
(303) 689-9693
Telcyta™
canfosfamide
Telik
Palo Alto, CA
third-line NSCLC
(see also lymphoma, ovarian)
P|ase lll corp|eled
(ê50) 815-ZZ00
Temodar
®
temozolomide
Merck
Whitehouse Station, NJ
SCLC
(see also leukemia)
P|ase ll
(800) 672-6372
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
NSCLC
(see also colorectal, kidney, liver,
pancreatic, sarcoma, other)
P|ase lll
(Z81) 991-0300
(9Z3) 911-2ê00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
51
LUNG CANCER
Product Name Sponsor Indication Development Status
topotecan liposomes injection Talon Therapeutics
San Mateo, CA
SCLC
(see also ovarian)
P|ase l
(ê50) 599-ê101
trametinib GlaxoSmithKline
Pson. Tr|ang|e Park, h0
second-line NSCLC
(see also leukemia, lymphoma,
multiple myeloma, pancreatic, skin)
P|ase ll
(888) 825-5219
Vargatef™
intedanib
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
second-line late-stage NSCLC
(combination therapy)
(see also ovarian)
P|ase lll
(800) 213-012Z
veglin
(VEGF antisense)
VasGene Therapeutics
Los Angeles, CA
mesothelioma
(see also kidney, skin)
P|ase l
(323) 221-7818
volociximab Abbott Laboratories
Abbott Park, IL
8|oçer ldec
Weston, MA
NSCLC P|ase ll
(81Z) 93Z-ê100
(Z81) 1ê1-2000
Xalkori
®
crizotinib
(Orphan Drug)
Plzer
New York, NY
lrsl-||re ALK-pos|l|ve N3CLC,
second-line ALK-positive NSCLC
(see also solid tumors)
--------------------------------------------------
NSCLC (combination therapy)
P|ase lll
(8ê0) Z32-515ê
-------------------------------------------
P|ase l/ll
(8ê0) Z32-515ê
YERVOY
®
ipilimumab
Bristol-Myers Squibb
Princeton, NJ
NSCLC, SCLC
(see also prostate, skin)
in clinical trials
(800) 332-205ê
Zolinza
®
vorinostat
(Orphan Drug)
Merck
Whitehouse Station, NJ
mesothelioma
(see also breast, leukemia,
lymphoma, multiple myeloma, other)
P|ase lll
(800) 672-6273
Zybrestat™
fosbretabulin
OXiGENE
South San Francisco, CA
lrsl-||re N3CLC
(see also ovarian)
P|ase ll
(ê50) ê35-Z000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
52
LYMPHOMA
Product Name Sponsor Indication Development Status
abexinostat
(HDAC inhibitor)
Pharmacyclics
Sunnyvale, CA
lymphoma
(see also sarcoma)
P|ase l/ll
(108) ZZ1-0330
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, breast, colorectal,
lung, ovarian, prostate, skin, other)
P|ase l/ll
(81Z) 93Z-ê100
Actimid
®
pomalidomide
Celgene
Summit, NJ
wa|derslror's racroç|oou||rer|a
(see also lung, multiple myeloma,
pancreatic)
P|ase l
(908) 673-9000
Adcetris™
brentuximab vedotin
Millennium Pharmaceuticals
Cambridge, MA
Seattle Genetics
Bothell, WA
post-transplant Hodgkin’s lymphoma
relapse prevention
(see also leukemia)
--------------------------------------------------
relapsed/refractory CD30-positive
non-Hodgkin’s lymphoma, relapsed/
refractory anaplastic large-cell
lymphoma
--------------------------------------------------
lrsl-||re arap|asl|c |arçe-ce||
|yrp|ora, lrsl-||re lodç||r's
lymphoma
P|ase lll
(800) 390-5êê3
(125) 52Z-1000
-------------------------------------------
P|ase ll
(800) 390-5êê3
(125) 52Z-1000
-------------------------------------------
P|ase l
(800) 390-5êê3
(125) 52Z-1000
Adcetris™
Companion Diagnostic
brentuximab vedotin companion
diagnostic
Millennium Pharmaceuticals
Cambridge, MA
Seattle Genetics
Bothell, WA
Ventana Medical Systems
Tuoson, /Z
cutaneous T-cell lymphoma
(diagnosis), T-cell lymphoma
(diagnosis)
in clinical trials
(617) 679-7000
(125) 52Z-1000
(800) 22Z-2155
AE03515ê
(XlAP |r||o|lor)
Aegera Therapeutics
Montreal, Canada
B-cell lymphoma
(see also leukemia)
P|ase l/ll
(511) 288-5532
AEZS-112 AEterna Zentaris
Basking Ridge, NJ
(see also solid tumors) P|ase l
(908) ê2ê-5128
$ÀQLWRU
®
everolimus
Novartis Pharmaceuticals
East Hanover, NJ
mantle cell lymphoma
(see also breast, kidney)
P|ase ll
(888) 669-6682
AFM13 Allred T|erapeul|cs
Heidelberg, Germany
second-line Hodgkin’s disease P|ase l
WWW.allred.cor
Alocrest™
vinorelbine liposomal
Talon Therapeutics
San Mateo, CA
non-Hodgkin’s lymphoma
(see also solid tumors)
P|ase l
(ê50) 588-ê101
Medicines in Development for Cancer
Medicines in Development Cancer 2012
53
LYMPHOMA
Product Name Sponsor Indication Development Status
AME-133v
(ocaratuzumab)
VENTRlK 8|olec|
0a||as, TX
non-Hodgkin’s lymphoma P|ase ll corp|eled
(211) 593-0500
Amplimexon
®
imexon
AmpliMed
Tuoson, /Z
second-line non-Hodgkin’s lymphoma P|ase ll
(520) 529-1000
amuvatinib
(VP1Z0)
Astex Pharmaceuticals
Dublin, OH
(see also lung) P|ase l
(925) 5ê0-0100
anti-CD22 mAb Abiogen Pharma
Pisa, Italy
B-cell lymphoma P|ase l
www.abiogen.com
Aplidin
®
plitidepsin
PharmaMar
Madrid, Spain
(see also multiple myeloma,
solid tumors)
P|ase l
www.pharmamar.com
AR-12 Arno Therapeutics
Flemington, NJ
(see also solid tumors) P|ase l
(862) 703-7170
AR-12 Arno Therapeutics
Flemington, NJ
(see also leukemia, multiple
myeloma)
P|ase l/ll
(862) 703-7170
Arranon
®
nelarabine
(Orphan Drug)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
lrsl-||re T-ce|| |yrp|ora
(see also leukemia)
--------------------------------------------------
second-line T-cell lymphoma
P|ase lll
(888) 669-6682
-------------------------------------------
P|ase l/ll
(888) 669-6682
Arzerra
®
ofatumumab
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
second-line diffuse large B-cell
lymphoma, second-line follicular
lymphoma
(see also leukemia)
--------------------------------------------------
wa|derslror's racroç|oou||rer|a
P|ase lll
(888) 825-5219
-------------------------------------------
P|ase ll
(888) 825-5219
ASP3026 Astellas Pharma US
0eerle|o, lL
late-stage B-cell lymphoma
(see also solid tumors)
P|ase l
(800) ê95-1321
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
non-Hodgkin’s lymphoma
(see also brain, leukemia, lung,
prostate, stomach)
P|ase ll
(ê10) 108-0301
AT-10ê/0eo|o-1113 Ascenta Therapeutics
Malvern, PA
Debiopharm
Lausanne, Switzerland
lymphoma
(see also leukemia)
P|ase l
(ê10) 108-0301
www.debiopharm.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
54
LYMPHOMA
Product Name Sponsor Indication Development Status
ATZ519
(CDK inhibitor)
Astex Pharmaceuticals
Dublin, CA
mantle cell lymphoma
(see also leukemia, multiple
myeloma, solid tumors)
P|ase ll
(925) 5ê0-0100
AT9283
(aurora/Jak2 inhibitor)
Astex Pharmaceuticals
Dublin, CA
non-Hodgkin’s lymphoma
(see also leukemia, multiple
myeloma, solid tumors)
P|ase l
(925) 5ê0-0100
autologous cancer vaccine 8ayer lrroval|or
Dusseldorf, Germany
Stellar Biotechnologies
Port Hueneme, CA
follicular lymphoma
(prevention of relapse)
P|ase l
(888) 812-293Z
(805) 188-2800
AVL-292
(Btk inhibitor)
Celgene
Summit, NJ
second-line non-Hodgkin’s
|yrp|ora, secord-||re wa|der-
slror's racroç|oou||rer|a
(see a|so |eu|er|a, urspec|led)
P|ase l
(908) 673-9000
Bcl-2 inhibitor
(ABT-199/GDC-0199)
Abbott Laboratories
Abbott Park, IL
Genentech
South San Francisco, CA
non-Hodgkin’s lymphoma
(see also leukemia)
P|ase l
(81Z) 93Z-ê100
(800) ê2ê-3553
belinostat
(Orphan Drug)
Spectrum Pharmaceuticals
Henderson, NV
peripheral T-cell lymphoma (PTCL)
(Fast Track)
(see also colorectal, leukemia, liver,
lung, ovarian, other)
P|ase ll
(Z02) 835-ê300
Bexxar
®
tositumomab and iodine
l-131 los|lurorao
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
mantle cell lymphoma
(combination therapy)
P|ase ll
(888) 825-5219
BiovaxID
®
B-cell lymphoma vaccine
(personalized lymphoma
vaccine)
8|ovesl lrlerral|ora|
Tamµa, FL
indolent follicular lymphoma
(Fast Track)
--------------------------------------------------
mantle cell lymphoma
P|ase lll
(813) 8ê1-2551
-------------------------------------------
P|ase ll
(813) 8ê1-2551
CC-115
(kinase inhibitor)
Celgene
Summit, NJ
non-Hodgkin’s lymphoma
(see also multiple myeloma,
solid tumors)
P|ase l
(908) 673-9000
CC-122 Celgene
Summit, NJ
non-Hodgkin’s lymphoma
(see also multiple myeloma,
solid tumors)
P|ase l
(908) 673-9000
CC-223
(mTOR inhibitor)
Celgene
Summit, NJ
non-Hodgkin’s lymphoma
(see also lung, multiple myeloma)
P|ase l
(908) 673-9000
CEP-9722
(PARP inhibitor)
Cephalon
Frazer, PA
mantle cell lymphoma (combination
therapy)
(see also lung)
P|ase l
(ê10) 311-0200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
55
LYMPHOMA
Product Name Sponsor Indication Development Status
Clearazide™
mechlorethamine gel
(Orphan Drug)
Ceptaris Therapeutics
Malvern, PA
cutaneous T-cell lymphoma
(Fast Track)
application submitted
(ê10) 9Z5-9290
CT-011 CureTech
Yavne, Israel
diffuse large B-cell lymphoma,
second-line follicular lymphoma
(combination therapy)
(see also colorectal, leukemia)
P|ase ll
www.curetechbio.com
darinaparsin
(Zl0-101)
(Orphan Drug)
Zl0PlARV 0rco|oçy
New York, NY
second-line peripheral T-cell
lymphoma
(see also liver, multiple myeloma,
solid tumors)
--------------------------------------------------
lrsl-||re per|p|era| T-ce|| |yrp|ora
(combination therapy), non-Hodgkin’s
lymphoma
P|ase ll
(ê1ê) 211-0Z00
-------------------------------------------
P|ase l
(ê1ê) 211-0Z00
0C03-1501A Genentech
South San Francisco, CA
non-Hodgkin’s lymphoma
(see also leukemia)
P|ase l
(800) ê2ê-3553
DCDT-2980S Genentech
South San Francisco, CA
recurrent non-Hodgkin’s lymphoma
(see also leukemia)
P|ase l
(800) ê2ê-3553
0l-Leu1ê-lL2 Alopexx Oncology
Waltham, MA
non-Hodgkin’s lymphoma P|ase l
(Z81) 19Z-9888
entinostat Syndax Pharmaceuticals
Waltham, MA
Hodgkin’s disease
(see also breast, colorectal, kidney,
leukemia, lung)
P|ase ll
(Z81) 119-1100
enzastaurin Eli Lilly
Indianapolis, IN
diffuse large B-cell lymphoma P|ase lll
(800) 515-59Z9
epratuzumab
(Orphan Drug)
lrrurored|cs
Morris Plains, NJ
UCB
Atlanta, GA
diffuse large B-cell lymphoma
(combination therapy), follicular
lymphoma (combination therapy)
(see also leukemia)
P|ase ll
(9Z3) ê05-8200
epratuzumab Y-90 lrrurored|cs
Morris Plains, NJ
diffuse large B-cell lymphoma
--------------------------------------------------
recurrent non-Hodgkin’s lymphoma
P|ase ll
(9Z3) ê05-8200
-------------------------------------------
P|ase l/ll
(9Z3) ê05-8200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
56
LYMPHOMA
Product Name Sponsor Indication Development Status
EZN-2968
(llF1-a|p|a |r||o|lor)
Enzon Pharmaceuticals
Piscataway, NJ
(see also solid tumors) P|ase l
(9Z3) 980-1500
Folotyn
®
pralatrexate
(Orphan Drug)
Allos Therapeutics
Westminster, CO
peripheral T-cell lymphoma
(lrsl-||re l|erapy)
(see also bladder, breast, lung)
--------------------------------------------------
B-cell non-Hodgkin’s lymphoma,
lymphoma (combination therapy)
--------------------------------------------------
cutaneous T-cell lymphoma
P|ase lll
(303) 12ê-ê2ê2
-------------------------------------------
P|ase ll
(303) 12ê-ê2ê2
-------------------------------------------
P|ase l
(303) 12ê-ê2ê2
forodesine
(Orphan Drug)
BioCryst Pharmaceuticals
Durham, NC
cutaneous T-cell lymphoma
(see also leukemia)
P|ase ll
(919) 859-1302
galiximab 8|oçer ldec
Cambridge, MA
non-Hodgkin’s lymphoma
(combination therapy)
--------------------------------------------------
lrsl-||re ror-lodç||r's |yrp|ora
(monotherapy)
P|ase ll corp|eled
(617) 679-2000
-------------------------------------------
P|ase l corp|eled
(617) 679-2000
00C-0319
(small molecule)
Genentech
South San Francisco, CA
non-Hodgkin’s lymphoma
(see also solid tumors)
P|ase l
(800) ê2ê-3553
00C-0125
(ChK1 inhibitor)
Genentech
South San Francisco, CA
(see also solid tumors) P|ase l
(800) ê2ê-3553
00C-05Z5 Genentech
South San Francisco, CA
(see also solid tumors) P|ase l
(800) ê2ê-3553
GDC-0917
(lAP arlaçor|sl)
Genentech
South San Francisco, CA
(see also solid tumors) P|ase l
(800) ê2ê-3553
GDC-0980
(Pl3 ||rase/rT0R dua|
inhibitor)
Genentech
South San Francisco, CA
non-Hodgkin’s lymphoma
(see also breast, solid tumors)
P|ase l
(800) ê2ê-3553
GS-1101
(Pl3K de|la |r||o|lor)
Gilead Sciences
Foster City, CA
indolent non-Hodgkin’s lymphoma
(see also leukemia)
P|ase ll
(800) 115-3235
03K1ê13ê1
(polio-like kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
non-Hodgkin’s lymphoma
(see also solid tumors)
P|ase l
(888) 825-5219
GSK690693
(AKT kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also solid tumors) P|ase l
(888) 825-5219
Medicines in Development for Cancer
Medicines in Development Cancer 2012
57
LYMPHOMA
Product Name Sponsor Indication Development Status
03K212ê158
(Pl3K/rT0R |r||o|lor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also solid tumors) P|ase l
(888) 825-5219
03K2111Z95
(protein kinase B inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also solid tumors) P|ase l
(888) 825-5219
iboctadekin GlaxoSmithKline
Pson. Tr|ang|e Park, h0
non-Hodgkin’s lymphoma
(combination therapy)
(see also ovarian)
P|ase l corp|eled
(888) 825-5219
ibrutinib
(PCl-32Zê5)
Janssen Biotech
Horsham, PA
Pharmacyclics
Sunnyvale, CA
diffuse large B-cell lymphoma,
mantle cell lymphoma
(see also leukemia, multiple
myeloma)
P|ase ll
(800) 52ê-ZZ3ê
(108) ZZ1-0330
lV0N529 lrruro0er
Waltham, MA
metastatic non-Hodgkin’s lymphoma P|ase l
(Z81) 895-0ê00
lNK128
(mTOR inhibitor)
lrle|||||re
La Jolla, CA
wa|derslror's racroç|oou||rer|a
(see also multiple myeloma, solid
tumors)
P|ase l
(858) Zê8-ê500
inotuzumab ozogamicin Plzer
New York, NY
aggressive non-Hodgkin’s lymphoma
(see also leukemia)
--------------------------------------------------
diffuse large B-cell lymphoma,
indolent non-Hodgkin’s lymphoma
P|ase lll
(8ê0) Z32-515ê
-------------------------------------------
P|ase ll
(8ê0) Z32-515ê
interleukin-12 gene therapy OncoSec Medical
San Diego, CA
cutaneous T-cell lymphoma
(see also skin)
P|ase ll
www.oncosec.com
l3F35 Memgen
San Diego, CA
follicular lymphoma, diffuse large cell
lymphoma, mantle cell lymphoma,
small lymphocytic lymphoma
(see also leukemia)
P|ase ll
(858) 521-5100
JNJ-2ê181585
(quisinostat)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
cutaneous T-cell lymphoma
(see also leukemia)
P|ase ll
(800) 81Z-528ê
LEE011
(C0K1/ê |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
(see also solid tumors) P|ase l
(888) 669-6682
L0Z10
(activated T-cells)
Lentigen
Gaithersburg, MD
University of Pennsylvania
Philadelphia, PA
diffuse large B-cell lymphoma,
follicular lymphoma, mantle-cell
lymphoma
(see also leukemia)
P|ase l
(301) 52Z-1200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
58
LYMPHOMA
Product Name Sponsor Indication Development Status
lucatumumab
(HDC122)
Novartis Pharmaceuticals
East Hanover, NJ
XOMA
Berkeley, CA
lymphoma
--------------------------------------------------
follicular lymphoma
P|ase l/ll
(888) 669-6682
-------------------------------------------
P|ase l
(888) 669-6682
Marqibo
®
vincristine liposomal
Talon Therapeutics
San Mateo, CA
non-Hodgkin’s lymphoma
(see also leukemia, skin, other)
P|ase ll
(ê50) 588-ê101
milatuzumab lrrurored|cs
Morris Plains, NJ
non-Hodgkin’s lymphoma
(see also leukemia, multiple
myeloma)
P|ase l/ll
(9Z3) ê05-8200
VK-Z95ê
(dinaciclib)
Merck
Whitehouse Station, NJ
mantle cell lymphoma
(see also leukemia)
P|ase ll
(800) 672-6372
MK-8808 Merck
Whitehouse Station, NJ
late-stage follicular lymphoma
(combination therapy)
P|ase l
(800) 672-6372
MLN8237
(alisertib)
Millennium Pharmaceuticals
Cambridge, MA
peripheral T-cell lymphoma
(see also solid tumors)
P|ase lll
(800) 390-5êê3
MLN9708
(ixazomib)
Millennium Pharmaceuticals
Cambridge, MA
|yrp|ora, wa|derslror's
macroglobulinemia
(see also multiple myeloma, solid
tumors)
P|ase l
(800) 390-5êê3
mocetinostat
(MGCD0103, HDAC inhibitor)
(Orphan Drug)
MethylGene
Montreal, Canada
diffuse large B-cell lymphoma,
follicular lymphoma
(see also leukemia, solid tumors)
P|ase ll
(511) 33Z-3333
mogamulizumab
(Orphan Drug)
Amgen
Tnousano Daks, 0/
cutaneous T-cell lymphoma,
peripheral T-cell lymphoma
P|ase ll
(800) ZZ2-ê13ê
navitoclax
(ABT-263)
Abbott Laboratories
Abbott Park, IL
(see also leukemia, lung) P|ase l/ll
(81Z) 93Z-ê100
NPl-0052
(marizomib)
Nereus Pharmaceuticals
San Diego, CA
(see also multiple myeloma,
solid tumors)
P|ase l
(858) 58Z-1090
obatoclax
(Orphan Drug)
Cephalon
Frazer, PA
lrsl-||re lo|||cu|ar |yrp|ora
(combination therapy)
(see also leukemia, lung, multiple
myeloma)
--------------------------------------------------
mantle cell lymphoma
P|ase ll corp|eled
(ê10) 311-0200
-------------------------------------------
P|ase l/ll corp|eled
(ê10) 311-0200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
59
LYMPHOMA
Product Name Sponsor Indication Development Status
obinutuzumab
(0A101/R0Z159)
8|oçer ldec
Weston, MA
Genentech
South San Francisco, CA
lrsl-||re ror-lodç||r's |yrp|ora
(combination therapy), second-line
non-Hodgkin’s lymphoma (com-
o|ral|or l|erapy), lrsl-||re 8-ce||
lymphoma (combination therapy)
(see also leukemia)
--------------------------------------------------
second-line non-Hodgkin’s lymphoma
(monotherapy)
P|ase lll
(Z81) 1ê1-2000
(800) ê2ê-3553
-------------------------------------------
P|ase ll
(Z81) 1ê1-2000
(800) ê2ê-3553
0N 013105 Onconova Therapeutics
Newtown, PA
(see also leukemia) P|ase l
(2êZ) Z59-3ê80
0N0-1059 ONO Pharmaceutical
Osaka, Japan
B-cell lymphoma P|ase l
www.ono.co.jp
oral azacitidine Celgene
Summit, NJ
(see also leukemia, lung,
solid tumors)
P|ase l
(908) 673-9000
03l-02Z
(TORC1/TORC2 inhibitor)
03l P|arraceul|ca|s
Farmingdale, NY
(see also kidney) P|ase l
(631) 962-0600
P 27600 Piramal Life Sciences
Mumbai, India
mantle cell lymphoma P|ase ll
www.piramallifesciences.com
perifosine AEterna Zentaris
Basking Ridge, NJ
lymphoma (combination therapy),
wa|derslror's racroç|oou||rer|a
(see also brain, colorectal, kidney,
leukemia, lung, multiple myeloma,
sarcoma, solid tumors, stomach)
P|ase ll
(908) ê2ê-5128
P01101Z Progen Pharmaceuticals
Queensland, Australia
(see also solid tumors) P|ase l
www.progen-pharma.com
pixantrone Cell Therapeutics
Seattle, WA
diffuse large B-cell lymphoma
(see also breast)
P|ase lll
(800) 215-2355
PLX3397
(CSF-1R kinase inhibitor)
Plexxikon
Berkeley, CA
recurrent or refractory Hodgkin’s
disease
(see also brain, leukemia, solid
tumors)
P|ase ll
(510) ê1Z-1000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
60
LYMPHOMA
Product Name Sponsor Indication Development Status
Revlimid
®
lenalidomide
Celgene
Summit, NJ
non-Hodgkin’s lymphoma
(see also leukemia)
P|ase lll
(908) 673-9000
RG7602 Genentech
South San Francisco, CA
(see also solid tumors) P|ase l
(800) ê2ê-3553
rigosertib Onconova Therapeutics
Newtown, PA
(see also leukemia, ovarian,
pancreatic)
P|ase ll
(2êZ) Z59-3ê80
Rituxan
®
rituxumab
(fast infusion)
8|oçer ldec
Weston, MA
Genentech
South San Francisco, CA
non-Hodgkin’s lymphoma application submitted
(Z81) 1ê1-2000
(800) ê2ê-3553
3AR215109
(XLZê5)
(Pl3K/rT0R |r||o|lor)
3arol u3
Bridgewater, NJ
Exelixis
South San Francisco, CA
non-Hodgkin’s lymphoma
(see also breast)
P|ase ll
(800) 981-2191
(ê50) 83Z-Z000
30N-Z5
(vorsetuzumab mafodotin)
Seattle Genetics
Bothell, WA
non-Hodgkin’s lymphoma
(see also kidney)
P|ase l
(125) 52Z-1000
3lP-111 Shape Pharmaceuticals
Cambridge, MA
cutaneous T-cell lymphoma P|ase l
www.shapepharma.com
sotrastaurin
(AEB071)
Novartis Pharmaceuticals
East Hanover, NJ
diffuse large B-cell lymphoma P|ase l
(888) 669-6682
stem cell therapy Benitec Biopharma
Sydney, Australia
City of Hope National Medical Center
Duarte, CA
Al03-re|aled |yrp|ora P|ase l
www.benitec.com
teglarinad Cephalon
Frazer, PA
(see also solid tumors) P|ase l
(ê10) 311-0200
Telcyta™
canfosfamide
Telik
Palo Alto, CA
diffuse large B-cell lymphoma,
mantle cell lymphoma, non-Hodgkin’s
lymphoma
(see also lung, ovarian)
P|ase ll
(ê50) 815-ZZ00
thiarabine Access Pharmaceuticals
0a||as, TX
(see also leukemia) P|ase l/ll
(215) 901-5100
Medicines in Development for Cancer
Medicines in Development Cancer 2012
61
LYMPHOMA
Product Name Sponsor Indication Development Status
tigatuzumab
(arl|-0R5 arl|oody)
Daiichi Sankyo
Parsippany, NJ
(see also breast, colorectal, liver,
ovarian, pancreatic)
P|ase l corp|eled
(9Z3) 911-2ê00
TKM-PLK1
(RNAi)
Tekmira Pharmaceuticals
Burnaby, Canada
(see also solid tumors) P|ase l
(ê01) 119-3200
trametinib GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also leukemia, lung, multiple
myeloma, pancreatic, skin)
P|ase l
(888) 825-5219
Treanda
®
bendamustine
Cephalon
Frazer, PA
lrsl-||re ror-lodç||r's |yrp|ora
(combination therapy)
(see also leukemia, multiple
myeloma)
--------------------------------------------------
second-line mantle cell lymphoma
(combination therapy)
application submitted
(ê10) 311-0200
-------------------------------------------
P|ase ll
(ê10) 311-0200
TRU-016
(humanized anti-CD37
therapeutic)
Emergent BioSolutions
Rockville, MD
non-Hodgkin’s lymphoma
(see also leukemia)
P|ase l/ll
(301) Z95-1800
uN83-51ê2 Drais Pharmaceuticals
Bridgewater, NJ
(see also solid tumors) P|ase l
(908) 895-1200
Velcade
®
bortezomib
Millennium Pharmaceuticals
Cambridge, MA
lrsl-||re rarl|e ce|| |yrp|ora
(see also leukemia, cancer-related,
other)
--------------------------------------------------
non-Hodgkin’s B-cell lymphoma
--------------------------------------------------
diffuse large B-cell lymphoma
P|ase lll
(800) 390-5êê3
-------------------------------------------
P|ase lll
(800) 390-5êê3
-------------------------------------------
P|ase ll
(800) 390-5êê3
veltuzumab lrrurored|cs
Morris Plains, NJ
non-Hodgkin’s lymphoma
(see also leukemia)
P|ase l/ll
(9Z3) ê05-8200
Vidaza
®
azacitidine
Celgene
Summit, NJ
(see also leukemia) P|ase lll
(908) 673-9000
VTX-2337 VentiRx Pharmaceuticals
Seattle, WA
B-cell lymphoma
(see also solid tumors)
--------------------------------------------------
lymphoma
P|ase l/ll
(20ê) ê89-2259
-------------------------------------------
P|ase l
(20ê) ê89-2259
Medicines in Development for Cancer
Medicines in Development Cancer 2012
62
LYMPHOMA
Product Name Sponsor Indication Development Status
XmAb
®
2513
(CD30-antigen inhibitor)
Xencor
Monrovia, CA
Hodgkin’s disease, T-cell lymphoma P|ase l
(ê2ê) 305-5900
YV155
(sepantronium)
Astellas Pharma US
0eerle|o, lL
non-Hodgkin’s lymphoma
(see also breast)
P|ase ll
(800) ê95-1321
zanolimumab
(Orphan Drug)
Emergent BioSolutions
Rockville, MD
cutaneous T-cell lymphoma
--------------------------------------------------
peripheral T-cell lymphoma
P|ase ll
(301) Z95-1800
-------------------------------------------
P|ase l
(301) Z95-1800
Zevalin
®
ibritumomab tiuxetan
Spectrum Pharmaceuticals
Henderson, NV
second-line diffuse large B-cell
lymphoma
--------------------------------------------------
mantle cell lymphoma
P|ase lll
(Z02) 835-ê300
-------------------------------------------
P|ase ll
(Z02) 835-ê300
Zolinza
®
vorinostat
Merck
Whitehouse Station, NJ
B-cell lymphoma
(see also breast, leukemia, lung,
multiple myeloma, other)
P|ase ll
(800) 672-6273
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
ACE-011
(dalantercept)
Acceleron Pharma
Cambridge, MA
(see also head/neck) P|ase l
(ê1Z) ê19-9200
Actimid
®
pomalidomide
(Orphan Drug)
Celgene
Summit, NJ
recurrent multiple myeloma
(see also lung, lymphoma,
pancreatic)
application submitted
(908) 673-9000
ACY-1215
(HDAC6 inhibitor)
Acetylon Pharmaceuticals
Boston, MA
P|ase l/ll
(ê1Z) 215-1300
ALXN6000
(samalizumab)
Alexion Pharmaceuticals
0nesn|re, 0T
(see also leukemia) P|ase l/ll corp|eled
(203) 2Z2-259ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
63
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
Aplidin
®
plitidepsin
(Orphan Drug)
PharmaMar
Madrid, Spain
(see also lymphoma, solid tumors) P|ase lll
www.pharmamar.com
AR-12 Arno Therapeutics
Flemington, NJ
(see also leukemia, lymphoma) P|ase l/ll
(862) 703-7170
ARRY-520
(KSP inhibitor)
Array BioPharma
Boulder, CO
multiple myeloma
(see also leukemia, solid tumors)
--------------------------------------------------
multiple myeloma (combination
therapy)
P|ase ll
(8ZZ) ê33-213ê
-------------------------------------------
P|ase l
(8ZZ) ê33-213ê
ATZ519
(CDK inhibitor)
Astex Pharmaceuticals
Dublin, CA
second-line multiple myeloma
(see also leukemia, lymphoma,
solid tumors)
P|ase l/ll
(925) 5ê0-0100
AT9283
(aurora/Jak2 inhibitor)
Astex Pharmaceuticals
Dublin, CA
(see also leukemia, lymphoma,
solid tumors)
P|ase ll
(925) 5ê0-0100
AUY922
(Hsp90 inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
(see also breast, colorectal, lung,
stomach)
P|ase l/ll
(888) 669-6682
BHQ880
(mAb)
Novartis Pharmaceuticals
East Hanover, NJ
(see also solid tumors) P|ase ll
(888) 669-6682
8l-505
(Orphan Drug)
8|olrverl lrlerral|ora|
Lund, Sweden
second-line late-stage multiple
myeloma
P|ase l
www.bioinvent.com
8lw-89ê2 Kyowa Hakko Kirin Pharma
Princeton, NJ
P|ase l/ll
(609) 919-1100
carl|zor|o
(Orphan Drug)
Onyx Pharmaceuticals
South San Francisco, CA
third-line multiple myeloma
(Fast Track)
(see also solid tumors)
--------------------------------------------------
multiple myeloma (combination
therapy)
application submitted
(ê50) 2êê-0000
-------------------------------------------
P|ase l/ll
(ê50) 2êê-0000
C83301
(noscapine)
Cougar Biotechnology
Raritan, NJ
P|ase l/ll
www.cougarbiotechnology.com
CC-115
(kinase inhibitor)
Celgene
Summit, NJ
(see also lymphoma, solid tumors) P|ase l
(908) 673-9000
CC-122 Celgene
Summit, NJ
(see also lymphoma, solid tumors) P|ase l
(908) 673-9000
CC-223
(mTOR inhibitor)
Celgene
Summit, NJ
(see also lung, lymphoma) P|ase l
(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
64
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
CP-18770
(delanzomib)
Cephalon
Frazer, PA
P|ase ll
(ê10) 311-0200
CX-1915
(CK2 inhibitor)
Cylene Pharmaceuticals
San Diego, CA
(see also solid tumors) P|ase l
(858) 8Z5-5100
daratumumab Genmab
Princeton, NJ
P|ase l/ll
(ê09) 130-2181
darinaparsin
(Zl0-101)
Zl0PlARV 0rco|oçy
New York, NY
(see also liver, lymphoma,
solid tumors)
P|ase ll
(ê1ê) 211-0Z00
0FRF-1539A Genentech
South San Francisco, CA
refractory metastatic multiple
myeloma
P|ase l
(800) ê2ê-3553
elotuzumab
(BMS-901608)
Bristol-Myers Squibb
Princeton, NJ
P|ase lll
(800) 332-205ê
ENMD-2076
(Orphan Drug)
EntreMed
Rockville, MD
relapsed or refractory multiple
myeloma
(see also ovarian, other)
P|ase l
(210) 8ê1-2ê00
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
second-line multiple myeloma
(see also breast, colorectal,
leukemia, liver, lung, pancreatic,
prostate, skin, stomach)
P|ase l
(Z81) 2Z1-8200
GL-0817 Gliknik
Baltimore, MD
(see also head/neck) P|ase ll
www.gliknik.com
GSK2110183
(protein kinase B inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also leukemia) P|ase l/ll
(888) 825-5219
GVAX
®
Myeloma
cancer vaccine
BioSante Pharmaceuticals
Lincolnshire, IL
P|ase ll
(81Z) 1Z8-0500
ibrutinib
(PCl-32Zê5)
Janssen Biotech
Horsham, PA
Pharmacyclics
Sunnyvale, CA
(see also leukemia, lymphoma) P|ase ll
(800) 52ê-ZZ3ê
(108) ZZ1-0330
imetelstat Geron
Menlo Park, CA
second-line multiple myeloma
(monotherapy)
(see also breast, leukemia, lung)
P|ase ll
(ê50) 1Z3-ZZ00
indatuximab ravtansine
(Orphan Drug)
Biotest
Dreieich, Germany
relapsed or refractory multiple
myeloma
P|ase l/ll
www.biotest.de
Medicines in Development for Cancer
Medicines in Development Cancer 2012
65
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
lNK128
(mTOR inhibitor)
lrle|||||re
La Jolla, CA
(see also lymphoma, solid tumors) P|ase l
(858) Zê8-ê500
lPl-2101
(arl|-KlR rAo)
lrrale P|arra
Marseille, France
multiple myeloma (monotherapy)
--------------------------------------------------
multiple myeloma (combination
therapy)
P|ase ll
www.innate-pharma.com
-------------------------------------------
P|ase l/ll
www.innate-pharma.com
Kw-21Z8 Kyowa Hakko Kirin Pharma
Princeton, NJ
multiple myeloma (combination
therapy)
P|ase l/ll
(609) 919-1100
L8l589
(panobinostat)
Novartis Pharmaceuticals
East Hanover, NJ
(see also kidney, leukemia, prostate,
solid tumors)
P|ase lll
(888) 669-6682
lorvotuzumab mertansine
(lV0N901)
lrruro0er
Waltham, MA
(see also lung) P|ase l
(Z81) 895-0ê00
mapatumumab Human Genome Sciences
Rockville, MD
multiple myeloma (combination
therapy)
(see also liver, lung)
P|ase ll
(301) 309-8501
melphalan intravenous
(captisol-enabled)
(Orphan Drug)
CyDex Pharmaceuticals
Lenexa, KS
P|ase ll
www.ligand.com/cydex
milatuzumab lrrurored|cs
Morris Plains, NJ
recurrent multiple myeloma
(see also leukemia, lymphoma)
P|ase l/ll
(9Z3) ê05-8200
MLN9708
(ixazomib)
Millennium Pharmaceuticals
Cambridge, MA
newly diagnosed multiple myeloma
(combination therapy), second-line
multiple myeloma
(see also lymphoma, solid tumors)
P|ase l/ll
(800) 390-5êê3
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also breast, colorectal, head/
neck, kidney, leukemia, liver, lung,
ovarian, other)
P|ase l/ll
(888) 812-293Z
NPl-0052
(marizomib)
Nereus Pharmaceuticals
San Diego, CA
(see also lymphoma, solid tumors) P|ase l
(858) 58Z-1090
obatoclax Cephalon
Frazer, PA
(see also leukemia, lung, lymphoma) P|ase l corp|eled
(ê10) 311-0200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
66
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
perifosine
(Orphan Drug)
AEterna Zentaris
Basking Ridge, NJ
recurrent multiple myeloma
(combination therapy)
(Fast Track)
(see also brain, colorectal, kidney,
leukemia, lung, lymphoma, sarcoma,
solid tumors, stomach)
P|ase lll
(908) ê2ê-5128
R0Z111
(MFGR-1877S)
Genentech
South San Francisco, CA
refractory metastatic multiple
myeloma
(see also solid tumors)
P|ase l
(800) ê2ê-3553
R0Z598
(antibody drug conjugate)
Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
sarar|ur 3V-153 |ex|drorar
injection
EUSA Pharma
Langhorne, PA
(see also breast, prostate, sarcoma,
other)
P|ase l/ll
(800) 833-3533
SF1126 Semafore Pharmaceuticals
Indianapolis, IN
(see also leukemia, solid tumors) P|ase l
(31Z) 8Zê-30Z5
siltuximab Janssen Biotech
Horsham, PA
(see also prostate, other) P|ase ll
(800) 52ê-ZZ3ê
SNS01-T
(nano-encapsulated gene
therapy)
(Orphan Drug)
Senesco Technologies
Bridgewater, NJ
second-line multiple myeloma P|ase l/ll
(908) 8ê1-1111
TH-302 Threshold Pharmaceuticals
South San Francisco, CA
(see also brain, leukemia, pancreatic,
sarcoma)
P|ase l/ll
(ê50) 1Z1-8200
TKl258
(dovitinib)
Novartis Pharmaceuticals
East Hanover, NJ
(see also breast, kidney, prostate,
skin, other)
P|ase ll
(888) 669-6682
trametinib GlaxoSmithKline
Pson. Tr|ang|e Park, h0
multiple myeloma
(see also leukemia, lung, lymphoma,
pancreatic, skin)
P|ase l/ll
(888) 825-5219
Treanda
®
bendamustine
Cephalon
Frazer, PA
second-line multiple myeloma
(combination therapy)
(see also leukemia, lymphoma)
P|ase l/ll
(ê10) 311-0200
Xgeva™
denosumab
Amgen
Tnousano Daks, 0/
(see also cancer-related, other) P|ase ll
(800) ZZ2-ê13ê
Zolinza
®
vorinostat
(Orphan Drug)
Merck
Whitehouse Station, NJ
metastatic multiple myeloma
(see also breast, leukemia, lung,
lymphoma, other)
P|ase lll
(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012
67
OVARIAN CANCER
Product Name Sponsor Indication Development Status
Å6 Angstrom Pharmaceuticals
Solana Beach, CA
(see also other) P|ase ll
(858) 311-235ê
abagovomab
(anti-idiotype mAb vaccine)
(Orphan Drug)
Menarini
Florence, Italy
P|ase lll
www.menarini.com
Abraxane
®
albumin-bound paclitaxel
Celgene
Summit, NJ
(see also bladder, breast, lung,
pancreatic, skin)
P|ase ll
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, breast, colorectal,
lung, lymphoma, prostate, skin,
other)
P|ase ll
(81Z) 93Z-ê100
AE37 peptide vaccine Antigen Express
Worcester, MA
(see also breast) P|ase l
(508) 852-8Z83
AEZS-108
(Orphan Drug)
AEterna Zentaris
Basking Ridge, NJ
(see also bladder, prostate, other) P|ase ll
(908) ê2ê-5128
Avastin
®
bevacizumab
(Orphan Drug)
Genentech
South San Francisco, CA
relapsed, platinum-sensitive ovarian
cancer
(see also brain, breast, colorectal,
lung, other)
--------------------------------------------------
lrsl-||re relaslal|c ovar|ar carcer
application submitted
(800) ê2ê-3553
-------------------------------------------
P|ase lll
(800) ê2ê-3553
BC-819
(gene therapy)
(Orphan Drug)
BioCancell Therapeutics
Jerusalem, Israel
late-stage ovarian cancer
(see also bladder, pancreatic)
P|ase l/ll
www.biocancell.com
belinostat Spectrum Pharmaceuticals
Henderson, NV
late-stage ovarian cancer
(combination therapy)
(see also colorectal, leukemia, liver,
lung, lymphoma, other)
P|ase ll corp|eled
(Z02) 835-ê300
cabozantinib
(XL181)
Exelixis
South San Francisco, CA
(see also breast, kidney, lung,
prostate, other)
P|ase ll
(ê50) 83Z-Z000
catumaxomab Fresenius Biotech North America
Waltham, MA
(see also other) P|ase ll
www.fresenius-biotech.com
CVac™
MUC-1 cancer vaccine
Prima BioMed
Sydney, Australia
P|ase ll/lll
www.primabiomed.com.au
Medicines in Development for Cancer
Medicines in Development Cancer 2012
68
OVARIAN CANCER
Product Name Sponsor Indication Development Status
DCVax
®
-Ovarian
dendritic cell-based vaccine
Northwest Biotherapeutics
Bethesda, MD
P|ase l
(210) 19Z-9021
0VuC-5Z51A Genentech
South San Francisco, CA
second-line ovarian cancer
(see also other)
P|ase l
(800) ê2ê-3553
DPX-0907 lrrurovacc|re
Halifax, Canada
(see also breast, prostate) P|ase l
(902) 192-1819
DPX-survivac cancer vaccine lrrurovacc|re
Halifax, Canada
P|ase l
(902) 192-1819
EZ850
(irofulven)
Eisai
Woodcliff Lake, NJ
(see also prostate, other) P|ase ll
(888) 122-1Z13
EC20
(technetium Tc-99m etarfolatide)
Endocyte
West Lafayette, IN
ovarian cancer (diagnosis)
(see also lung)
P|ase lll
www.endocyte.com
EC115
(vintafolide)
Endocyte
West Lafayette, IN
Merck
Whitehouse Station, NJ
platinum-resistant ovarian cancer
(see also lung)
P|ase lll
www.endocyte.com
(800) 672-6372
EGEN-001
(Orphan Drug)
EGEN
Huntsville, AL
(see also colorectal, other) P|ase ll
(25ê) 512-00ZZ
elesclomol Synta Pharmaceuticals
Lexington, MA
(see also leukemia, lung) P|ase ll
(Z81) 2Z1-8200
ENMD-2076
(Orphan Drug)
EntreMed
Rockville, MD
platinum-resistant ovarian cancer
(see also multiple myeloma, other)
P|ase ll
(210) 8ê1-2ê00
etirinotecan pegol
(NKTR-102)
(Orphan Drug)
Nektar Therapeutics
San Francisco, CA
platinum-resistant ovarian cancer
(see also breast, colorectal, solid
tumors)
P|ase ll
(855) 182-ê58Z
FANG™ Vaccine
autologous tumor cell vaccine
Gradalis
0arro||ron, TX
adjuvant ovarian cancer
(see also colorectal, skin)
P|ase ll
(211) 112-8100
folate binding protein (E39)
vaccine
Galena Biopharma
Lake Oswego, OR
(see also breast, other) P|ase l/ll
(855) 855-1253
iboctadekin GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also lymphoma) P|ase l corp|eled
(888) 825-5219
Medicines in Development for Cancer
Medicines in Development Cancer 2012
69
OVARIAN CANCER
Product Name Sponsor Indication Development Status
lVT-1012 |rrurol|erapeul|c
vaccine
lrrurolope
Doylestown, PA
(see also breast) P|ase l
(215) 253-1180
iniparib
(83l-201)
3arol u3
Bridgewater, NJ
(see also breast, lung) P|ase ll
(800) 981-2191
Karenitecin
®
cositecan
BioNumerik Pharmaceuticals
$an /nron|o, TX
advanced ovarian cancer
(see also lung, solid tumors)
P|ase lll
(210) ê11-1Z01
KHK-2866 Kyowa Hakko Kirin Pharma
Princeton, NJ
ovarian cancer (combination therapy)
(see also solid tumors)
P|ase l
(609) 919-1100
VK-1ZZ5
(wee1 |r||o|lor)
Merck
Whitehouse Station, NJ
second-line ovarian cancer P|ase ll
(800) 672-6372
MORAb-003
(farletuzumab)
Eisai
Woodcliff Lake, NJ
platinum-sensitive ovarian cancer
(see also lung)
P|ase lll
(888) 122-1Z13
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
lrsl-||re ovar|ar carcer
(see also breast, colorectal,
head/neck, kidney, leukemia, liver,
lung, multiple myeloma, other)
P|ase ll
(888) 812-293Z
00X-12Z OncoGenex Pharmaceuticals
Bothell, WA
(see also breast, lung) P|ase l
(125) ê8ê-1500
olaratumab
(LY3012207)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
(see also brain) P|ase ll
(800) 515-59Z9
ombrabulin
(AVE8062)
3arol u3
Bridgewater, NJ
second-line ovarian cancer
(see also lung, sarcoma)
P|ase ll
(800) 981-2191
Opaxio™
paclitaxel poliglumex
Cell Therapeutics
Seattle, WA
(see also brain, lung, stomach, other) P|ase lll
(800) 215-2355
oregovomab
(Orphan Drug)
Quest PharmaTech
Edmonton, Canada
P|ase l/ll
(Z80) 118-1100
03l-90ê
(l0F-1R/1R lyros|rase ||rase
inhibitor)
03l P|arraceul|ca|s
Farmingdale, NY
(see also lung, other) P|ase ll
(631) 962-0600
OVax
®
autologous cell vaccine
(Orphan Drug)
AVAX Technologies
Philadelphia, PA
P|ase l/ll
(215) 211-9Zê0
Medicines in Development for Cancer
Medicines in Development Cancer 2012
70
OVARIAN CANCER
Product Name Sponsor Indication Development Status
phenoxodiol Marshall Edwards
San Diego, CA
second-line late-stage ovarian cancer
(Fast Track)
(see also prostate, other)
P|ase lll
(858) Z92-ê300
picoplatin Ponaird Pharmaceuticals
Seattle, WA
(see also colorectal, lung, prostate) P|ase ll
(206) 281-7001
Quinamed
®
aroralde
Cephalon
Frazer, PA
(see also breast, prostate) P|ase ll
(ê10) 311-0200
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
ovarian cancer (combination therapy)
(see also brain, colorectal,
head/neck, lung, pancreatic,
sarcoma, skin, solid tumors)
--------------------------------------------------
ovarian cancer (monotherapy)
P|ase ll
(103) êZ0-Z3ZZ
-------------------------------------------
P|ase l
(103) êZ0-Z3ZZ
R0Z158 Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
R0Z599
(antibody drug conjugate)
Genentech
South San Francisco, CA
(see also lung) P|ase l
(800) ê2ê-3553
RG7600
(antibody drug conjugate)
Genentech
South San Francisco, CA
platinum-resistant ovarian cancer
(see also pancreatic)
P|ase l
(800) ê2ê-3553
rigosertib Onconova Therapeutics
Newtown, PA
(see also leukemia, lymphoma,
pancreatic)
P|ase ll
(2êZ) Z59-3ê80
rucaparib Clovis Oncology
Boulder, CO
(see also breast) P|ase ll
(303) ê25-5000
sagopilone Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also breast, prostate) P|ase ll corp|eled
(888) 812-293Z
3AR25ê212 (VV-121)
(anti-ErbB3 mAb)
Merrimack Pharmaceuticals
Cambridge, MA
3arol u3
Bridgewater, NJ
(see also breast, lung) P|ase l
(800) 981-2191
SG2000 Spirogen
London, United Kingdom
P|ase ll
www.spirogen.com
squalamine
(Orphan Drug)
OHR Pharmaceutical
New York, NY
resistant ovarian cancer P|ase ll
(212) ê82-8152
Telcyta™
canfosfamide
Telik
Palo Alto, CA
(see also lung, lymphoma) P|ase lll corp|eled
(ê50) 815-ZZ00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
71
OVARIAN CANCER
Product Name Sponsor Indication Development Status
tigatuzumab
(arl|-0R5 arl|oody)
Daiichi Sankyo
Parsippany, NJ
(see also breast, colorectal, liver,
lymphoma, pancreatic)
P|ase ll
(9Z3) 911-2ê00
topotecan liposomes injection Talon Therapeutics
San Mateo, CA
(see also lung) P|ase l
(ê50) 588-ê101
trabectedin
(Orphan Drug)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
second-line ovarian cancer
(see also breast, prostate, sarcoma)
P|ase lll
(800) 81Z-528ê
TRC 105
(ENG protein inhibitor)
TRACON Pharmaceuticals
San Diego, CA
(see also breast, prostate, other) P|ase ll
(858) 550-0Z80
trebananib
(AMG386)
Amgen
Tnousano Daks, 0/
(see also breast, colorectal, kidney,
liver, stomach, other)
P|ase lll
(800) ZZ2-ê13ê
Vargatef™
intedanib
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
lrsl-||re |ale-slaçe ovar|ar carcer
(combination therapy)
(see also lung)
P|ase lll
(800) 213-012Z
vosaroxin Sunesis Pharmaceuticals
South San Francisco, CA
(see also leukemia) P|ase ll
(ê50) 2êê-3Z39
Votrient™
pazopanib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also kidney, other) P|ase lll
(888) 825-5219
Zybrestat™
fosbretabulin
(Orphan Drug)
OXiGENE
South San Francisco, CA
(see also lung) P|ase ll
(ê50) ê35-Z000
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Abraxane
®
albumin-bound paclitaxel
(Orphan Drug)
Celgene
Summit, NJ
(see also bladder, breast, lung,
ovarian, skin)
P|ase lll
(908) 673-9000
Actimid
®
pomalidomide
Celgene
Summit, NJ
(see also lung, lymphoma,
multiple myeloma)
P|ase l/ll
(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
72
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
anti-MUC1 mAb Quest PharmaTech
Edmonton, Canada
P|ase l/ll
(Z80) 118-1100
anti-PSCA mAb Agensys
Santa Monica, CA
Astellas Pharma US
0eerle|o, lL
metastatic pancreatic cancer
(combination therapy)
P|ase ll
(800) ê95-1321
apricoxib
(TG01)
Tragara Pharmaceuticals
San Diego, CA
pancreatic (combination therapy)
(see also lung)
P|ase ll
(858) 350-ê900
Archexin
®
RX-0201
(Orphan Drug)
Rexahn Pharmaceuticals
Rockville, MD
metastatic pancreatic cancer
(combination therapy)
P|ase ll
(210) 2ê8-5300
A30-5VE Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
metastatic pancreatic cancer
(see also prostate)
P|ase l
(800) ê95-1321
(125) 52Z-1000
bavituximab Peregrine Pharmaceuticals
Tusr|n, 0/
lrsl-||re parcreal|c carcer
(see also liver, lung)
P|ase ll
(Z15) 508-ê000
BAY 86-9766
(MEK inhibitor)
Ardea Biosciences
San Diego, CA
Bayer HealthCare Pharmaceuticals
Wayne, NJ
lrsl-||re parcreal|c carcer
(combination therapy)
(see also liver)
P|ase l/ll
(888) 812-293Z
BC-819
(gene therapy)
(Orphan Drug)
BioCancell Therapeutics
Jerusalem, Israel
lrsl-||re |ale-slaçe parcreal|c carcer
(combination therapy)
(Fast Track)
(see also bladder, ovarian)
P|ase ll
www.biocancell.com
Chk1 inhibitor
(LY2603618)
Eli Lilly
Indianapolis, IN
(see also lung) P|ase ll
(800) 515-59Z9
CO-101
(lipid drug conjugate of
gemcitabine)
(Orphan Drug)
Clovis Oncology
Boulder, CO
lrsl-||re relaslal|c parcreal|c
cancer, second-line metastatic
pancreatic cancer
P|ase ll
(303) ê25-5000
CO-101
companion diagnostic
(|ENT1 llC assay)
Clovis Oncology
Boulder, CO
Ventana Medical Systems
Tuoson, /Z
pancreatic cancer (diagnosis) in clinical trials
(303) ê25-5000
CPl-ê13
(Orphan Drug)
Cornerstone Pharmaceuticals
Cranbury, NJ
combination therapy
(see also other)
P|ase l/ll
(ê09) 109-Z050
Medicines in Development for Cancer
Medicines in Development Cancer 2012
73
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
CRS-207
(cancer vaccine)
Aduro BioTech
Berkeley, CA
metastatic pancreatic cancer
(combination therapy)
P|ase ll
(510) 818-1100
dalotuzumab
(VK-0ê1ê)
Merck
Whitehouse Station, NJ
(see also breast, lung, other) P|ase l/ll
(800) 672-6372
encapsulated cell therapy
(macrobeads)
Roços|r lrsl|lule
New York, NY
refractory metastatic pancreatic
cancer
(see also colorectal, prostate)
P|ase ll
(212) Z1ê-15êê
FG-3019
(connective tissue growth
factor)
FibroGen
San Francisco, CA
P|ase ll
(115) 9Z8-1200
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
(see also breast, colorectal,
leukemia, liver, lung, multiple
myeloma, prostate, skin, stomach)
P|ase ll
(Z81) 2Z1-8200
ganitumab
(AV0 1Z9)
Amgen
Tnousano Daks, 0/
lrsl-||re relaslal|c parcreal|c carcer
(combination therapy)
(see also breast, colorectal, lung,
sarcoma)
P|ase lll
(800) ZZ2-ê13ê
0l-1000 0|ooelrrure
Louisville, CO
(see also colorectal, lung) P|ase ll
(303) ê25-2Z00
glufosfamide
(Orphan Drug)
Eleison Pharmaceuticals
Princeton, NJ
pancreatic cancer (Fast Track) P|ase lll corp|eled
(215) 551-3530
03-êê21
(monoclonal antibody)
Gilead Sciences
Foster City, CA
(see also colorectal) P|ase ll
(800) 115-3235
GV1001
(hTERT RNA vaccine)
KAEL-GemVax
Seoul, South Korea
P|ase l
www.kaelgemvax.com
GVAX
®
Pancreatic
cancer vaccine
(Orphan Drug)
BioSante Pharmaceuticals
Lincolnshire, IL
Aduro BioTech
Berkeley, CA
P|ase ll
(81Z) 1Z8-0500
(510) 818-1100
HyperAcute
®
Pancreas
algenpantucel-L
(Orphan Drug)
NewLink Genetics
Ames, IA
P|ase lll
(515) 29ê-5555
lVP321 lrrulep
Châtenay-Malabry, France
P|ase l
www.immutep.org
lNN0-20ê
(Orphan Drug)
CytRx
Los Angeles, CA
pancreatic ductal adenocarcinoma
(see also sarcoma, solid tumors)
P|ase ll
(310) 82ê-5ê18
Medicines in Development for Cancer
Medicines in Development Cancer 2012
74
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Istodax
®
romidepsin
Celgene
Summit, NJ
(see also kidney, prostate, other) P|ase l/ll
(908) 673-9000
-DNDÀ™
ruxolitinib
lrcyle
Wilmington, DE
(see also other) P|ase ll
(855) 11ê-2983
KD032
(ras/mTOR inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
(see also lung) P|ase l/ll corp|eled
(Z21) ZZ8-ê100
L0E225
(erismodegib)
Novartis Pharmaceuticals
East Hanover, NJ
neoadjuvant pancreatic cancer
(see also leukemia, solid tumors,
skin)
P|ase l/ll
(888) 669-6682
LE-DT
(liposomal docetaxel)
lrsys T|erapeul|cs
Phoenix, AZ
lrsl-||re parcreal|c carcer P|ase ll
(602) 910-2617
V102
(low molecular weight heparin)
Momenta Pharmaceuticals
Cambridge, MA
metastatic pancreatic cancer P|ase l/ll
(ê1Z) 191-9Z00
masitinib AB Science USA
Short Hills, NJ
(see also stomach) P|ase lll
(9Z3) 218-213Z
MM-398
(nanotherapeutic)
(Orphan Drug)
Merrimack Pharmaceuticals
Cambridge, MA
metastatic pancreatic cancer P|ase ll
(ê1Z) 111-1000
naptumomab estafenatox Active Biotech
Lund, Sweden
(see also kidney, lung) P|ase l corp|eled
www.activebiotech.com
NPC-1C
(ensituximab)
(Orphan Drug)
Neogenix Oncology
Rockville, MD
late-stage, metastatic pancreatic
cancer
(see also colorectal)
P|ase l
(301) 917-6893
paclitaxel polymeric micelle
formulation
Samyang Biopharmaceuticals
Seoul, South Korea
late-stage pancreatic cancer P|ase ll
www.samyangpharm.com
PancAtak™
gene therapy
Advantagene
Auburndale, MA
P|ase l
(ê1Z) 91ê-5115
PCl-2Z183
(laclor vlla |r||o|lor)
Pharmacyclics
Sunnyvale, CA
metastatic pancreatic cancer
(combination therapy)
P|ase ll
(108) ZZ1-0330
PEGPH20
(pegylated recombinant
human hyaluronidase)
Halozyme Therapeutics
San Diego, CA
P|ase l/ll
(858) Z91-8889
Medicines in Development for Cancer
Medicines in Development Cancer 2012
75
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
PHY906 PhytoCeutica
heu laven, 0T
(see also colorectal, liver,
cancer-related)
P|ase l/ll
(203) ZZZ-31ê2
polyclonal antibody stimulator
(Orphan Drug)
Cancer Advances
Durham, NC
(see also colorectal, stomach) P|ase lll
(919) 361-2162
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
pancreatic cancer (combination
therapy)
(see also brain, colorectal, head/
neck, lung, ovarian, sarcoma, skin,
solid tumors)
P|ase ll
(103) êZ0-Z3ZZ
Rexin-G
®
(Orphan Drug)
Epeius Biotechnologies
San Marino, CA
metastatic pancreatic cancer
(Fast Track)
(see also breast, sarcoma)
P|ase l/ll
(ê2ê) 111-êê95
RG7600
(antibody drug conjugate)
Genentech
South San Francisco, CA
platinum-resistant pancreatic cancer
(see also ovarian)
P|ase l
(800) ê2ê-3553
rigosertib Onconova Therapeutics
Newtown, PA
(see also leukemia, lymphoma,
ovarian)
P|ase ll/lll
(2êZ) Z59-3ê80
RP101 RESprotect
Dresden, Germany
P|ase ll/lll
www.resprotect.de
SecreFlo™
synthetic human secretin
Repligen
Waltham, MA
pancreatic cancer (diagnosis) Phase 0
(Z81) 250-0111
SPRYCEL
®
dasatinib
Bristol-Myers Squibb
Princeton, NJ
(see also brain, breast, prostate,
other)
in clinical trials
(800) 332-205ê
TH-302 Threshold Pharmaceuticals
South San Francisco, CA
(see also brain, leukemia, multiple
myeloma, sarcoma)
P|ase ll
(ê50) 1Z1-8200
tigatuzumab
(arl|-0R5 arl|oody)
Daiichi Sankyo
Parsippany, NJ
(see also breast, colorectal, liver,
lymphoma, ovarian)
P|ase ll corp|eled
(9Z3) 911-2ê00
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
(see also colorectal, kidney, liver,
lung, sarcoma, other)
P|ase l
(Z81) 991-0300
(9Z3) 911-2ê00
trametinib GlaxoSmithKline
Pson. Tr|ang|e Park, h0
lrsl-||re parcreal|c carcer
(see also leukemia, lung, lymphoma,
multiple myeloma, skin)
P|ase ll
(888) 825-5219
uridine triacetate
(PN101)
we||slal T|erapeul|cs
Gaithersburg, MD
(see also stomach) P|ase lll
(210) ê31-2500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
76
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Virulizin
®
Lorus Therapeutics
Toronro, 0anaoa
P|ase lll
(11ê) Z98-1200
Y-90 clivatuzumab
(Orphan Drug)
lrrurored|cs
Morris Plains, NJ
lrsl-||re parcreal|c carcer
(Fast Track)
P|ase l/ll
(9Z3) ê05-8200
PROSTATE CANCER
Product Name Sponsor Indication Development Status
99rTc-VlP-1105 Vo|ecu|ar lrs|ç|l P|arraceul|ca|s
Cambridge, MA
prostate cancer (diagnosis) P|ase l
(ê1Z) 192-5551
A8l-008
(nab
®
-docetaxel)
Celgene
Summit, NJ
lrsl-||re |orrore-relraclory proslale
cancer
P|ase l/ll
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
(see also brain, breast, colorectal,
lung, lymphoma, ovarian, skin, other)
P|ase l
(81Z) 93Z-ê100
AEZS-108 AEterna Zentaris
Basking Ridge, NJ
(see also bladder, ovarian, other) P|ase ll
(908) ê2ê-5128
arl|-0X10 rAo AgonOx
Portland, OR
P|ase l
(800) 979-7202
AP1903 Bellicum Pharmaceuticals
lousron, TX
(see also cancer-related) P|ase l/ll
(Z13) 311-ê1Z2
Apatone
®
ascorbic acid/menadione
lC-VedTec|
San Diego, CA
P|ase l/ll
(ê19) Z19-ê500
APC-100 Adamis Pharmaceuticals
San Diego, CA
P|ase l/ll
www.adamispharmaceuticals.
com
ARC-100 Archer Biosciences
New York, NY
hormone-refractory prostate cancer
(see also brain, breast, skin)
P|ase ll
(ê1ê) Z1Z-9090
ARN-509 Aragon Pharmaceuticals
San Diego, CA
hormone-refractory prostate cancer P|ase l/ll
(858) 3ê9-Zê00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
77
PROSTATE CANCER
Product Name Sponsor Indication Development Status
A30-5VE Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
castration-resistant prostate cancer
(see also pancreatic)
P|ase l
(800) ê95-1321
(125) 52Z-1000
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
hormone-refractory prostate cancer
(combination therapy)
(see also brain, leukemia, lung,
lymphoma, stomach)
--------------------------------------------------
hormone-sensitive prostate cancer
P|ase ll
(ê10) 108-0301
-------------------------------------------
P|ase l
(ê10) 108-0301
AZ03511
(androgen receptor
down-regulator)
AstraZeneca
Wilmington, DE
P|ase l
(800) 236-9933
bafetinib CytRx
Los Angeles, CA
second-line metastatic hormone-
refractory prostate cancer
(see also brain, leukemia)
P|ase ll
(310) 82ê-5ê18
BPX-101
(dendritic cell vaccine)
Bellicum Pharmaceuticals
lousron, TX
P|ase l/ll
(Z13) 311-ê1Z2
cabozantinib
(XL181)
Exelixis
South San Francisco, CA
castration-resistant prostate cancer
(see also breast, kidney, lung,
ovarian, other)
P|ase lll
(ê50) 83Z-Z000
CBLC102
(mepacrine)
Cleveland BioLabs
Buffalo, NY
lrcuror
Moscow, Russia
hormone-refractory prostate cancer P|ase ll corp|eled
(Z1ê) 819-ê810
CD1089
(seocalcitol)
Cougar Biotechnology
Raritan, NJ
P|ase l
www.cougarbiotechnology.com
cilengitide EMD Serono
Rockland, MA
(see also brain) P|ase lll
(800) 283-8088
custirsen
(OGX-011/TV-1011)
OncoGenex Pharmaceuticals
Bothell, WA
Teva Pharmaceuticals
T|kva, lsrae|
lrsl-||re proslale carcer (coro|ra-
tion therapy), second-line hormone-
refractory prostate cancer (combina-
tion therapy) (Fast Track)
(see also lung)
P|ase lll
(125) ê8ê-1500
CYT-500 EUSA Pharma
Langhorne, PA
P|ase l
(800) 833-3533
DPX-0907 lrrurovacc|re
Halifax, Canada
(see also breast, ovarian) P|ase l
(902) 192-1819
Medicines in Development for Cancer
Medicines in Development Cancer 2012
78
PROSTATE CANCER
Product Name Sponsor Indication Development Status
DSTP-3086S Genentech
South San Francisco, CA
metastatic hormone-refractory
prostate cancer
P|ase l
(800) ê2ê-3553
EZ850
(irofulven)
Eisai
Woodcliff Lake, NJ
hormone-refractory prostate cancer
(see also ovarian, other)
P|ase ll
(888) 122-1Z13
EV0-525Z9Z
(anti-integrin mAb)
EMD Serono
Rockland, MA
metastatic castration-resistant
prostate cancer
P|ase ll/lll
(800) 283-8088
emepepimut-S EMD Serono
Rockland, MA
Oncothyreon
Seattle, WA
newly-diagnosed prostate cancer
(see also lung)
P|ase ll
(800) 283-8088
encapsulated cell therapy
(macrobeads)
Roços|r lrsl|lule
New York, NY
refractory metastatic prostate cancer
(see also colorectal, pancreatic)
P|ase ll
(212) Z1ê-15êê
enzalutamide
(MDV3100)
Astellas Pharma
Tokyo, Jaµan
Medivation
San Francisco, CA
hormone-refractory prostate cancer
(Fast Track)
P|ase lll
(115) 513-31Z0
EPO-806
(patupilone)
Novartis Pharmaceuticals
East Hanover, NJ
(see also brain) P|ase ll
(888) 669-6682
EZN-11Zê
(antisense oligonucleotide)
Enzon Pharmaceuticals
Piscataway, NJ
P|ase l
(9Z3) 980-1500
Firmagon
®
degarelix
Ferring Pharmaceuticals
Parsippany, NJ
3-month formulation
--------------------------------------------------
neoadjuvant therapy
P|ase lll
(973) 796-1600
-------------------------------------------
P|ase lll
(973) 796-1600
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
second-line hormone-refractory
prostate cancer
(see also breast, colorectal,
leukemia, liver, lung, multiple
myeloma, pancreatic, skin, stomach)
P|ase ll
(Z81) 2Z1-8200
Gleevec
®
imatinib
Novartis Pharmaceuticals
East Hanover, NJ
hormone-refractory prostate cancer
(see also lung, skin, other)
P|ase ll
(888) 669-6682
GRNVAC1
(dendritic cell vaccine)
Argos Therapeutics
Durham, NC
Geron
Menlo Park, CA
(see also leukemia) P|ase l/ll
(ê50) 1Z3-ZZ00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
79
PROSTATE CANCER
Product Name Sponsor Indication Development Status
0Tx-Z58
(selective estrogen receptor
alpha agonist)
GTx
Vemµn|s, Th
lrsl-||re advarced proslale carcer,
second-line advanced prostate
cancer
P|ase ll
(901) 523-9Z00
GVAX
®
Prostate
cancer vaccine
BioSante Pharmaceuticals
Lincolnshire, IL
Aduro BioTech
Berkeley, CA
(Fast Track) P|ase lll
(81Z) 1Z8-0500
(510) 818-1100
Halaven
®
eribulin
Eisai
Woodcliff Lake, NJ
(see also lung, sarcoma) P|ase ll
(888) 122-1Z13
lE3235 Harbor Therapeutics
San Diego, CA
hormone-refractory prostate cancer P|ase l/ll
(858) 58Z-9333
intetumumab Janssen Biotech
Horsham, PA
(see also skin) P|ase ll corp|eled
(800) 52ê-ZZ3ê
lRX1201 lo T|erapeul|cs
Santa Ana, CA
P|ase ll
www.io-therapeutics.com
l3l3-ElF1E
Rx
ls|s P|arraceul|ca|s
Carlsbad, CA
prostate cancer (combination
therapy)
(see also lung)
P|ase ll
(800) êZ9-1Z1Z
Istodax
®
romidepsin
Celgene
Summit, NJ
(see also kidney, pancreatic, other) P|ase ll
(908) 673-9000
J 591 Lu-1ZZ
(anti-PMSA mAb)
BZL Biologics
New York, NY
metastatic prostate cancer,
non-metastatic prostate cancer
P|ase ll
(212) 315-55Z5
JNJ-2ê8511ê5
(Hdm2 inhibitor)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
(see also lung, solid tumors) P|ase l
(800) 81Z-528ê
KX2-391 Kinex Pharmaceuticals
Buffalo, NY
(see also leukemia) P|ase ll
(716) 898-8626
L8l589
(panobinostat)
Novartis Pharmaceuticals
East Hanover, NJ
(see also kidney, leukemia, multiple
myeloma, solid tumors)
P|ase ll
(888) 669-6682
LFA102
(anti-prolactin receptor
antibody)
Novartis Pharmaceuticals
East Hanover, NJ
XOMA
Berkeley, CA
(see also breast) P|ase l
(888) 669-6682
L0R-2010 Lorus Therapeutics
Toronro, 0anaoa
metastatic prostate cancer
(see also breast, colorectal, kidney,
leukemia)
P|ase ll
(11ê) Z98-1200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
80
PROSTATE CANCER
Product Name Sponsor Indication Development Status
VER-101
(GnRH antagonist)
Merrion Pharmaceuticals
Wilmington, DE
P|ase l
(910) Z99-181Z
MVA-BN
®
PRO
antigen cancer vaccine
8N lrruroT|erapeul|cs
Mountain View, CA
P|ase l/ll
(ê50) ê81-1êê0
NeuVax™
carcer vacc|re EZ5
Galena Biopharma
Lake Oswego, OR
(see also breast) P|ase l/ll
(855) 855-1253
nimotuzumab YM Biosciences USA
Lehigh Valley, PA
(see also brain, breast) P|ase ll
(ê10) 5ê0-0ê00
NX-1207 Nymox Pharmaceutical
Quebec, Canada
P|ase ll
(800) 936-9669
ODM-201
(androgen receptor antagonist)
Endo Pharmaceuticals
Chadds Ford, PA
Orion
Espoo, Finland
castration-resistant prostate cancer P|ase ll
(800) 1ê2-3ê3ê
oncolytic virus CZ BioMed
Tamµa, FL
P|ase l
(813) ê00-1088
0ryvax-105
anti-idiotype cancer vaccine
105A0Z
VaxOnco
Seoul, South Korea
P|ase ll
www.vaxonco.com
Onyvax-P
(prostate cancer vaccine)
VaxOnco
Seoul, South Korea
P|ase ll
ozarelix Spectrum Pharmaceuticals
Henderson, NV
hormone-dependent prostate cancer P|ase ll
(Z02) 835-ê300
PEG arginine deiminase
(A0l-PE0 20)
Polaris Pharmaceuticals
San Diego, CA
prostate cancer
(combination therapy)
(see also liver, skin, other)
P|ase l
(858) 152-êê88
phenoxodiol Marshall Edwards
San Diego, CA
prostate cancer (Fast Track)
(see also ovarian, other)
P|ase ll corp|eled
(858) Z92-ê300
picoplatin Ponaird Pharmaceuticals
Seattle, WA
(see also colorectal, lung, prostate) P|ase ll
(206) 281-7001
ProstAtak™
gene therapy
Advantagene
Auburndale, MA
adjuvant prostate cancer
(Fast Track)
P|ase lll
(ê1Z) 91ê-5115
Medicines in Development for Cancer
Medicines in Development Cancer 2012
81
PROSTATE CANCER
Product Name Sponsor Indication Development Status
prostate cancer vaccine
(anti-GnRH)
Novartis Vaccines & Diagnostics
Cambridge, MA
Pepscan Therapeutics
Lelystad, Netherlands
P|ase l/ll
(617) 871-7000
Prostvac™
rilimogene galvacirepvec
8V lrruroT|erapeul|cs
Mountain View, CA
castration-resistant prostate cancer
(Fast Track)
P|ase lll
(ê50) ê81-1êê0
Provenge
®
sipuleucel-T
Dendreon
Seattle, WA
recurrent early-stage prostate cancer
--------------------------------------------------
neoadjuvant early-stage prostate
cancer
P|ase lll
(8ZZ) 25ê-1515
-------------------------------------------
P|ase ll
(8ZZ) 25ê-1515
PRX-302 Sophiris Bio
La Jolla, CA
P|ase ll
(858) ZZZ-1Zê0
PSMA ADC
(anti-drug conjugate)
Progenics Pharmaceuticals
Tarryroun, hY
P|ase l
(911) Z89-2800
PSMA protein vaccine
(recombinant soluble)
Progenics Pharmaceuticals
Tarryroun, hY
P|ase l
(911) Z89-2800
PSMA VRP therapeutic vaccine Progenics Pharmaceuticals
Tarryroun, hY
P|ase l
(911) Z89-2800
PX-866 Oncothyreon
Seattle, WA
hormone-refractory prostate cancer
(see also brain, head/neck, lung)
P|ase ll
(206) 801-2100
Quinamed
®
aroralde
Cephalon
Frazer, PA
(see also breast, ovarian) P|ase ll
(ê10) 311-0200
RElC çere l|erapy Momotaro-Gene
Okayama, Japan
P|ase l
www.mt-gene.com
ridaforolimus ARlA0 P|arraceul|ca|s
Cambridge, MA
Merck
Whitehouse Station, NJ
(see also breast, kidney, lung,
sarcoma, other)
P|ase ll
(800) 672-6372
sagopilone Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also breast, ovarian) P|ase ll corp|eled
(888) 812-293Z
sarar|ur 3V-153 |ex|drorar
injection
EUSA Pharma
Langhorne, PA
(see also breast, multiple myeloma,
sarcoma, other)
P|ase ll
(800) 833-3533
siltuximab Janssen Biotech
Horsham, PA
hormone-refractory prostate cancer
(see also multiple myeloma, other)
P|ase l
(800) 52ê-ZZ3ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
82
PROSTATE CANCER
Product Name Sponsor Indication Development Status
SPRYCEL
®
dasatinib
Bristol-Myers Squibb
Princeton, NJ
(see also brain, breast, pancreatic,
other)
in clinical trials
(800) 332-205ê
TAK-118
(Kl331R prole|r açor|sl)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
TAK-700
(orteronel)
Millennium Pharmaceuticals
Cambridge, MA
lrsl-||re relaslal|c proslale carcer
(combination therapy), second-line
metastatic prostate cancer
(combination therapy)
--------------------------------------------------
prostate cancer
P|ase lll
(800) 390-5êê3
-------------------------------------------
P|ase ll
(800) 390-5êê3
tasquinimod
(TASQ)
Active Biotech
Lund, Sweden
metastatic prostate cancer
--------------------------------------------------
second-line metastatic prostate
cancer
P|ase lll
www.activebiotech.com
-------------------------------------------
P|ase l
www.activebiotech.com
TeloB-Vax
telomerase cancer vaccine
Adamis Pharmaceuticals
San Diego, CA
P|ase l
www.adamispharmaceuticals.
com
tesetaxel Genta
Berkeley Heights, NJ
(see also bladder, breast, skin,
stomach)
P|ase ll
(908) 286-9800
tigapotide Kotinos Pharmaceuticals
New York, NY
hormone-refractory prostate cancer P|ase ll
(212) 935-3000
TKl258
(dovitinib)
Novartis Pharmaceuticals
East Hanover, NJ
(see also breast, kidney, multiple
myeloma, skin, other)
P|ase ll
(888) 669-6682
TNFerade™
golnerminogene pradenovec
GenVec
Gaithersburg, MD
(see also head/neck, skin, stomach) P|ase l
(8ZZ) 913-ê832
TOK-001 Tokai Pharmaceuticals
Cambridge, MA
castration-resistant prostate cancer P|ase l
(ê1Z) 225-1305
trabectedin Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
(see also breast, ovarian, sarcoma) P|ase ll
(800) 81Z-528ê
TRC 105
(ENG protein inhibitor)
TRACON Pharmaceuticals
San Diego, CA
(see also breast, ovarian, other) P|ase l/ll
(858) 550-0Z80
Medicines in Development for Cancer
Medicines in Development Cancer 2012
83
PROSTATE CANCER
Product Name Sponsor Indication Development Status
Trofex™
|olo|aslal l-121
Vo|ecu|ar lrs|ç|l P|arraceul|ca|s
Cambridge, MA
prostate cancer (diagnosis) P|ase l
(ê1Z) 191-5551
TroVax
®
tumor-associated antigen
vaccine
Oxford BioMedica
Oxford, United Kingdom
hormone-refractory prostate cancer
(combination therapy)
P|ase ll
www.oxfordbiomedica.co.uk
vT-1ê1 Viamet Pharmaceuticals
Morrisville, NC
P|ase l/ll
(919) 1êZ-8539
YERVOY
®
ipilimumab
Bristol-Myers Squibb
Princeton, NJ
prostate cancer (post-hormonal
therapy), prostate cancer
(post-chemotherapy)
(see also lung, skin)
in clinical trials
(800) 332-205ê
Zaltrap™
al|oercepl
Regeneron Pharmaceuticals
Tarryroun, hY
3arol u3
Bridgewater, NJ
lrsl-||re ardroçer-|rdeperderl
prostate cancer
(see also colorectal)
P|ase lll
(911) 315-Z100
(800) 981-2191
Zytiga
®
abiraterone
Janssen Biotech
Horsham, PA
lrsl-||re relaslal|c proslale carcer
(see also breast)
--------------------------------------------------
neoadjuvant prostate cancer
P|ase lll
(800) 52ê-ZZ3ê
-------------------------------------------
P|ase ll
(800) 52ê-ZZ3ê
SARCOMA
Product Name Sponsor Indication Development Status
8l9 l-131 rAo United Therapeutics
Silver Spring, MD
soft tissue sarcoma
(see also brain, other)
P|ase l
(301) 608-9292
abexinostat
(HDAC inhibitor)
Pharmacyclics
Sunnyvale, CA
sarcoma
(see also lymphoma)
P|ase l/ll
(108) ZZ1-0330
brivanib
(VEGFR/FGFR kinase inhibitor)
Bristol-Myers Squibb
Princeton, NJ
(see also colorectal, liver) P|ase ll
(800) 332-205ê
cancer vaccine MabVax Therapeutics
San Diego, CA
(see also breast) P|ase ll
(858) 259-9105
ganitumab
(AV0 1Z9)
Amgen
Tnousano Daks, 0/
(see also breast, colorectal, lung,
pancreatic)
P|ase ll
(800) ZZ2-ê13ê
Halaven
®
eribulin
Eisai
Woodcliff Lake, NJ
(see also lung, prostate) P|ase lll
(888) 122-1Z13
Medicines in Development for Cancer
Medicines in Development Cancer 2012
84
SARCOMA
Product Name Sponsor Indication Development Status
lNN0-20ê
(Orphan Drug)
CytRx
Los Angeles, CA
soft tissue sarcoma
(see also pancreatic, solid tumors)
P|ase ll
(310) 82ê-5ê18
Junovan™
mifamurtide
(Orphan Drug)
Millennium Pharmaceuticals
Cambridge, MA
osteosarcoma P|ase lll
(800) 390-5êê3
ombrabulin
(AVE8062)
3arol u3
Bridgewater, NJ
(see also lung, ovarian) P|ase lll
(800) 981-2191
palifosfamide
(Zl0-201)
(Orphan Drug)
Zl0PlARV 0rco|oçy
New York, NY
lrsl-||re soll l|ssue sarcora
(combination therapy)
(see also lung, solid tumors)
--------------------------------------------------
second-line soft tissue sarcoma
(combination therapy)
--------------------------------------------------
soft tissue sarcoma (monotherapy)
P|ase lll
(ê1ê) 211-0Z00
-------------------------------------------
P|ase ll
(ê1ê) 211-0Z00
-------------------------------------------
P|ase l/ll
(ê1ê) 211-0Z00
perifosine AEterna Zentaris
Basking Ridge, NJ
(see also brain, colorectal, kidney,
leukemia, lung, lymphoma, multiple
myeloma, solid tumors, stomach)
P|ase ll
(908) ê2ê-5128
PV-00101 PharmaMar
Madrid, Spain
Ewing’s sarcoma
(see also cervical, other)
P|ase ll
www.pharmamar.com
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
(see also brain, colorectal, head/
neck, lung, ovarian, pancreatic, skin,
solid tumors)
P|ase ll
(103) êZ0-Z3ZZ
Rexin-G
®
(Orphan Drug)
Epeius Biotechnologies
San Marino, CA
osteosarcoma
(see also breast, pancreatic)
--------------------------------------------------
soft tissue sarcoma
P|ase ll
(ê2ê) 111-êê95
-------------------------------------------
P|ase l/ll
(ê2ê) 111-êê95
ridaforolimus
(Orphan Drug)
ARlA0 P|arraceul|ca|s
Cambridge, MA
Merck
Whitehouse Station, NJ
metastatic sarcoma (Fast Track)
(see also breast, kidney, lung,
prostate, other)
--------------------------------------------------
sarcoma
application submitted
(800) 672-6372
(ê2ê) 111-êê95
-------------------------------------------
P|ase ll
(800) 672-6372
(ê2ê) 111-êê95
robatumumab Merck
Whitehouse Station, NJ
osteosarcoma, sarcoma
(see also colorectal, solid tumors)
P|ase ll
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012
85
SARCOMA
Product Name Sponsor Indication Development Status
sarar|ur 3V-153 |ex|drorar
injection
EUSA Pharma
Langhorne, PA
osteosarcoma
(see also breast, multiple myeloma,
prostate, other)
P|ase l/ll
(800) 833-3533
saridegib
(Orphan Drug)
lrlr|ly P|arraceul|ca|s
Cambridge, MA
chondrosarcoma
(inoperable/unresectable)
P|ase ll
(ê1Z) 153-1000
TH-302
(Orphan Drug)
Threshold Pharmaceuticals
South San Francisco, CA
soft tissue sarcoma
(see also brain, leukemia, multiple
myeloma, pancreatic)
P|ase lll
(ê50) 1Z1-8200
tivantinib
(ARQ 197)
(Orphan Drug)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
soft tissue sarcoma
(see also colorectal, kidney, liver,
lung, pancreatic, other)
P|ase ll
(Z81) 991-0300
(9Z3) 911-2ê00
trabectedin
(Orphan Drug)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
soft tissue sarcoma
(see also breast, ovarian, prostate)
--------------------------------------------------
soft tissue sarcoma (adolescents and
children)
P|ase lll
(800) 81Z-528ê
-------------------------------------------
P|ase ll
(800) 81Z-528ê
SKIN CANCER
Product Name Sponsor Indication Development Status
Abraxane
®
albumin-bound paclitaxel
(Orphan Drug)
Celgene
Summit, NJ
malignant melanoma
(see also bladder, breast, lung,
ovarian, pancreatic)
P|ase lll
(908) 673-9000
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
malignant melanoma
(see also brain, breast, colorectal,
lung, lymphoma, ovarian, prostate,
other)
P|ase ll
(81Z) 93Z-ê100
Ad-lL-12 0NA l|erapeul|c
(lNXN-2001)
Zl0PlARV 0rco|oçy
New York, NY
malignant melanoma P|ase l
(ê1ê) 211-0Z00
Allovectin
®
velimogene aliplasmid
(Orphan Drug)
Vical
San Diego, CA
lrsl-||re ra||çrarl re|arora P|ase lll
(858) ê1ê-1100
Medicines in Development for Cancer
Medicines in Development Cancer 2012
86
SKIN CANCER
Product Name Sponsor Indication Development Status
ALT-801 Altor BioScience
Miramar, FL
malignant melanoma
(see also other)
P|ase l/ll
(951) 113-8ê00
anti-PD1
(8V3-93ê558)
Bristol-Myers Squibb
Princeton, NJ
melanoma
(see also kidney, lung)
P|ase ll
(800) 332-205ê
APN301
(c|11.18 rAo/|rler|eu||r-2
fusion protein)
Apeiron Biologics
Vienna, Austria
malignant melanoma
(see also brain)
P|ase ll
www.apeiron-biologics.com
ARC-100 Archer Biosciences
New York, NY
malignant melanoma (combination
therapy)
(see also brain, breast, prostate)
P|ase ll
(ê1ê) Z1Z-9090
ARRY-162
(MEK inhibitor)
Array BioPharma
Boulder, CO
malignant melanoma (BRAFV600E
or NRAS mutations)
(see also solid tumors)
P|ase ll
(8ZZ) ê33-213ê
astuprotimut-R
(VA0E-A3 arl|çer-spec|lc
cancer immunotherapeutic)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
malignant melanoma
(see also lung)
--------------------------------------------------
inoperable/unresectable malignant
melanoma
P|ase lll
(888) 825-5219
-------------------------------------------
P|ase ll
(888) 825-5219
autologous stem cell therapy California Stem Cells
Irvine, CA
malignant melanoma P|ase ll
(919) 531-9119
c31510 Cytotech
Natick, MA
basal cell cancer, squamous call
cancer
P|ase ll
(ê15) 515-5138
Cavatak™
coxsackievirus A21
(Orphan Drug)
Viralytics
Pymble, Australia
malignant melanoma P|ase ll
www.viralytics.com
CB-10-01
cancer vaccine
Cosmo Pharmaceuticals
Lainate, Italy
malignant melanoma P|ase ll
www.cosmopharmaceuticals.
com
CDX-011
(glembatumumab vedotin)
Celldex Therapeutics
Needham, MA
malignant melanoma
(see also breast)
P|ase ll
(Z81) 133-0ZZ1
CYT107
(interleukin-7)
Cytheris
Rockville, MD
malignant melanoma
(see also kidney)
P|ase l
(301) 231-0151
0C-lL-12 0NA l|erapeul|c
(lNXN-3001)
Zl0PlARV 0rco|oçy
New York, NY
malignant melanoma P|ase l
(ê1ê) 211-0Z00
0E0N-ê52êA Genentech
South San Francisco, CA
malignant melanoma P|ase l
(800) ê2ê-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012
87
SKIN CANCER
Product Name Sponsor Indication Development Status
dendritic cancer cell vaccine EMD Millipore
Billerica, MA
malignant melanoma P|ase l
(Z81) 533-ê000
EZ050 Eisai
Woodcliff Lake, NJ
late-stage malignant melanoma
(see also brain, head/neck, liver,
solid tumors, stomach)
P|ase l/ll
(888) 122-1Z13
E7080
(lenvatinib)
Eisai
Woodcliff Lake, NJ
melanoma
(see also brain, other)
P|ase ll
(888) 122-1Z13
ecromeximab Life Science Pharmaceuticals
0ar|en, 0T
malignant melanoma (combination
therapy)
P|ase ll
(203) ê5ê-2500
Erivedge™
vismodegib
Genentech
South San Francisco, CA
early-stage basal cell cancer
(resectable)
P|ase ll
(800) ê2ê-3553
FANG™ Vaccine
autologous tumor cell vaccine
Gradalis
0arro||ron, TX
malignant melanoma
(see also colorectal, ovarian)
P|ase ll
(211) 112-8100
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
malignant melanoma
(see also breast, colorectal,
leukemia, liver, lung, multiple
myeloma, pancreatic, prostate,
stomach)
P|ase ll
(Z81) 2Z1-8200
GDC-0973
(MEK inhibitor)
Genentech
South San Francisco, CA
second-line metastatic malignant
melanoma (combination therapy)
(see also solid tumors)
P|ase l
(800) ê2ê-3553
Gleevec
®
imatinib
Novartis Pharmaceuticals
East Hanover, NJ
malignant melanoma
(see also lung, prostate, other)
P|ase ll
(888) 669-6682
03K211813ê
(BRaf protein kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
lrsl-||re 8RAF rulal|or-pos|l|ve |ale-
stage malignant melanoma
(see also brain, lung)
--------------------------------------------------
BRAF mutation-positive metastatic
malignant melanoma (combination
therapy)
P|ase lll
(888) 825-5219
-------------------------------------------
P|ase ll
(888) 825-5219
03K2211ê58A
(cancer vaccine)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
metastatic malignant melanoma P|ase l
(888) 825-5219
03K2302025A
(cancer vaccine)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
lrsl-||re relaslal|c ra||çrarl
melanoma
P|ase l
(888) 825-5219
Medicines in Development for Cancer
Medicines in Development Cancer 2012
88
SKIN CANCER
Product Name Sponsor Indication Development Status
HyperAcute
®
Melanoma
melanoma vaccine
NewLink Genetics
Ames, IA
malignant melanoma P|ase ll
(515) 29ê-5555
lVC-çp100
(cancer vaccine)
lrrurocore
Oxon, United Kingdom
malignant melanoma Phase 0
www.immunocore.com
Imprime PGG
®
Biothera
Eagan, MN
malignant melanoma
(see also colorectal, leukemia, lung)
P|ase l
(ê51) êZ5-0300
lNC8213ê0 lrcyle
Wilmington, DE
malignant melanoma
(see also solid tumors)
P|ase ll
(855) 11ê-2983
interleukin-12 gene therapy OncoSec Medical
San Diego, CA
malignant melanoma, merkel cell
carcinoma
(see also lymphoma)
P|ase ll
www.oncosec.com
intetumumab Janssen Biotech
Horsham, PA
malignant melanoma
(see also prostate)
P|ase l/ll
(800) 52ê-ZZ3ê
L0E225
(erismodegib)
Novartis Pharmaceuticals
East Hanover, NJ
basal cell cancer
(see also leukemia, pancreatic,
solid tumors)
P|ase ll
(888) 669-6682
L0K9Z1
(wNT s|çra||rç pal|Way
inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
malignant melanoma
(see also breast)
P|ase l
(888) 669-6682
LGX818
(RAF inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
metastatic malignant melanoma
(see also colorectal)
P|ase l
(888) 669-6682
Lymphoseek
®
Tc-99m tilmanocept
Navidea Pharmaceuticals
Dublin, OH
malignant melanoma (diagnosis)
(see also breast, head/neck)
application submitted
(ê11) Z93-Z500
M-200 prophage cancer vaccine
(vitespen)
(Orphan Drug)
Agenus
Lexington, MA
metastatic melanoma
(Fast Track)
P|ase lll
(Z81) êZ1-1100
Marqibo
®
vincristine liposomal
(Orphan Drug)
Talon Therapeutics
San Mateo, CA
malignant melanoma
(see also leukemia, lymphoma,
other)
P|ase ll
(ê50) 588-ê101
melanoma DNA vaccine lc|or Ved|ca| 3yslers
San Diego, CA
Memorial Sloan-Kettering
Cancer Center
New York, NY
malignant melanoma P|ase l
(858) 550-2022
V0RAo-001 Eisai
Woodcliff Lake, NJ
malignant melanoma P|ase ll
(888) 122-1Z13
Medicines in Development for Cancer
Medicines in Development Cancer 2012
89
SKIN CANCER
Product Name Sponsor Indication Development Status
ruparloslal (Pl-88)
(Orphan Drug)
Progen Pharmaceuticals
Queensland, Australia
malignant melanoma
(see also liver)
P|ase ll
www.progen.com.au
MVax
®
melanoma vaccine
AVAX Technologies
Philadelphia, PA
malignant melanoma P|ase lll
(215) 211-9Zê0
NX-101 NexGenix
New York, NY
derra| reurolororaloses P|ase ll
(212) 9Z1-300ê
Ontak
®
denileukin diftitox
Eisai
Woodcliff Lake, NJ
malignant melanoma P|ase ll
(888) 122-1Z13
PEG arginine deiminase
(A0l-PE0 20)
Polaris Pharmaceuticals
San Diego, CA
metastatic malignant melanoma
(see also liver, prostate, other)
P|ase ll
(858) 152-êê88
Picato
®
ingenol mebutate
LEO Pharma
Parsippany, NJ
basal cell cancer P|ase ll
(8ZZ) 191-153ê
POL-103A
(melanoma vaccine)
(Orphan Drug)
Polynoma
San Diego, CA
malignant melanoma P|ase lll
(858) 205-2501
PRAVE arl|çer-spec|lc carcer
immunotherapeutic
(recombinant)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
metastatic malignant melanoma
(see also lung)
P|ase l
(888) 825-5319
PTl-188 Pain Therapeutics
/usr|n, TX
malignant melanoma P|ase l corp|eled
(512) 501-2111
PV-10
(rose bengal sodium)
(Orphan Drug)
Provectus Pharmaceuticals
rnoxv|||e, Th
malignant melanoma
(see also liver)
P|ase ll corp|eled
(8êê) 591-5999
RAF2ê5
(raf kinase inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
malignant melanoma
(see also solid tumors)
P|ase l
(888) 669-6682
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
malignant melanoma
(see also brain, colorectal,
head/neck, lung, ovarian, pancreatic,
sarcoma, solid tumors)
P|ase ll
(103) êZ0-Z3ZZ
R0Z25ê
(BRAF kinase inhibitor)
Roche
Nutley, NJ
malignant melanoma P|ase l
(9Z3) 235-5000
RG7636
(antibody drug conjugate)
Roche
Nutley, NJ
malignant melanoma P|ase l
(800) ê2ê-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012
90
SKIN CANCER
Product Name Sponsor Indication Development Status
talminogene laherparepvec Amgen
Tnousano Daks, 0/
malignant melanoma P|ase lll
(800) ZZ2-ê13ê
Tasigna
®
nilotinib
Novartis Pharmaceuticals
East Hanover, NJ
malignant melanoma (c-Kit mutation)
(see also leukemia, stomach)
P|ase lll
(888) 669-6682
tesetaxel
(Orphan Drug)
Genta
Berkeley Heights, NJ
malignant melanoma
(see also bladder, breast, prostate,
stomach)
P|ase ll
(908) 286-9800
TKl258
(dovitinib)
Novartis Pharmaceuticals
East Hanover, NJ
malignant melanoma
(see also breast, kidney, multiple
myeloma, prostate, other)
P|ase l/ll
(888) 669-6682
TNFerade™
golnerminogene pradenovec
GenVec
Gaithersburg, MD
malignant melanoma
(see also head/neck, prostate,
stomach)
P|ase ll
(8ZZ) 913-ê832
trametinib GlaxoSmithKline
Pson. Tr|ang|e Park, h0
malignant melanoma (monotherapy)
(see also leukemia, lung, lymphoma,
multiple myeloma, pancreatic)
--------------------------------------------------
malignant melanoma (combination
therapy)
P|ase lll
(888) 825-5219
-------------------------------------------
P|ase ll
(888) 825-5219
veglin
(VEGF antisense)
VasGene Therapeutics
Los Angeles, CA
Kaposi’s sarcoma
(see also lung, kidney)
P|ase l
(323) 221-7818
YERVOY
®
ipilimumab
Bristol-Myers Squibb
Princeton, NJ
melanoma (adjuvant therapy),
melanoma brain metastases
(see also lung, prostate)
in clinical trials
(800) 332-205ê
Zadaxin
®
thymalfasin alfa 1
(Orphan Drug)
SciClone Pharmaceuticals
Foster City, CA
malignant melanoma
(see also liver)
P|ase ll/lll
(ê50) 358-315ê
SOLID TUMORS
Product Name Sponsor Indication Development Status
AbGn-7 AbGenomics
Los Altos, CA
P|ase l
(ê50) 988-9912
A8l-009
(sirolimus albumin bound)
Celgene
Summit, NJ
P|ase l
(908) 673-9000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
91
SOLID TUMORS
Product Name Sponsor Indication Development Status
A8T-318
(aurora kinase inhibitor)
Abbott Laboratories
Abbott Park, IL
late-stage solid tumors
(see also other)
P|ase l
(81Z) 93Z-ê100
ABT-700
(c-Met inhibitor)
Abbott Laboratories
Abbott Park, IL
P|ase l
(81Z) 93Z-ê100
ABT-767
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
P|ase l
(81Z) 93Z-ê100
ABT-806
(EGFR inhibitor)
Abbott Laboratories
Abbott Park, IL
P|ase l
(81Z) 93Z-ê100
AC220
(quizartinib)
Ambit Biosciences
San Diego, CA
Astellas Pharma US
0eerle|o, lL
(see also leukemia) P|ase l
(858) 331-2100
(800) ê95-1321
AEZS-112 AEterna Zentaris
Basking Ridge, NJ
(see also lymphoma) P|ase l
(908) ê2ê-5128
Al-850 Acusphere
Lexington, MA
P|ase l
(ê1Z) ê18-8800
AL8-1095ê1(a)
(tubulin inhibitor)
AVRl
Albany, NY
Bessor Pharma
Framingham, MA
P|ase l
www.amriglobal.com
AlloStim™ lrruroval|ve T|erap|es
Shoham, Israel
(see also other) P|ase l/ll
www.immunovative.co.il
Alocrest™
vinorelbine liposomal
Talon Therapeutics
San Mateo, CA
(see also lymphoma) P|ase l
(ê50) 588-ê101
AMG 208
(c-Met inhibitor)
Amgen
Tnousano Daks, 0/
P|ase l
(800) ZZ2-ê13ê
AMG 337
(c-Met inhibitor)
Amgen
Tnousano Daks, 0/
P|ase l
(800) ZZ2-ê13ê
AMG 780
(angioprotein inhibitor)
Amgen
Tnousano Daks, 0/
P|ase l
(800) ZZ2-ê13ê
AMG 820
(c-fms antagonist)
Amgen
Tnousano Daks, 0/
P|ase l
(800) ZZ2-ê13ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
92
SOLID TUMORS
Product Name Sponsor Indication Development Status
AMG 900
(aurora kinase inhibitor)
Amgen
Tnousano Daks, 0/
(see also other) P|ase l
(800) ZZ2-ê13ê
AVP-221 Amplimmune
Gaithersburg, MD
P|ase l
(301) 309-9800
anti-CD137
(8V3-êê3513)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
arl|-l0F-1R rAo Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
anti-PD-L1
(8V3-93ê559)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
Aplidin
®
plitidepsin
PharmaMar
Madrid, Spain
(see also lymphoma, multiple
myeloma)
P|ase l
www.pharmamar.com
AR-12 Arno Therapeutics
Flemington, NJ
(see also lymphoma) P|ase l
(862) 703-7170
AR-67 Arno Therapeutics
Flemington, NJ
(see also brain, leukemia) P|ase l
(862) 703-7170
ARQ 092
(AKT inhibitor)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
inoperable/unresectable late-stage
solid tumors
P|ase l
(Z81) 991-0300
(9Z3) 911-2ê00
ARQ 621
(Eç5 |r||o|lor)
ArQule
Woburn, MA
late-stage solid tumors
(see also other)
P|ase l
(Z81) 991-0300
ARQ 736
(BRAF inhibitor)
ArQule
Woburn, MA
late-stage solid tumors P|ase l
(Z81) 991-0300
ARQ 761
(E2F1 stimulant)
ArQule
Woburn, MA
P|ase l
(Z81) 991-0300
ARRY-162
(MEK inhibitor)
Array BioPharma
Boulder, CO
late-stage solid tumors
(see also skin)
P|ase l
(8ZZ) ê33-213ê
ARRY-520
(KSP inhibitor)
Array BioPharma
Boulder, CO
(see also leukemia,
multiple myeloma)
P|ase l
(8ZZ) ê33-213ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
93
SOLID TUMORS
Product Name Sponsor Indication Development Status
ASG-22ME Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
P|ase l
(800) ê95-1321
(125) 52Z-1000
ASP3026 Astellas Pharma US
0eerle|o, lL
late-stage solid tumors
(see also lymphoma)
P|ase l
(800) ê95-1321
ATZ519
(CDK inhibitor)
Astex Pharmaceuticals
Dublin, CA
(see also leukemia, lymphoma,
multiple myeloma)
P|ase l
(925) 5ê0-0100
AT9283
(aurora/Jak2 inhibitor)
Astex Pharmaceuticals
Dublin, CA
(see also leukemia, lymphoma,
multiple myeloma)
P|ase l
(925) 5ê0-0100
AT13387
(Hsp90 inhibitor)
Astex Pharmaceuticals
Dublin, CA
refractory solid tumors
(see also stomach)
P|ase l
(925) 5ê0-0100
ATl-1123
(docetaxel liposomal)
Azaya Therapeutics
$an /nron|o, TX
P|ase l
(210) 311-êê00
AZ01180
(JAK1/JAK2 inhibitor)
AstraZeneca
Wilmington, DE
P|ase l
(800) 236-9933
AZ02011
(TOR kinase inhibitor)
AstraZeneca
Wilmington, DE
P|ase l
(800) 236-9933
AZ0151Z
(FGFR tyrosine kinase inhibitor)
AstraZeneca
Wilmington, DE
P|ase ll
(800) 236-9933
AZ053ê3
(AKT inhibitor)
Astex Pharmaceuticals
Dublin, CA
AstraZeneca
Wilmington, DE
P|ase l
(800) 236-9933
AZD8330
(ARRY-121Z01)
(MEK inhibitor)
Array BioPharma
Boulder, CO
AstraZeneca
Wilmington, DE
P|ase l
(800) 236-9933
AZD8931
(erbB kinase inhibitor)
AstraZeneca
Wilmington, DE
(see also breast) P|ase ll
(800) 236-9933
8AY 10-00391
(Pan-CDK inhibitor)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
late-stage solid tumors P|ase l
(888) 812-293Z
8AY Z9-1ê20
(antibody-drug conjugate)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
P|ase l
(888) 812-293Z
Medicines in Development for Cancer
Medicines in Development Cancer 2012
94
SOLID TUMORS
Product Name Sponsor Indication Development Status
8AY 80-ê91ê Bayer HealthCare Pharmaceuticals
Wayne, NJ
P|ase l
(888) 812-293Z
8AY 8Z-2213
(llF-1ἀ pathway inhibitor)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
P|ase l
(888) 812-293Z
8AY 91-9313
(antibody drug conjugate)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
P|ase l
(888) 812-293Z
88l503
(stemness kinase inhibitor)
Boston Biomedical
Norwood, MA
late-stage solid tumors P|ase l
(781) 278-0900
88lê08
(stemness inhibitor)
Boston Biomedical
Norwood, MA
late-stage solid tumors P|ase l
(781) 278-0900
belotecan OnKor Pharmaceuticals
Seattle, WA
P|ase ll
(20ê) ê91-1121
8EZ235
(kinase inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l/ll
(888) 669-6682
BGJ398
(FGF-R kinase inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(888) 669-6682
BGT226
(VT0R/Pl3K |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l/ll
(888) 669-6682
BHQ880
(mAb)
Novartis Pharmaceuticals
East Hanover, NJ
(see also multiple myeloma) P|ase l
(888) 669-6682
8l-811283
(aurora kinase B inhibitor)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
(see also leukemia) P|ase l
(800) 213-012Z
8l-8312êê 8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
P|ase l
(800) 213-012Z
8l-83ê815
(lç01-|aroda)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
P|ase l
(800) 213-012Z
8l-81Z325 8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
P|ase l
(800) 213-012Z
Medicines in Development for Cancer
Medicines in Development Cancer 2012
95
SOLID TUMORS
Product Name Sponsor Indication Development Status
8l-853520
(TYK2 inhibitor)
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
P|ase l
(800) 213-012Z
8ll8 015 8|oçer ldec
Cambridge, MA
P|ase l corp|eled
(617) 679-2000
8ll8 028 8|oçer ldec
Cambridge, MA
P|ase l corp|eled
(617) 679-2000
8lN0-011
(docetaxel nanopharmaceutical)
8lN0 8|osc|erces
Cambridge, MA
P|ase l
(ê1Z) 191-3100
BMN-673
(PARP inhibitor)
BioMarin Pharmaceuticals
Novato, CA
(see also other) P|ase l/ll
(115) 50ê-êZ00
803181
(Eç5 |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(888) 669-6682
BYL719
(Pl3K-a|p|a |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
late-stage solid tumors P|ase l
(888) 669-6682
CA-18C3 XBiotech
/usr|n, TX
(see also cancer-related, other) P|ase l/ll
(512) 38ê-2900
CALAA 01
(siRNA)
Calando Pharmaceuticals
Pasadena, CA
P|ase l
(626) 683-7200
carl|zor|o Onyx Pharmaceuticals
South San Francisco, CA
(see also multiple myeloma) P|ase ll
(ê50) 2êê-0000
C8P-501
(peptide mimetic)
CanBas
Shizouka, Japan
(see also lung) P|ase l
www.canbas.co.jp
CC-115
(kinase inhibitor)
Celgene
Summit, NJ
(see also lymphoma, multiple
myeloma)
P|ase l
(908) 673-9000
CC-122 Celgene
Summit, NJ
(see also lymphoma, multiple
myeloma)
P|ase l
(908) 673-9000
CDX-1127 Celldex Therapeutics
Needham, MA
(see also other) P|ase l
(Z81) 133-0ZZ1
C0X-1101
(cancer vaccine)
Celldex Therapeutics
Needham, MA
solid tumors expressing the
NY-ESO-1 protein
P|ase l/ll
(Z81) 133-0ZZ1
CEP-11981
(vE0F-R/TlE2 ||rase |r||o|lor)
Cephalon
Frazer, PA
P|ase l corp|eled
(ê10) 311-0200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
96
SOLID TUMORS
Product Name Sponsor Indication Development Status
CG201
(cancer vaccine)
CG Therapeutics
Seattle, WA
P|ase ll
(20ê) 33ê-5ê01
CRLX101 Cerulean Pharma
Cambridge, MA
late-stage solid tumors P|ase l/ll
(ê1Z) 551-9ê00
crolibulin EpiCept
Tarryroun, hY
P|ase l/ll
(911) ê0ê-3500
CUDC-101 Curis
Lexington, MA
P|ase l
(ê1Z) 503-ê500
CVX 060
(PF-0185ê881)
(Ang2 antagonist)
Plzer
New York, NY
(see also kidney) P|ase l
(8ê0) Z32-515ê
CX-1915
(CK2 inhibitor)
Cylene Pharmaceuticals
San Diego, CA
(see also multiple myeloma) P|ase l
(858) 8Z5-5100
CYC116
(aurora kinase/VEGFR2
inhibitor)
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
P|ase l
(908) 51Z-Z330
CYT-6091
(Aurimune)
Cyllrrure 3c|erces
Rockville, MD
P|ase l
(301) 825-3011
D-1MT NewLink Genetics
Ames, IA
(see also breast) P|ase l
(515) 29ê-5555
D-3263
(TRPM8 protein stimulant)
Dendreon
Seattle, WA
P|ase l
(8ZZ) 25ê-1515
dacomitinib
(PF-00299801)
Plzer
New York, NY
(see also lung) P|ase ll
(8ê0) Z32-515ê
darinaparsin
(Zl0-101)
Zl0PlARV 0rco|oçy
New York, NY
(see also liver, lymphoma,
multiple myeloma)
P|ase l
(ê1ê) 211-0Z00
03-2218 Daiichi Sankyo
Parsippany, NJ
P|ase l
(9Z3) 911-2ê00
03-Z123 Daiichi Sankyo
Parsippany, NJ
P|ase l
(9Z3) 911-2ê00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
97
SOLID TUMORS
Product Name Sponsor Indication Development Status
EZ050 Eisai
Woodcliff Lake, NJ
metastatic solid tumors
(see also brain, head/neck, liver,
skin, stomach)
P|ase l/ll
(888) 122-1Z13
EC17 Endocyte
West Lafayette, IN
P|ase l
www.endocyte.com
EC0189 Endocyte
West Lafayette, IN
P|ase l
www.endocyte.com
elsamitrucin Spectrum Pharmaceuticals
Henderson, NV
late-stage solid tumors P|ase l
(Z02) 835-ê300
EV0-12110ê3
(c-Met kinase inhibitor)
EMD Serono
Rockland, MA
P|ase l
(800) 283-8088
enavatuzumab Abbott Laboratories
Abbott Park, IL
P|ase l
(81Z) 93Z-ê100
EP-100 Esperance Pharmaceuticals
Baton Rouge, LA
P|ase l
(225) ê15-8911
ETBX-011
cancer vaccine
Etubics
Seattle, WA
late-stage metastatic solid tumors P|ase l
(20ê) 838-5110
etirinotecan pegol
(NKTR-102)
Nektar Therapeutics
San Francisco, CA
combination therapy
(see also breast, colorectal, ovarian)
P|ase l
(855) 182-ê58Z
EZN-2208
(PE0-3N38, lrlecar peço|)
Enzon Pharmaceuticals
Piscataway, NJ
solid tumors (pediatric)
(see also breast, colorectal)
--------------------------------------------------
combination therapy
P|ase l/ll
(9Z3) 980-1500
-------------------------------------------
P|ase l
(9Z3) 980-1500
EZN-2968
(llF1-a|p|a |r||o|lor)
Enzon Pharmaceuticals
Piscataway, NJ
(see also lymphoma) P|ase l
(9Z3) 980-1500
lc|aluzurao
(AV-299)
AVEO Pharmaceuticals
Cambridge, MA
(see also lung) P|ase l
(ê1Z) 299-5000
luc|c|al|de F-18 GE Healthcare
Waukesha, WI
Nal|ora| Carcer lrsl|lule
Bethesda, MD
solid tumors (diagnosis) P|ase ll
(2ê2) 513-1000
FP-1039/HGS1036 Five Prime Therapeutics
South San Francisco, CA
Human Genome Sciences
Rockville, MD
late-stage solid tumors P|ase l
(115) 3ê5-5ê00
(301) 309-8501
Medicines in Development for Cancer
Medicines in Development Cancer 2012
98
SOLID TUMORS
Product Name Sponsor Indication Development Status
G-202 GenSpera
$an /nron|o, TX
P|ase l
(210) 1Z9-8112
GC1008
(fresolimumab)
Genzyme
Cambridge, MA
P|ase l
(ê1Z) 252-Z500
GDC-0032
(Pl3 ||rase |r||o|lor)
Genentech
South San Francisco, CA
metastatic solid tumors P|ase l
(800) ê2ê-3553
GDC-0068
(Akt inhibitor)
Genentech
South San Francisco, CA
P|ase l/ll
(800) ê2ê-3553
00C-0319
(small molecule)
Genentech
South San Francisco, CA
(see also lymphoma) P|ase l
(800) ê2ê-3553
00C-0125
(ChK1 inhibitor)
Genentech
South San Francisco, CA
(see also lymphoma) P|ase l
(800) ê2ê-3553
00C-05Z5 Genentech
South San Francisco, CA
(see also lymphoma) P|ase l
(800) ê2ê-3553
GDC-0623
(MEK inhibitor)
Genentech
South San Francisco, CA
metastatic solid tumors P|ase l
(800) ê2ê-3553
GDC-0917
(lAP arlaçor|sl)
Genentech
South San Francisco, CA
(see also lymphoma) P|ase l
(800) ê2ê-3553
GDC-0973
(MEK inhibitor)
Genentech
South San Francisco, CA
(see also skin cancer) P|ase l
(800) ê2ê-3553
GDC-0980
(Pl3 ||rase/rT0R dua|
inhibitor)
Genentech
South San Francisco, CA
(see also breast, lymphoma) P|ase l
(800) ê2ê-3553
0erzê11282
(toposisomerase-1 inhibitor)
Genzyme
Cambridge, MA
P|ase l
(800) 981-2191
00Tl-2118 Kirax
Bonita Springs, FL
P|ase l
(239) 111-5100
0l-ê301
(brachyury peptide vaccine)
0|ooelrrure
Louisville, CO
P|ase l
(303) ê25-2Z00
GL-ONC1 Genelux
San Diego, CA
P|ase l
(858) 183-0021
GO-203-2c Genus Oncology
Vernon Hills, IL
late-stage solid tumors P|ase l
(81Z) 519-ê500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
99
SOLID TUMORS
Product Name Sponsor Indication Development Status
03K1ê13ê1
(polio-like kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also lymphoma) P|ase l
(888) 825-5219
GSK690693
(AKT kinase inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also lymphoma) P|ase l
(888) 825-5219
GSK1070916A
(selective aurora kinase B/C
inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
P|ase l
(888) 825-5219
03K212ê158
(Pl3K/rT0R |r||o|lor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also lymphoma) P|ase l
(888) 825-5219
03K2111Z95
(protein kinase B inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
(see also lymphoma) P|ase l
(888) 825-5219
03K225ê098
(FAK inhibitor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
P|ase l
(888) 825-5219
GSK2636771
(Pl3K oela-se|ecl|ve |r||o|lor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
P|ase l
(888) 825-5219
HSP990
(heat shock protein)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(888) 669-6682
l0F-1R arlaçor|sl
(8V3-Z5180Z)
Bristol-Myers Squibb
Princeton, NJ
P|ase ll
(800) 332-205ê
lVF-001
(cancer vaccine)
lrruroFrorl|er
Tokyo, Jaµan
NY-ESO-1 antigen-expressing solid
tumors
P|ase l
www.immunofrontier.com
lV0N388 lrruro0er
Waltham, MA
P|ase l
(Z81) 895-0ê00
lNC280
(c-Met inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l/ll
(888) 669-6682
lNC8213ê0 lrcyle
Wilmington, DE
(see also skin) P|ase l/ll
(855) 11ê-2983
indium-111 (ABT-806) Abbott Laboratories
Abbott Park, IL
solid tumors (diagnosis) P|ase l
(81Z) 93Z-ê100
lNK128
(mTOR inhibitor)
lrle|||||re
La Jolla, CA
(see also lymphoma, multiple
myeloma)
P|ase l
(858) Zê8-ê500
lNK111Z
(Pl3KĮ |r||o|lor)
lrle|||||re
La Jolla, CA
P|ase l
(858) Zê8-ê500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
100
SOLID TUMORS
Product Name Sponsor Indication Development Status
lNN0-20ê CytRx
Los Angeles, CA
(see also pancreatic, sarcoma) P|ase l/ll
(310) 82ê-5ê18
lNN0-305
(wT-1 vacc|re)
CytRx
Los Angeles, CA
(see also leukemia) P|ase l
(310) 82ê-5ê18
Jl-101
(angiogenesis inhibitor)
Jubilant Biosys
Malvern, PA
P|ase l/ll
(ê10) 210-8ê90
JNJ-2ê8511ê5
(Hdm2 inhibitor)
Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
late-stage solid tumors
(see also lung, prostate)
P|ase l
(800) 81Z-528ê
JX-929 Jennerex Biotherapeutics
San Francisco, CA
P|ase l
(115) 281-888ê
Karenitecin
®
8NP1350
BioNumerik Pharmaceuticals
$an /nron|o, TX
solid tumors (adults and pediatric)
(see also lung, ovarian)
P|ase l
(210) ê11-1Z01
KHK-2866 Kyowa Hakko Kirin Pharma
Princeton, NJ
advanced solid tumors
(see also ovarian)
P|ase l
(609) 919-1100
L8l589
(panobinostat)
Novartis Pharmaceuticals
East Hanover, NJ
(see also kidney, leukemia, multiple
myeloma, prostate)
P|ase l
(888) 669-6682
LClê99
(aldosterone synthase inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase ll
(888) 669-6682
LCL161
(lAP |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(888) 669-6682
L0E225
(erismodegib)
Novartis Pharmaceuticals
East Hanover, NJ
solid tumors (adults and pediatric)
(see also leukemia, pancreatic, skin)
P|ase l
(888) 669-6682
LDK378
(ALK inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(888) 669-6682
LEE011
(C0K1/ê |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
(see also lymphoma) P|ase l
(888) 669-6682
LE050ê
(Smo antagonist)
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(888) 669-6682
L-MDAM BioNumerik Pharmaceuticals
$an /nron|o, TX
P|ase l
(210) ê11-1Z01
L0R 253
(MTF-1 inhibitor)
Lorus Therapeutics
Toronro, 0anaoa
metastatic solid tumors P|ase l
(11ê) Z98-1200
Medicines in Development for Cancer
Medicines in Development Cancer 2012
101
SOLID TUMORS
Product Name Sponsor Indication Development Status
LP-261 Locus Pharmaceuticals
Blue Bell, PA
P|ase l
(215) 358-2000
lurbinectedin PharmaMar
Madrid, Spain
(see also leukemia) P|ase l
www.pharmamar.com
VE-113
(NADH oxidase inhibitor)
Marshall Edwards
San Diego, CA
refractory solid tumors P|ase l
(858) Z92-ê300
VE0l-5ê5
(anti-CEA BiTE)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
P|ase l
(800) 236-9933
(301) 398-0000
VE0l-5Z3
(arl|-l0F rAo)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
P|ase l
(800) 236-9933
(301) 398-0000
VE0l-0ê39
(arl|-de|la-|||e 1 rAo)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
P|ase l
(800) 236-9933
(301) 398-0000
VE0l-3ê1Z
(anti-ANG-2 mAb)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
P|ase l
(800) 236-9933
(301) 398-0000
MG-1102 Green Cross
Yongin, South Korea
Mogam Biotechnology Research
lrsl|lule
Yongin, South Korea
second-line solid tumors P|ase l
www.eng.greencross.com
MGA271
(anti-B7-H3)
MacroGenics
Rockville, MD
refractory metastatic solid tumors P|ase l
(301) 251-51Z2
MGAH22 (anti-HER2 mAb) MacroGenics
Rockville, MD
P|ase l
(301) 251-51Z2
VlNT152êA Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
VK-119ê Merck
Whitehouse Station, NJ
P|ase l corp|eled
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012
102
SOLID TUMORS
Product Name Sponsor Indication Development Status
VK-31Z5 Merck
Whitehouse Station, NJ
metastatic late-stage solid tumors P|ase l
(800) 672-6372
VK-182Z
(PARP inhibitor)
Merck
Whitehouse Station, NJ
P|ase l
(800) 672-6372
VK-5108/vX-ê89
(aurora kinase A inhibitor)
Merck
Whitehouse Station, NJ
Vertex Pharmaceuticals
Cambridge, MA
P|ase l
(800) 672-6372
(ê1Z) 111-ê100
VK-8212 Merck
Whitehouse Station, NJ
(see also leukemia) P|ase l
(800) 672-6372
MLN0128 Millennium Pharmaceuticals
Cambridge, MA
(see also other) P|ase l
(800) 390-5êê3
VLN0518
(tandutinib)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
MLN1117 Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
VLN2180
(raf kinase inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
VLN1921
(NEDD8 inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
(see also other) P|ase l
(800) 390-5êê3
MLN8237
(alisertib)
Millennium Pharmaceuticals
Cambridge, MA
(see also lymphoma) P|ase ll
(800) 390-5êê3
MLN9708
(ixazomib)
Millennium Pharmaceuticals
Cambridge, MA
(see also lymphoma, multiple
myeloma)
P|ase l
(800) 390-5êê3
VV-151
(EGFR antagonist)
Merrimack Pharmaceuticals
Cambridge, MA
P|ase l
(ê1Z) 111-1000
mocetinostat
(MGCD0103, HDAC inhibitor)
MethylGene
Montreal, Canada
(see also leukemia, lymphoma) P|ase l/ll
(511) 33Z-3333
MPDL-3280A Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012
103
SOLID TUMORS
Product Name Sponsor Indication Development Status
V3C20151038
(MEK inhibitor)
EMD Serono
Rockland, MA
P|ase l
(800) 283-8088
MTKi-328 BeiGene
Beijing, China
P|ase l
www.beigene.com
MTRN-2696 Spectrum Pharmaceuticals
Henderson, NV
P|ase l
(Z02) 835-ê300
NKP-1339 Niiki Pharma
Hoboken, NJ
P|ase l
(201) Z10-5512
NKTR-105
(pegylated docetaxel)
Nektar Therapeutics
San Francisco, CA
P|ase l
(115) 182-5300
NV3-111ê351
(CDC7 protein kinase inhibitor)
Nerviano Medical Services
Nerviano, Italy
P|ase l
www.nervianoms.com
NMS-1286937
(PlK-1 |r||o|lor)
Nerviano Medical Services
Nerviano, Italy
P|ase l
www.nervianoms.com
NPl-0052
(marizomib)
Nereus Pharmaceuticals
San Diego, CA
(see also lymphoma, multiple
myeloma)
P|ase l
(858) 58Z-1090
olaparib
(PARP inhibitor)
AstraZeneca
Wilmington, DE
P|ase l
(800) 236-9933
Omapro™
omacetaxine
Cephalon
Frazer, PA
(see also leukemia) P|ase ll
(ê10) 311-0200
0VP-18R5
(wrl pal|Way)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
OncoMed Pharmaceuticals
Redwood City, CA
P|ase l
(888) 812-283Z
(ê50) 995-8200
OMP-21M18
(0LL1 |r||o|lor)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
OncoMed Pharmaceuticals
Redwood City, CA
P|ase l
(888) 825-5219
(ê50) 995-8200
0VP-59R5
(notch pathway)
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
OncoMed Pharmaceuticals
Redwood City, CA
P|ase l
(888) 825-5219
(ê50) 995-8200
omtriptolide Pharmagenesis
Redwood City, CA
Pierre Fabre Pharmaceuticals
Parsippany, NJ
P|ase l
(ê50) 812-Z0ê0
www.pierre-fabre.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
104
SOLID TUMORS
Product Name Sponsor Indication Development Status
ONT-10
(cancer vaccine)
Oncothyreon
Seattle, WA
P|ase l
(206) 769-9219
ONX-0801 Onyx Pharmaceuticals
South San Francisco, CA
P|ase l
(ê50) 2êê-0000
0P8-51ê02 Otsuka America Pharmaceutical
Rockville, MD
P|ase l
(800) 5ê2-39Z1
oprozomib Onyx Pharmaceuticals
South San Francisco, CA
P|ase l
(ê50) 2êê-0000
oral azacitidine Celgene
Summit, NJ
(see also leukemia, lung, lymphoma) P|ase ll
(908) 673-9000
ortataxel Spectrum Pharmaceuticals
Henderson, NV
taxane-refractory solid tumors P|ase ll
(Z02) 835-ê300
03l-930
(c-kit/VEGFR-2)
03l P|arraceul|ca|s
Farmingdale, NY
P|ase l
(631) 962-0600
p28 peptide CDG Therapeutics
Chicago, IL
P|ase l
www.cdgti.com
paclitaxel liposomal Sun Pharma
Mumbai, India
P|ase l
www.sunpharma.com
palifosfamide
(Zl0-201)
Zl0PlARV 0rco|oçy
New York, NY
(see also lung, sarcoma) P|ase l
(ê1ê) 211-0Z00
pbi-shRNA™ STMN1 LP
(anti-stathim gene therapy)
Gradalis
0arro||ron, TX
P|ase l
(211) 112-8100
perifosine AEterna Zentaris
Basking Ridge, NJ
solid tumors (pediatric)
(see also brain, colorectal, kidney,
leukemia, lung, lymphoma, multiple
myeloma, sarcoma, stomach)
P|ase l
(908) ê2ê-5128
PF-00337210
(VEGFR2 antagonist)
Plzer
New York, NY
P|ase l corp|eled
(8ê0) Z32-515ê
PF-0311ê9ê2
(ALK-1 mAb)
Plzer
New York, NY
P|ase l
(8ê0) Z32-515ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
105
SOLID TUMORS
Product Name Sponsor Indication Development Status
PF-01ê05112
(arl|-Į5ȕ1 |rleçr|r rAo)
Plzer
New York, NY
P|ase l
(8ê0) Z32-515ê
PF-01ê91502
(Pl3K/rT0R |r||o|lor)
Plzer
New York, NY
(see also other) P|ase l
(8ê0) Z32-515ê
PF-05212381
(rT0R/Pl3K |r||o|lor)
Plzer
New York, NY
(see also other) P|ase l
(8ê0) Z32-515ê
P01101Z Progen Pharmaceuticals
Queensland, Australia
(see also lymphoma) P|ase l
www.progen-pharma.com
PLX3397
(CSF-1R kinase inhibitor)
Plexxikon
Berkeley, CA
metastatic solid tumors
(see also brain, leukemia, lymphoma)
P|ase l
(510) ê1Z-1000
PV-0ê0181 PharmaMar
Madrid, Spain
P|ase l
www.pharmamar.com
PNT2258
(bcl-2 oncogene inhibitor)
ProNAi Therapeutics
Ann Arbor, MI
P|ase l
(2ê9) 815-8098
PRl-Z21
(CBP/catenin inhibitor)
PRl3V 8|oLao
Yokohama, Japan
P|ase l
www.prismbiolab.com
PRLX93936 Prolexys Pharmaceuticals
$a|r Lake 0|ry, uT
P|ase l
PTC299 PTC Therapeutics
$ourn P|a|nle|o, hJ
(see also breast, other) P|ase ll
(908) 222-7000
purine nucleoside
phosphorylase
gene therapy
PNP Therapeutics
Birmingham, AL
P|ase l
www.pnptherapeutics.com
PwT3359Z
(Pl3K a|p|a/rT0R ||rase)
Pathway Therapeutics
San Francisco, CA
P|ase l
www.pathwaytx.com
08l-139 Quintessence Biosciences
Madison, WI
P|ase l
(ê08) 111-2950
RAF2ê5
(raf kinase inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
(see also skin) P|ase l/ll
(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012
106
SOLID TUMORS
Product Name Sponsor Indication Development Status
regorafenib Bayer HealthCare Pharmaceuticals
Wayne, NJ
(see also colorectal, kidney, lung,
stomach)
P|ase l
(888) 812-283Z
Reolysin
®
reovirus
Oncolytics Biotech
Calgary, Canada
solid tumors (pediatric)
(see also brain, colorectal,
head/neck, lung, ovarian, pancreatic,
sarcoma, skin)
P|ase l
(103) êZ0-Z3ZZ
RG7112
(MDM2 antagonist)
Roche
Nutley, NJ
(see also other) P|ase l
(9Z3) 235-5000
RG7116
(ErbB-3 receptor antagonist)
Roche
Nutley, NJ
P|ase l
(9Z3) 235-5000
R0Z155
(anti-CSF-1R mAb)
Roche
Nutley, NJ
P|ase l
(9Z3) 235-5000
RG7167
(ClF/VEK |r||o|lor)
Roche
Nutley, NJ
P|ase l
(9Z3) 235-5000
R0Z301
(MAP/raf inhibitor)
Roche
Nutley, NJ
P|ase l
(9Z3) 235-5000
RG7321
(Pl3KĮ |r||o|lor)
Genentech
South San Francisco, CA
Roche
Nutley, NJ
P|ase ll
(800) ê2ê-3553
(9Z3) 235-5000
R0Z31Z
(NRP1 antagonist)
Genentech
South San Francisco, CA
Roche
Nutley, NJ
P|ase l
(800) ê2ê-3553
(9Z3) 235-5000
R0Z35ê
(C011 arl|çer |r||o|lor)
Roche
Nutley, NJ
P|ase l
(9Z3) 235-5000
RG7388
(MDM2 inhibitor)
Roche
Nutley, NJ
(see also other) P|ase l
(9Z3) 235-5000
R0Z111
(HFGR-1877S)
Genentech
South San Francisco, CA
(see also multiple myeloma) P|ase l
(800) ê2ê-3553
R0Z11ê
(mAb)
Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
R0Z591
(mAb)
Genentech
South San Francisco, CA
advanced solid tumors P|ase l
(800) ê2ê-3553
Medicines in Development for Cancer
Medicines in Development Cancer 2012
107
SOLID TUMORS
Product Name Sponsor Indication Development Status
RG7602 Genentech
South San Francisco, CA
(see also lymphoma) P|ase l
(800) ê2ê-3553
robatumumab Merck
Whitehouse Station, NJ
solid tumors (combination therapy)
(see also colorectal, sarcoma)
--------------------------------------------------
solid tumors (pediatric)
P|ase ll
(800) 672-6372
-------------------------------------------
P|ase l
(800) 672-6372
RRx-001 RadioRx
Mountain View, CA
P|ase l
(ê50) ê81-9885
sapacitabine
(CYC682)
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
(see also leukemia, lung) P|ase l
(908) 51Z-Z330
3AR125811
(Met kinase inhibitor)
3arol u3
Bridgewater, NJ
P|ase l
(800) 981-2191
3AR153192
(arl|-0LL1 rAo)
3arol u3
Bridgewater, NJ
P|ase l
(800) 981-2191
3AR215108/V3C193ê3ê98
combination therapy
(Pl3K |r||o|lor/VEK |r||o|lor)
Merck Serono
Geneva, Switzerland
3arol u3
Bridgewater, NJ
P|ase l
(800) 981-2191
3AR215109/V3C193ê3ê98
combination therapy
(Pl3K-rT0R |r||o|lor/VEK
inhibitor)
Merck Serono
Geneva, Switzerland
3arol u3
Bridgewater, NJ
P|ase l
(800) 981-2191
3AR25ê212
(MM-121)
companion diagnostic
Merrimack Pharmaceuticals
Cambridge, MA
3arol u3
Bridgewater, NJ
solid tumors (diagnosis) P|ase ll
(800) 981-2191
3AR30ZZ1ê
(REGN910)
(anti-Ang2 mAb)
Regeneron Pharmaceuticals
Tarryroun, hY
3arol u3
Bridgewater, NJ
P|ase l
(911) 31Z-Z000
(800) 981-2191
3AR5êêê58
(maytansin-loaded anti-DS6)
3arol u3
Bridgewater, NJ
DS6-positive solid tumors P|ase l
(800) 981-2191
SB989
(pracinostat)
3¯8l0
Oakland, CA
late-stage solid tumors
(see also leukemia, other)
P|ase l
(ê50) Z30-28ê0
Medicines in Development for Cancer
Medicines in Development Cancer 2012
108
SOLID TUMORS
Product Name Sponsor Indication Development Status
3Cl-900353 Merck
Whitehouse Station, NJ
P|ase l
(800) 672-6372
seliciclib
(CYC202)
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
(see also head/neck) P|ase l
(908) 51Z-Z330
selumetinib
(AZ0ê211/ARRY-11288ê)
(MEK inhibitor)
AstraZeneca
Wilmington, DE
P|ase ll
(800) 236-9933
selumetinib
(AZ0ê211/ARRY-11288ê)/
MK2206 combination
(MEK/AKT inhibitor)
AstraZeneca
Wilmington, DE
Merck
Whitehouse Station, NJ
P|ase l
(800) 236-9933
(800) 672-6372
SF1126 Semafore Pharmaceuticals
Indianapolis, IN
(see also leukemia, multiple
myeloma)
P|ase l
(31Z) 8Zê-30Z5
s|rolaxe| lv Taxolog
Fa|rle|o, hJ
P|ase l
(8êê) 829-ê5ê1
solid tumor immunotherapy
(mAb)
Genentech
South San Francisco, CA
P|ase l
(800) ê2ê-3553
sonepcizumab Lpath
San Diego, CA
P|ase l
(858) êZ8-0800
3Pl-1ê20
(endothelin B receptor agonist)
Spectrum Pharmaceuticals
Henderson, NV
P|ase l
(Z02) 835-ê300
TAG vaccine Gradalis
0arro||ron, TX
P|ase l
(211) 112-8100
TAK-385
(gonadotrophin
hormone-releasing hormone
receptor antagonist)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
TAK-111
(hedgehog signaling pathway
inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
TAK-701
(HGF inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
TAK-733
(MEK inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
Medicines in Development for Cancer
Medicines in Development Cancer 2012
109
SOLID TUMORS
Product Name Sponsor Indication Development Status
TAK-960
(Plk1 inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
P|ase l
(800) 390-5êê3
teglarinad Cephalon
Frazer, PA
(see also lymphoma) P|ase l
(ê10) 311-0200
terameprocol Erimos Pharmaceuticals
lousron, TX
so||d lurors (lv-|rlus|or)
(see also brain, cervical, head/neck,
other)
P|ase l
(Z13) 511-2000
TKM-PLK1
(RNAi)
Tekmira Pharmaceuticals
Burnaby, Canada
(see also lymphoma) P|ase l
(ê01) 119-3200
TL-32711
(birinapant)
TetraLogic Pharmaceuticals
Malvern, PA
(see also leukemia) P|ase l/ll
(610) 889-9900
TLC-388 TLC Biopharmaceuticals
South San Francisco, CA
P|ase l
(ê50) 8Z2-881ê
TRC093
(lç01 rAo)
TRACON Pharmaceuticals
San Diego, CA
P|ase l corp|eled
(858) 550-0Z80
TRC102
(DNA repair inhibitor)
TRACON Pharmaceuticals
San Diego, CA
P|ase l
(858) 550-0Z80
tremelimumab
(arl|-CTLA1 rAo)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
P|ase ll
(800) 236-9933
(301) 398-0000
TST-10088 Cangene
Winnipeg, Canada
P|ase l
(201) 2Z5-1200
u3-15ê5
(anti-HB-EGF antibody)
Amgen
Tnousano Daks, 0/
Daiichi Sankyo US
Parsippany, NJ
P|ase l
(800) ZZ2-ê13ê
(9Z3) 911-2ê00
uN83-51ê2 Drais Pharmaceuticals
Bridgewater, NJ
(see also lymphoma) P|ase l
(908) 895-1200
v931/v935 Merck
Whitehouse Station, NJ
P|ase l corp|eled
(800) 672-6372
v935
(telomerase inhibitor vaccine)
Geron
Menlo Park, CA
Merck
Whitehouse Station, NJ
P|ase l
(ê50) 1Z3-ZZ00
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012
110
SOLID TUMORS
Product Name Sponsor Indication Development Status
VGX-100
(VEGF-C mAb)
Circadian Technologies
Victoria, Australia
P|ase l
www.circadian.com.au
VTX-2337 VentiRx Pharmaceuticals
Seattle, WA
(see also lymphoma) P|ase l
(20ê) ê89-2259
vX15 Vaccinex
Rochester, NY
P|ase l
(585) 2Z1-2Z00
wX-uK1 w||ex
Munich, Germany
P|ase l
www.wilex.de
X-82
(dual VEGFR/PDGFR inhibitor)
Tyrogenex
West Palm Beach, FL
advanced solid tumors P|ase l
(5ê1) 835-935ê
Xalkori
®
crizotinib
Plzer
New York, NY
(see also lung) P|ase l
(8ê0) Z32-515ê
XMT-1001 Mersana Therapeutics
Cambridge, MA
P|ase l
(ê1Z) 198-0020
XMT-1107 Mersana Therapeutics
Cambridge, MA
P|ase l
(ê1Z) 198-0020
STOMACH CANCER
Product Name Sponsor Indication Development Status
AT-101
(oral pan Bcl-2 inhibitor)
Ascenta Therapeutics
Malvern, PA
late-stage esophageal cancer
(combination therapy)
(see also brain, leukemia, lung,
lymphoma, prostate)
P|ase l/ll
(ê10) 108-0301
AT13387
(Hsp90 inhibitor)
Astex Pharmaceuticals
Dublin, CA
late-stage gastrointestinal stromal
lurors (0l3T) (secord-||re l|erapy)
(see also solid tumors)
P|ase ll
(925) 5ê0-0100
AUY922
(Hsp90 inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
secord-||re 0l3T
(see also breast, colorectal, lung,
multiple myeloma)
P|ase ll
(888) 669-6682
8ll8 2021 8|oçer ldec
Cambridge, MA
0l3T
(see also breast)
P|ase ll corp|eled
(617) 679-2000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
111
STOMACH CANCER
Product Name Sponsor Indication Development Status
crenolanib
(CP-8ê8-59ê)
AROG Pharmaceuticals
0a||as, TX
0l3T
(see also brain)
P|ase ll
(211) 591-0002
EZ050 Eisai
Woodcliff Lake, NJ
gastric cancer (combination therapy)
(see also brain, head/neck, liver,
skin, solid tumors)
P|ase l/ll
(888) 122-1Z13
ERBITUX
®

cetuximab
Bristol-Myers Squibb
Princeton, NJ
Eli Lilly
Indianapolis, IN
gastric cancer
(see also colorectal)
in clinical trials
(800) 332-205ê
(800) 515-59Z9
ganetespib
(Hsp90i)
Synta Pharmaceuticals
Lexington, MA
esophageal cancer, gastric cancer,
0l3T
(see also breast, colorectal,
leukemia, liver, lung, multiple
myeloma, pancreatic, prostate, skin)
P|ase ll
(Z81) 2Z1-8200
masitinib
(Orphan Drug)
AB Science USA
Short Hills, NJ
0l3T
(see also pancreatic)
P|ase lll
(9Z3) 218-213Z
Opaxio™
paclitaxel poliglumex
Cell Therapeutics
Seattle, WA
esophageal cancer
(see also brain, lung, ovarian, other)
P|ase ll
(800) 215-2355
perifosine AEterna Zentaris
Basking Ridge, NJ
0l3T
(see also brain, colorectal, kidney,
leukemia, lung, lymphoma, multiple
myeloma, sarcoma, solid tumors)
P|ase ll
(908) ê2ê-5128
polyclonal antibody stimulator
(Orphan Drug)
Cancer Advances
Durham, NC
gastric cancer
(see also colorectal, pancreatic)
P|ase lll
(919) 361-2162
ramucirumab
(lVC-11218)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
gastric cancer
(see also breast, colorectal)
P|ase lll
(800) 515-59Z9
regorafenib
(Orphan Drug)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
0l3T (Fasl Trac|)
(see also colorectal, kidney, lung,
solid tumors)
P|ase lll
(888) 812-283Z
S-1 Taiho Pharma U.S.A.
Princeton, NJ
gastric cancer P|ase lll
(ê09) Z50-5300
Tasigna®
nilotinib
(Orphan Drug)
Novartis Pharmaceuticals
East Hanover, NJ
0l3T
(see also leukemia, skin)
P|ase lll
(888) 669-6682
Medicines in Development for Cancer
Medicines in Development Cancer 2012
112
STOMACH CANCER
Product Name Sponsor Indication Development Status
telatinib
(Orphan Drug)
ACT Biotech
San Francisco, CA
gastric cancer (combination therapy)
(see also colorectal)
P|ase ll
(115) 230-3900
tesetaxel
(Orphan Drug)
Genta
Berkeley Heights, NJ
gastric cancer
(see also bladder, breast, prostate,
skin)
P|ase ll
(908) 286-9800
TNFerade™
golnerminogene pradenovac
GenVec
Gaithersburg, MD
esophageal cancer
(see also head/neck, prostate, skin)
P|ase ll
(8ZZ) 913-ê832
trebananib
(AMG386)
Amgen
Tnousano Daks, 0/
esophageal cancer, gastric cancer
(see also breast, colorectal, kidney,
liver, ovarian, other)
P|ase ll
(800) ZZ2-ê13ê
Tykerb
®
lapatinib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
gastric cancer
(see also breast, head/neck)
P|ase lll
(888) 825-5219
uridine triacetate
(PN101)
we||slal T|erapeul|cs
Gaithersburg, MD
gastric cancer
(see also pancreatic)
P|ase ll
(210) ê31-2500
Xeloda
®
capecitabine
Genentech
South San Francisco, CA
esophageal cancer
(see also brain, colorectal, liver)
P|ase ll
(800) ê2ê-3553
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
AG103 ActoGenix
Zwijnaarde, Belgium
oral mucositis associated with cancer
treatment
P|ase l
www.actogenix.com
AP1903 Bellicum Pharmaceuticals
lousron, TX
graft-versus-host disease
(see also prostate)
P|ase l
(Z13) 311-ê1Z2
ARX-02
(sufentanil sublingual)
AcelRx Pharmaceuticals
Redwood City, CA
breakthrough cancer pain P|ase ll
(ê50) 21ê-3500
CA-18C3 XBiotech
/usr|n, TX
cancer-related cachexia
(see also other, solid tumors)
P|ase l/ll
(512) 38ê-2900
Medicines in Development for Cancer
Medicines in Development Cancer 2012
113
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
C01100
(oltipraz)
Canopus BioPharma
Studio City, CA
chemotherapy- and radiation-induced
mucositis
P|ase ll
www.canopusbiopharma.com
CLT-008 Cellerant Therapeutics
San Carlos, CA
chemotherapy-related neutropenia
(see also other)
P|ase l/ll
(ê50) 232-2122
dronabinol oral solution lN3Y3 T|erapeul|cs
Phoenix, AZ
chemotherapy-induced nausea and
vomiting
P|ase lll
(602) 910-2617
Eê011 Eisai
Woodcliff Lake, NJ
oral mucositis P|ase lll
(888) 122-1Z13
Emend
®
aprepitant
Merck
Whitehouse Station, NJ
chemotherapy-induced nausea and
vomiting (pediatric)
P|ase lll
(800) 672-6372
Emend
®
IV
aprepitant
Merck
Whitehouse Station, NJ
chemotherapy-induced nausea and
vomiting (pediatric)
P|ase l
(800) 672-6372
fentanyl inhalation Akela Pharma
/usr|n, TX
cancer pain P|ase ll/lll
(512 831-0119
ferroportin mAb Eli Lilly
Indianapolis, IN
anemia associated with cancer P|ase l
(800) 515-59Z9
fulranumab Johnson & Johnson Pharmaceutical
Research & Development
Raritan, NJ
cancer pain (adjunctive treatment) P|ase ll
(800) 81Z-528ê
hepcidin mAb Eli Lilly
Indianapolis, IN
anemia associated with cancer P|ase l
(800) 515-59Z9
LG631 Lentigen
Gaithersburg, MD
chemoprotection in patients
undergoing treatment for
glioblastoma
P|ase l
(301) 52Z-1200
mesenchymal stem cell therapy
(Orphan Drug)
Mesoblast
New York, NY
for bone marrow regeneration in
patients undergoing bone marrow
transplantation
P|ase lll
(212) 880-2060
morphine intranasal Marina Biotech
Bothell, WA
cancer pain P|ase ll
(125) 908-3ê00
MultiStem
®
stem cell therapy
(Orphan Drug)
Athersys
Cleveland, OH
graft-versus-host disease in patients
undergoing bone marrow transplant
P|ase l
(21ê) 131-9900
Medicines in Development for Cancer
Medicines in Development Cancer 2012
114
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
nabiximols Otsuka America Pharmaceutical
Rockville, MD
cancer pain (adjunctive treatment) P|ase lll
(800) 5ê2-39Z1
netupitant/palonosetron Helsinn Therapeutics
Bridgewater, NJ
chemotherapy-induced nausea and
vomiting
P|ase lll
(908) 231-1135
NP-2 gene therapy
(intradermal)
Diamyd Medical
Pittsburgh, PA
cancer pain P|ase ll
(112) ZZ0-1310
Nplate
®
romiplostim
Amgen
Tnousano Daks, 0/
chemotherapy-associated
thrombocytopenia
P|ase ll
(800) ZZ2-ê13ê
PHY906 PhytoCeutica
heu laven, 0T
chemotherapy-induced
gastrointestinal disorders
(see also colorectal, liver, pancreatic)
P|ase l/ll
(203) ZZZ-31ê2
Prochymal
®
remestemcel-L
(Orphan Drug)
Osiris Therapeutics
Columbia, MD
graft-versus-host disease P|ase lll
(113) 515-1800
ProDermaCel™
norepinephrine topical
ProCertus BioPharm
Madison, WI
prevention of oral mucositis,
prevention of radiation-induced skin
damage
P|ase l/ll
(608) 273-8862
Promacta
®
eltrombopag
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
chemotherapy-induced
thrombocytopenia
P|ase ll
(888) 669-6682
R0l-2001 REGiMMUNE
Santa Clara, CA
graft-versus-host disease P|ase l/ll
www.regimmune.com
rolapitant TESARO
Waltham, MA
chemotherapy-induced nausea and
vomiting
P|ase lll
(339) 970-0900
SGX201 Soligenix
Princeton, NJ
acute radiation enteritis in patients
with cancer
P|ase l/ll
(ê09) 538-8200
sotatercept
(ACE-011)
Celgene
Summit, NJ
chemotherapy-induced anemia
(see also other)
P|ase ll/lll
(908) 673-9000
tanezumab Plzer
New York, NY
cancer pain (adjunctive treatment) P|ase ll
(8ê0) Z32-515ê
Tavocept
®
dimesna
BioNumerik Pharmaceuticals
$an /nron|o, TX
chemoprotection
(see also lung)
P|ase lll
(210) ê11-1Z01
Medicines in Development for Cancer
Medicines in Development Cancer 2012
115
CANCER/CHEMOTHERAPY-RELATED CONDITIONS
Product Name Sponsor Indication Development Status
T-cell replacement therapy Bellicum Pharmaceuticals
lousron, TX
graft-versus-host disease in patients
with late-stage cancer undergoing
bone marrow transplantation
P|ase l
(Z13) 311-ê1Z2
Tl-9102
(Orphan Drug)
Kiadis Pharma
Amsterdam, Netherlands
graft-versus-host disease P|ase l/ll
www.kiadis.com
TXA127 Tarix Pharmaceuticals
Cambridge, MA
chemotherapy-induced
thrombocytopenia
P|ase ll
www.tarixpharma.com
Velcade
®
bortezomib
Millennium Pharmaceuticals
Cambridge, MA
steroid-refractory graft-versus-host
disease
(see also leukemia, lymphoma,
other)
P|ase ll
(800) 390-5êê3
XEN-21Z1 Xenome
Queensland, Australia
cancer pain P|ase ll
www.xenome.com
Xgeva™
denosumab
Amgen
Tnousano Daks, 0/
prevention of cancer-related bone
damage or malignant hypercalcemia
(see also multiple myeloma, other)
P|ase lll
(800) ZZ2-ê13ê
OTHER CANCERS
Product Name Sponsor Indication Development Status
8l9 l-131 rAo United Therapeutics
Silver Spring, MD
peritoneal cancer
(see also brain, sarcoma)
P|ase l
(301) 608-9292
Å6 Angstrom Pharmaceuticals
Solana Beach, CA
gynecologic cancer
(see also ovarian)
P|ase l
(858) 311-235ê
A8T-318
(aurora kinase inhibitor)
Abbott Laboratories
Abbott Park, IL
hematological malignancies
(see also solid tumors)
P|ase l
(81Z) 93Z-ê100
ABT-888
(veliparib)
(PARP inhibitor)
Abbott Laboratories
Abbott Park, IL
fallopian tube cancer
(see also brain, breast, colorectal,
lung, lymphoma, ovarian, prostate,
skin)
P|ase ll
(81Z) 93Z-ê100
AEZS-108 AEterna Zentaris
Basking Ridge, NJ
late-stage endometrial cancer
(see also bladder, ovarian, prostate)
P|ase ll
(908) ê2ê-5128
AlloStim™ lrruroval|ve T|erap|es
Shoham, Israel
hematological malignancies
(see also solid tumors)
P|ase l/ll
www.immunovative.co.il
Medicines in Development for Cancer
Medicines in Development Cancer 2012
116
OTHER CANCERS
Product Name Sponsor Indication Development Status
Alpharadin
®
radium-223 chloride
Bayer HealthCare Pharmaceuticals
Wayne, NJ
bone metastases from
castration-resistant prostate cancer
(see also solid tumors)
application submitted
(888) 812-283Z
ALT-801 Altor BioScience
Miramar, FL
urogenital cancer
(see also skin)
P|ase l/ll
(951) 113-8ê00
AMG 319
(Pl3K-de|la |r||o|lor)
Amgen
Tnousano Daks, 0/
hematological malignancies P|ase l
(800) ZZ2-ê13ê
AMG 900
(aurora kinase inhibitor)
Amgen
Tnousano Daks, 0/
hematological malignancies
(see also solid tumors)
P|ase l
(800) ZZ2-ê13ê
anti-CD70 ADC
(8V3-93ê5ê1)
Bristol-Myers Squibb
Princeton, NJ
hematological malignancies P|ase l
(800) 332-205ê
arl|-CXCR1
(8V3-93ê5ê1)
Bristol-Myers Squibb
Princeton, NJ
hematological malignancies P|ase l
(800) 332-205ê
ARQ 621
(Eç5 |r||o|lor)
ArQule
Woburn, MA
hematological malignancies
(see also solid tumors)
P|ase l
(Z81) 991-0300
Avastin
®
bevacizumab
Genentech
South San Francisco, CA
high-risk carcinoid tumor
(see also brain, breast, colorectal,
lung, ovarian)
P|ase lll
(800) ê2ê-3553
BAY 10-02670 Bayer HealthCare Pharmaceuticals
Wayne, NJ
uterine leiomyoma P|ase l
(888) 812-293Z
belinostat Spectrum Pharmaceuticals
Henderson, NV
peritoneal cancer, thymoma
(see also colorectal, leukemia, liver,
lung, lymphoma, ovarian)
--------------------------------------------------
lrsl-||re l|yrora
--------------------------------------------------
recurrent hematological malignancies
(combination therapy)
P|ase ll
(Z02) 835-ê300
-------------------------------------------
P|ase l/ll
(Z02) 835-ê300
-------------------------------------------
P|ase l
(Z02) 835-ê300
BKM120
(Pl3K |r||o|lor)
Novartis Pharmaceuticals
East Hanover, NJ
second-line endometrial cancer,
second-line urogenital cancer
(see also brain, breast, lung)
P|ase ll
(888) 669-6682
BMN-673
(PARP inhibitor)
BioMarin Pharmaceuticals
Novato, CA
hematological malignancies P|ase l
(115) 50ê-êZ00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
117
OTHER CANCERS
Product Name Sponsor Indication Development Status
BP-100-1-01 Bio-Path
Ogden, Utah
hematological malignancies P|ase l
(801) 580-232ê
CA-18C3 XBiotech
/usr|n, TX
hematological malignancies
(see also cancer-related, solid
tumors)
P|ase l
(512) 38ê-2900
cabozantinib
(XL181)
(Orphan Drug)
Exelixis
South San Francisco, CA
medullary thyroid cancer
(see also breast, kidney, lung,
ovarian, prostate)
P|ase lll
(ê50) 83Z-Z000
catumaxomab Fresenius Biotech North America
Waltham, MA
malignant ascites
(see also ovarian)
P|ase ll
www.fresenius-biotech.com
CDX-1127 Celldex Therapeutics
Needham, MA
hematological malignancies
(see also solid tumors)
P|ase l
(Z81) 133-0ZZ1
clodronic acid Bayer HealthCare Pharmaceuticals
Wayne, NJ
bone metastases P|ase lll
(888) 812-293Z
CLT-008 Cellerant Therapeutics
San Carlos, CA
hematological malignancies
(see also cancer-related)
P|ase l
(ê50) 232-2122
CPl-ê13
(Orphan Drug)
Cornerstone Pharmaceuticals
Cranbury, NJ
hematological malignancies
(see also pancreatic)
P|ase l
(ê09) 109-Z050
dalotuzumab
(VK-0ê1ê)
Merck
Whitehouse Station, NJ
neuroendocrine tumors
(see also breast, lung, pancreatic)
P|ase ll
(800) 672-6372
0VuC-5Z51A Genentech
South San Francisco, CA
lrsl-||re la||op|ar luoe carcer,
second-line peritoneal cancer
(see also ovarian)
P|ase l
(800) ê2ê-3553
0N21-02
(lapuleucel-T)
dendritic cell vaccine
Dendreon
Seattle, WA
high-risk, HER2-positive urogenital
cancer (adjuvant therapy)
P|ase ll
(8ZZ) 25ê-1515
E7080
(lenvatinib)
Eisai
Woodcliff Lake, NJ
thyroid cancer
(see also brain, skin)
--------------------------------------------------
endometrial cancer
P|ase lll
(888) 122-1Z13
-------------------------------------------
P|ase ll
(888) 122-1Z13
EZ850
(irofulven)
Eisai
Woodcliff Lake, NJ
thyroid cancer
(see also ovarian, prostate)
P|ase ll
(888) 122-1Z13
efatutazone Daiichi Sankyo
Parsippany, NJ
thyroid cancer
(see also colorectal, lung)
P|ase l/ll
(9Z3) 911-2ê00
Medicines in Development for Cancer
Medicines in Development Cancer 2012
118
OTHER CANCERS
Product Name Sponsor Indication Development Status
EGEN-001 EGEN
Huntsville, AL
fallopian tube cancer,
peritoneal cancer
(see also colorectal, ovarian)
P|ase ll
(25ê) 512-00ZZ
elagolix Abbott Laboratories
Abbott Park, IL
Neurocrine Biosciences
San Diego, CA
uterine leiomyoma P|ase ll
(81Z) 938-ê100
(858) ê1Z-Zê00
ENMD-2076 EntreMed
Rockville, MD
late-stage cancer
(see also multiple myeloma, ovarian)
P|ase l
(210) 8ê1-2ê00
Femara
®
letrozole
Novartis Pharmaceuticals
East Hanover, NJ
recurrent, metastatic endometrial
cancer (combination therapy)
P|ase ll
(888) 669-6682
folate binding protein (E39)
vaccine
Galena Biopharma
Lake Oswego, OR
endometrial cancer
(see also breast, ovarian)
P|ase l/ll
(855) 855-1253
fostamatinib
(SYK inhibitor)
AstraZeneca
Wilmington, DE
Rigel Pharmaceuticals
South San Francisco, CA
hematological malignancies P|ase ll
(800) 236-9933
(ê50) ê21-1100
Gleevec
®
imatinib
Novartis Pharmaceuticals
East Hanover, NJ
lorora
(see also lung, prostate, skin)
P|ase ll
(888) 669-6682
Inlyta
®
axitinib
Plzer
New York, NY
thyroid cancer
(see also kidney, liver)
P|ase ll
(8ê0) Z32-515ê
lPl-115 lrlr|ly P|arraceul|ca|s
Cambridge, MA
hematological malignancies P|ase l
(ê1Z) 153-1000
Istodax
®
romidepsin
Celgene
Summit, NJ
hematological malignancies
(see also kidney, pancreatic,
prostate)
P|ase l
(908) 673-9000
IXEMPRA
®

ixabepilone
Bristol-Myers Squibb
Princeton, NJ
endometrial cancer in clinical trials
(800) 332-205ê
-DNDÀ™
ruxolitinib
lrcyle
Wilmington, DE
hematological malignancies
(see also pancreatic)
P|ase ll
(855) 11ê-2983
K8001 KaloBios Pharmaceuticals
South San Francisco, CA
hematological malignancies P|ase l
(ê50) 213-3100
Marqibo
®
vincristine liposomal
Talon Therapeutics
San Mateo, CA
pediatric cancers
(see also leukemia, lymphoma, skin)
P|ase l/ll
(ê50) 588-ê101
Medicines in Development for Cancer
Medicines in Development Cancer 2012
119
OTHER CANCERS
Product Name Sponsor Indication Development Status
VE0l-551
(anti-CD19 mAb)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
hematological malignancies P|ase l
(800) 236-9933
(301) 398-0000
MER-101
(zoledronic acid oral)
Merrion Pharmaceuticals
Wilmington, NC
bone metastases P|ase ll
www/merrionpharma.com
Mirena
®
levonorgestrel-releasing
intrauterine system
Bayer HealthCare Pharmaceuticals
Wayne, PA
endometrial cancer,
endometrial hyperplasia
P|ase ll
(888) 812-293Z
VK-0Z52
(notch signaling pathway
inhibitor)
Merck
Whitehouse Station, NJ
central nervous system (CNS) cancer
in patients ages 3-21
(see also breast)
P|ase l
(800) 672-6372
MK-2206
(c-akt inhibitor)
Merck
Whitehouse Station, NJ
inoperable/unresectable
neuroendocrine tumors
(see also breast)
P|ase ll
(800) 672-6372
MLN0128 Millennium Pharmaceuticals
Cambridge, MA
hematological malignancies
(see also solid tumors)
P|ase l
(800) 390-5êê3
VLN1921
(NEDD8 inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
hematological malignancies
(see aslo solid tumors)
P|ase l
(800) 390-5êê3
motesanib Amgen
Tnousano Daks, 0/
thyroid cancer
(see also breast, colorectal, lung)
P|ase ll
(800) ZZ2-ê13ê
moxetumomab pasudotox
(CAT-8015)
AstraZeneca
Wilmington, DE
Vedlrrure
Gaithersburg, MD
hematological malignancies P|ase l
(800) 236-9933
(301) 398-0000
MSC1936369B EMD Serono
Rockland, MA
hematological malignancies P|ase l/ll
(800) 283-8088
Nexavar
®
sorafenib
Bayer HealthCare Pharmaceuticals
Wayne, NJ
thyroid cancer
(see also breast, colorectal,
head/neck, kidney, leukemia, liver,
lung, multiple myeloma, ovarian)
--------------------------------------------------
neuroendocrine tumors
P|ase lll
(888) 812-293Z
-------------------------------------------
P|ase l
(888) 812-293Z
NiCord
®
umbilical cord blood stem cell
therapy
Gamida Cell
Jerusalem, Israel
hematological malignancies P|ase l/ll
www.gamida-cell.com
Medicines in Development for Cancer
Medicines in Development Cancer 2012
120
OTHER CANCERS
Product Name Sponsor Indication Development Status
NTX-010 Neotropix
Malvern, PA
neuroendocrine tumors
(see also lung)
P|ase l
www.neotropix.com
Opaxio™
paclitaxel poliglumex
Cell Therapeutics
Seattle, WA
fallopian tube cancer,
peritoneal cancer
(see also brain, lung, ovarian,
stomach)
P|ase lll
(800) 215-2355
OPR-003 EUSA Pharma
Langhorne, PA
Vaccinex
Rochester, NY
hematological malignancies P|ase l
(800) 833-3533
(585) 2Z1-2Z00
03l-90ê
(l0F-1R/1R lyros|rase ||rase
inhibitor)
03l P|arraceul|ca|s
Farmingdale, NY
adrenocortical carcinoma
(see also lung, ovarian)
P|ase lll
(631) 962-0600
PEG arginine deiminase
(A0l-PE0 20)
Polaris Pharmaceuticals
San Diego, CA
pediatric cancer
(see also liver, prostate, skin)
P|ase l
(858) 152-êê88
PF-01ê91502
(Pl3K/rT0R |r||o|lor)
Plzer
New York, NY
endometrial cancer
(see also solid tumors)
P|ase ll
(8ê0) Z32-515ê
PF-05212381
(rT0R/Pl3K |r||o|lor)
Plzer
New York, NY
endometrial cancer
(see also solid tumors)
P|ase ll
(8ê0) Z32-515ê
PlA818125 Nerviano Medical Services
Nerviano, Italy
thymoma P|ase ll
www.nervianoms.com
phenoxodiol Marshall Edwards
San Diego, CA
fallopian tube cancer (combination
therapy)
(see also ovarian, prostate)
P|ase l/ll
(858) Z92-ê300
PV-00101 PharmaMar
Madrid, Spain
endometrial cancer
(see also cervical, sarcoma)
P|ase ll
www.pharmamar.com
PTC299 PTC Therapeutics
$ourn P|a|nle|o, hJ
central nervous system (CNS) cancer
in children
(see also breast, solid tumors)
P|ase ll
(908) 222-7000
RG7112
(MDM2 antagonist)
Roche
Nutley, NJ
hematological malignancies
(see also solid tumors)
P|ase l
(9Z3) 235-5000
RG7388
(MDM2 inhibitor)
Roche
Nutley, NJ
hematological malignancies
(see also solid tumors)
P|ase l
(9Z3) 235-5000
R0Z593
(mAb)
Roche
Nutley, NJ
hematological malignancies P|ase l
(9Z3) 235-5000
Medicines in Development for Cancer
Medicines in Development Cancer 2012
121
OTHER CANCERS
Product Name Sponsor Indication Development Status
R0Z59ê
(antibody drug conjugate)
Genentech
South San Francisco, CA
hematological malignancies P|ase l
(800) ê2ê-3553
ridaforolimus ARlA0 P|arraceul|ca|s
Cambridge, MA
Merck
Whitehouse Station, NJ
endometrial cancer
(see also breast, kidney, lung,
prostate, sarcoma)
P|ase ll
(800) 672-6372
rintatolimod Hemispherx Biopharma
Philadelphia, PA
cancer vaccine adjuvant P|ase l/ll
(215) 988-0080
sarar|ur 3V-153 |ex|drorar
injection
EUSA Pharma
Langhorne, PA
bone metastases
(see also breast, multiple myeloma,
prostate, sarcoma)
P|ase lll
(800) 833-3533
3AR3119
(maytansin-loaded anti-CD19
mAb)
3arol u3
Bridgewater, NJ
lrruro0er
Needham, MA
B-cell malignancies P|ase ll
(800) 981-2191
(Z81) 895-0ê00
3AR215108
(XL11Z)
(ora| Pl3K |r||o|lor)
3arol u3
Bridgewater, NJ
Exelixis
South San Francisco, CA
endometrial cancer
(see also breast)
P|ase ll
(800) 981-2191
(ê50) 83Z-Z000
3ARê50981
(anti-CD38 naked mAb)
3arol u3
Bridgewater, NJ
hematological malignancies P|ase l
(800) 981-2191
SB989
(pracinostat)
3¯8l0
Oakland, CA
hematological malignancies
(see also leukemia, solid tumors)
P|ase l
(ê50) Z30-28ê0
siltuximab Janssen Biotech
Horsham, PA
giant lymph node hyperplasia
(see also multiple myeloma, prostate)
P|ase ll
(800) 52ê-ZZ3ê
SOM230
(pasireotide)
Novartis Pharmaceuticals
East Hanover, NJ
carcinoid tumors
--------------------------------------------------
meningioma, neuroendocrine tumors
P|ase lll
(888) 669-6682
-------------------------------------------
P|ase ll
(888) 669-6682
sotatercept
(ACE-011)
Celgene
Summit, NJ
cancer metastases
(see also cancer-related)
P|ase ll
(908) 673-9000
SPRYCEL
®
dasatinib
Bristol-Myers Squibb
Princeton, NJ
pediatric cancer
(see also brain, breast, pancreatic,
prostate)
in clinical trials
(800) 332-205ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
122
OTHER CANCERS
Product Name Sponsor Indication Development Status
StemEx
®
carlecortemcel-L
(Orphan Drug)
Gamida Cell
Jerusalem, Israel
Teva North America
North Wales, PA
hematological malignancies
(Fast Track)
P|ase lll
(888) 838-2872
TAK-901
(aurora kinase B inhibitor)
Millennium Pharmaceuticals
Cambridge, MA
hematological malignancies P|ase l
(800) 390-5êê3
Tarceva
®
erlotinib
Genentech
South San Francisco, CA
03l P|arraceul|ca|s
Farmingdale, NY
gynecological cancer
(see also brain, breast, head/neck,
leukemia, liver, lung)
P|ase ll
(800) ê2ê-3553
(631) 962-0600
telapristone Repros Therapeutics
Tne wooo|anos, TX
uterine leiomyoma P|ase l/ll
(281) Z19-3100
terameprocol Erimos Pharmaceuticals
lousron, TX
hematological malignancies
(intravenous)
(see also brain, cervical, head/neck,
solid tumors)
P|ase l
(Z13) 511-2000
TG02 3¯8l0
Oakland, CA
Tragara Pharmaceuticals
San Diego, CA
hematological malignancies P|ase l
(ê50) 235-5539
(858) 350-ê900
tivantinib
(ARQ 197)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
germ cell and embryonal neoplasms
(see also colorectal, kidney, liver,
lung, pancreatic, sarcoma)
P|ase ll
(Z81) 991-0300
(9Z3) 911-2ê00
TKl258
(dovitinib)
Novartis Pharmaceuticals
East Hanover, NJ
second-line endometrial cancer,
urothelial carcinoma
(see also breast, kidney, multiple
myeloma, prostate, skin)
P|ase ll
(888) 669-6682
TRC 105
(ENG protein inhibitor)
TRACON Pharmaceuticals
San Diego, CA
fallopian tube cancer, peritoneal
cancer
(see also breast, ovarian, prostate)
P|ase ll
(858) 550-0Z80
trebananib (AMG386) Amgen
Tnousano Daks, 0/
fallopian tube cancer, peritoneal
cancer
(see also breast, colorectal, kidney,
liver, stomach)
P|ase lll
(800) ZZ2-ê13ê
Medicines in Development for Cancer
Medicines in Development Cancer 2012
123
OTHER CANCERS
Product Name Sponsor Indication Development Status
ulipristal walsor P|arraceul|ca|s
Parsippany, NJ
uterine leiomyoma P|ase lll
(800) 900-1ê11
VB-111 VBL Therapeutics
Or Yehuda, Israel
thyroid cancer
(see also brain)
P|ase l/ll
www.vblrx.com
Velcade
®
bortezomib
Millennium Pharmaceuticals
Cambridge, MA
adenocarcinoma (combination
therapy)
(see also leukemia, lymphoma,
cancer-related)
P|ase ll
(800) 390-5êê3
volasertib 8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
urogenital cancer P|ase ll
(800) 213-012Z
Votrient™
pazopanib
GlaxoSmithKline
Pson. Tr|ang|e Park, h0
fallopian tube cancer,
peritoneal cancer
(see also kidney, ovarian)
P|ase lll
(888) 825-5219
Xgeva™
denosumab
Amgen
Tnousano Daks, 0/
prevention of bone metastases in
men with castrate-resistant prostate
cancer
(see also cancer-related, multiple
myeloma)
--------------------------------------------------
prevention of bone metastases
in women with early-stage breast
cancer
--------------------------------------------------
giant cell tumor of bone
application submitted
(800) ZZ2-ê13ê
-------------------------------------------
P|ase lll
(800) ZZ2-ê13ê
-------------------------------------------
P|ase ll
(800) ZZ2-ê13ê
Zelboraf
®
vemurafenib
Genentech
South San Francisco, CA
Plexxikon
Berkeley, CA
inoperable/unresectable thyroid
cancer
(see also brain, colorectal)
P|ase ll
(800) ê2ê-3553
(510) ê1Z-1000
Zolinza
®
vorinostat
Merck
Whitehouse Station, NJ
gynecological cancer, peritoneal
cancer
(see also breast, leukemia, lung,
lymphoma, multiple myeloma)
P|ase l/ll
(800) 672-6273
Medicines in Development for Cancer
Medicines in Development Cancer 2012
124
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
A8C291ê10 Apogee Biotechnology
Hummelstown, PA
late-stage disease P|ase l
(813) Z92-3120
A8l-011
(nab
®
-5101)
Celgene
Summit, NJ
P|ase l
(908) 673-9000
AFX-9901 Afecta Pharmaceuticals
Irvine, CA
in clinical trials
(919) 253-1ê88
AGS-6MF Agensys
Santa Monica, CA
Astellas Pharma US
0eerle|o, lL
P|ase l
(800) ê95-1321
AGS-16M8F Agensys
Santa Monica, CA
Astellas Pharma US
0eerle|o, lL
P|ase l
(800) ê95-1321
ALT-836 Altor BioScience
Miramar, FL
P|ase l/ll
(951) 113-8ê00
arl|-KlR
(8V3-98ê015)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
anti-LAG3
(BMS-986016)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
ANX-511
(docetaxel for injectable
emulsion)
ADVENTRX Pharmaceuticals
San Diego, CA
P|ase l
(858) 552-08êê
ARRY-300
(MEK inhibitor)
Array BioPharma
Boulder, CO
Novartis Pharmaceuticals
East Hanover, NJ
P|ase l
(8ZZ) ê33-213ê
(888) 669-6682
ARRY-382
(c-fms antagonist)
Array BioPharma
Boulder, CO
Celgene
Summit, NJ
metastatic cancer P|ase l
(8ZZ) ê33-213ê
(908) 673-9000
AVL-292
(Btk inhibitor)
Celgene
Summit, NJ
(see also leukemia, lymphoma) P|ase l
(908) 673-9000
B7-2/GM-CSF
cancer gene therapy vaccine
NuVax Therapeutics
Tusr|n, 0/
P|ase l
(Z11) 505-11ê1
8AY 91-9392
(PET imaging)
Bayer HealthCare Pharmaceuticals
Wayne, NJ
cancer (diagnosis) P|ase l
(888) 812-293Z
Medicines in Development for Cancer
Medicines in Development Cancer 2012
125
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
cancer vaccine lrrur|lor u3A
Vancouver, Canada
P|ase l/ll
www.immunitor.com
cancer vaccine
(lorocyle vacc|re)
Cytokine PharmaSciences
King of Prussia, PA
P|ase l
(610) 687-1776
carboxyamidotriazole orotate
(CTO)
Tactical Therapeutics
New York, NY
P|ase l
(212) ê51-9ê53
C8L8502 Cleveland BioLabs
Buffalo, NY
P|ase l
(Z1ê) 819-ê810
C0K 1/ê |r||o|lor
(LY2835219)
Eli Lilly
Indianapolis, IN
P|ase ll
(800) 515-59Z9
CDX-301
(Fms-like tyrosine kinase 3
ligand)
Celldex Therapeutics
Needham, MA
P|ase l
(Z81) 133-0ZZ1
cell therapy Cell Medica
London, United Kingdom
Center for Cell and Gene Therapy
lousron, TX
P|ase ll
www.cellmedica.co.uk
CEN-109 Centella Therapeutics
Palo Alto, CA
cancer (diagnosis) P|ase ll
www.centellatx.com
Chk1 inhibitor Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
c-Met inhibitor Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
c-Met mAb
(LY28Z5358)
Eli Lilly
Indianapolis, IN
P|ase ll
(800) 515-59Z9
CSF-1R mAb
(lVC-C31)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
P|ase l
(800) 515-59Z9
curmucin Signpath Pharma
Quakertown, PA
P|ase l
(267) 772-0107
CXCR1 pepl|de |r||o|lor
(LY2510921)
Eli Lilly
Indianapolis, IN
P|ase ll
(800) 515-59Z9
Medicines in Development for Cancer
Medicines in Development Cancer 2012
126
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
cytotropic heterogeneous
molecular lipids
(CHML)
Glory Pharmaceuticals
Vienna, VA
P|ase l
(Z03) 201-1Z03
DM-CHOC-PEN Dekk-Tec
New Orleans, LA
P|ase l
(501) 583-ê135
EC0225 Endocyte
West Lafayette, IN
P|ase l
www.endocyte.com
E0FR/l0FR larder adrecl|r
(8V3-9ê1210)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
elF-1E A30
(LY22Z5Z9ê)
Eli Lilly
Indianapolis, IN
P|ase ll
(800) 515-59Z9
fenretinide intravenous CerRx
Luooook, TX
P|ase l
www.cerrx.com
FGF receptor inhibitor Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
luorapac|r ACEA Biosciences
San Diego, CA
P|ase l
(866) 308-2232
gemcitabine prodrug Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
0l-ê20Z
(cancer vaccine)
0|ooelrrure
Louisville, CO
P|ase l
(303) ê25-2Z00
GSK3 inhibitor
(LY2090311)
Eli Lilly
Indianapolis, IN
P|ase ll
(800) 515-59Z9
l8l-8000 luYA 8|osc|erce lrlerral|ora|
San Diego, CA
Quintiles
Pson. Tr|ang|e Park, h0
P|ase l
www.huyabio.com
hedgehog antagonist
(LY2910ê80)
Eli Lilly
Indianapolis, IN
P|ase ll
(800) 515-59Z9
hTERT plasmid DNA cancer
vaccine
Merck
Whitehouse Station, NJ
Vical
San Diego, CA
P|ase l
(800) 672-6372
Medicines in Development for Cancer
Medicines in Development Cancer 2012
127
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
lL-21
(8V3-9821Z0)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
lr-111-0AC
imaging agent
Mayo Clinic
Rochester, MN
Naviscan
San Diego, CA
cancer (diagnosis) P|ase l
www.mayoclinic.org
l3l3-3TAT3
Rx
ls|s P|arraceul|ca|s
Carlsbad, CA
P|ase l
(800) êZ9-1Z1Z
JAK2 inhibitor Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
masoprocol TriAct Therapeutics
San Francisco, CA
P|ase ll
(115) ê02-Z19Z
MK-8033
(c-Met/RON protein inhibitor)
Merck
Whitehouse Station, NJ
P|ase l
(800) 672-6372
new molecular entity Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
notch inhibitor Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
notch inhibitor
(8V3-90ê021)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
OPB-31121 Otsuka America Pharmaceutical
Rockville, MD
P|ase l
(800) 5ê2-39Z1
p38 MAP inhibitor (1) Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
p38 MAP inhibitor (2) Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
p70/AKT inhibitor Eli Lilly
Indianapolis, IN
P|ase l
(800) 515-59Z9
P8-35Z Puma Biotechnology
Los Angeles, CA
P|ase l
(121) 218-ê500
Medicines in Development for Cancer
Medicines in Development Cancer 2012
128
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
P8l-05201 Phoenix Biotechnology
$an /nron|o, TX
P|ase l
(210) 828-13Z3
P0-0325901 Plzer
New York, NY
P|ase l
(8ê0) Z32-515ê
PD-0332991 Plzer
New York, NY
P|ase ll
(8ê0) Z32-515ê
PF-03081011
(gamma-secretase inhibitor)
Plzer
New York, NY
P|ase l
(8ê0) Z32-515ê
PF-01119913
(sonic hedgehog pathway
inhibitor)
Plzer
New York, NY
P|ase l
(8ê0) Z32-515ê
PF-050825êê
(CD137 antigen agonist mAb)
Plzer
New York, NY
P|ase l
(8ê0) Z32-515ê
Proleukin
®
aldesleukin
(subcutaneous)
Prometheus Laboratories
San Diego, CA
P|ase ll
(888) 892-8391
PRT6207
(3y|-spec|lc |r||o|lor)
8|oçer ldec
Cambridge, MA
Portola Pharmaceuticals
South San Francisco, CA
P|ase l
(Z81) 1ê1-2000
(ê50) 21ê-Z000
RON mAb
(lVC-R0N8)
Eli Lilly
Indianapolis, IN
lrC|ore 3yslers
Bridgewater, NJ
P|ase l
(800) 515-59Z9
3815Z8
(JAK2 inhibitor)
3¯8l0
Oakland, CA
P|ase l
(ê50) 235-5539
SCH-900776 Merck
Whitehouse Station, NJ
P|ase ll
(800) 672-6372
SMO antagonist
(BMS-833923)
Bristol-Myers Squibb
Princeton, NJ
P|ase l
(800) 332-205ê
SR13668 3Rl lrlerral|ora|
Menlo Park, CA
cancer (prevention) Phase 0
(ê50) 859-2000
V930/V932
(plasmid DNA vaccine)
Merck
Whitehouse Station, NJ
Vical
San Diego, CA
P|ase l
(800) 672-6372
(858) ê1ê-1100
Medicines in Development for Cancer
Medicines in Development Cancer 2012
129
UNSPECIFIED CANCER
Product Name Sponsor Indication Development Status
VEGFR3 mAb
(lVC-3C5)
Eli Lilly
Indianapolis, IN
lrC|ore
Bridgewater, NJ
P|ase l
(800) 515-59Z9
XmAb
®

anti-cancer mAb
8oe|r|rçer lrçe||e|r
Pharmaceuticals
P|ogele|o, 0T
Xencor
Monrovia, CA
P|ase l
(800) 213-012Z
(ê2ê) 305-5900
Medicines in Development for Cancer
Tne oonrenr ol rn|s reµorr nas oeen oora|neo rnrougn |nousrry souroes ano rne /o|s "P&0 lns|gnr´ oaraoase oaseo on rne |aresr |nlormar|on. Report
current as of May 16, 2012. Tne |nlormar|on may nor oe oomµrenens|ve. For more sµeo|lo |nlormar|on aoour a µarr|ou|ar µroouor, oonraor rne |no|-
v|oua| oomµany o|reor|y or go ro uuu.o||n|oa|rr|a|s.gov. Tne enr|re ser|es ol Veo|o|nes |n 0eve|oµmenr |s ava||ao|e on PnPV/´s ueo s|re.
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info
Prov|ded as a Puo||c 3erv|ce oy P|RVA. Fourded |r 1958 as l|e P|arraceul|ca| Varulaclurers Assoc|al|or.
Copyright © 2012 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.
3KDUPDFHXWLFDO5HVHDUFKDQG0DQXIDFWXUHUVRI$PHULFD‡950 F 3lreel, Nw, was||rçlor, 0C 20001
Medicines in Development Cancer 2012
130
Glossary
actinic keratoses—Roughness and thicken-
ing of the skin caused by overexposure to the
sur's u|lrav|o|el rays. ll car deçererale |rlo a
skin cancer called squamous cell carcinoma.
adenocarcinoma—Malignant tumor derived
from a gland or glandular tissue.
adjunctive treatment—An auxiliary treatment
that is secondary to the main treatment.
adjuvant—A substance or drug that aids
another substance in its action.
allogeneic—Refers to having cell types that
are distinct and cause reactions in the immune
system.
application submitted—An application for
marketing has been submitted by the company
to the Food and Drug Administration (FDA).
ascites÷Excess lu|d |r l|e space oelWeer
the tissues lining the abdomen and abdominal
organs (the peritoneal cavity).
basal cell cancer—Cancer of the lower layers
of the skin.
B-cell—A class of white blood cells important
to the body’s immune system.
biliary—Relating to bile.
carcinoma—A malignant tumor that arises
from epithelial tissues, such as skin.
cervical—Relating to the neck of the uterus.
chemoprotection—A therapeutic technique in
which bone marrow cells are removed from an
individual with cancer and are genetically modi-
led lo W|l|slard ||ç|er doses ol c|erol|erapy
before being returned to the donor.
cholangiocarcinoma—A malignancy of the
biliary duct system that may originate in the
liver and extrahepatic bile ducts. More than 90
percent are adenocarcinomas, and the remain-
der are squamous cell tumors. Cholangiocarci-
roras lerd lo çroW s|oW|y ard lo |rl|lrale l|e
walls of the ducts. Each year, approximately
2,500 cases occur, ard l|e averaçe |rc|derce
is 1 case per 100,000 people per year.
cutaneous—Pertaining to the skin.
dysplasia—Abnormal tissue development.
gastric—Of or relating to the stomach.
GIST÷0aslro|rlesl|ra| (0l) slrora| carcer
|s ar urcorror luror ol l|e 0l lracl. Nol
a|| 0l3Ts are carcerous, sore are oer|çr.
Although these cancers can arise anywhere
|r l|e 0l lracl, l|ey occur rosl oller |r l|e
stomach (60% to 70%) and less commonly
in the small intestine (20% to 30%). The rest
are found in the esophagus, large intestine,
rectum, and anus. About 80% of people diag-
rosed W|l| 0l3T are o|der l|ar 50. ll |s s||ç|l|y
more common in men. Blacks are more likely
lo deve|op 0l3Ts l|ar W||les.
glioblastoma—A fast growing and highly
malignant type of brain tumor arising from glial
(supporting) cells within the brain. There are
aooul lve lo 10 reW cases per r||||or popu|a-
tion per year in the United States.
glioma—A type of brain tumor arising from the
supporting glial cells within the brain. Gliomas
make up about 60 percent of all primary brain
tumors and are frequently malignant.
graft-versus-host disease (GVHD)—A
complication in bone marrow transplants where
immune system cells attack the transplant
recipient’s tissues.
head and neck cancer—The term given to a
variety of malignant tumors that develop in the
mouth, throat, paranasal sinuses, nasal cavity,
larynx, and salivary glands. Many authorities
also include skin tumors of the face and neck
and tumors of the cervical lymph nodes. There
are more than half a million survivors of oral,
head, and neck cancer living in the United
States today.
hematological malignancies—Cancers of the
blood or blood-forming tissues, such as leuke-
mia, Hodgkin’s and non-Hodgkin’s lympho-
mas, Al03-re|aled ra||çrarc|es, multiple
myeloma, myelodysplasia and myeloprolifera-
tive disorders.
hepatocellular cancer/carcinoma—A cancer
that begins in the liver cells.
hyperuricemia—An abnormally high uric acid
level in the blood.
imaging agent—A substance used to enhance
x-ray images of organs and spaces in the body.
intraepithelial neoplasia, anal (AIN) & cervi-
cal (CIN)÷AlN |s a corsequerce ol c|ror|c
human papillomavirus infection in the anal
canal and appears to be driven by high viral
|oads ol |urar pap|||orav|rus. w|al |s |roWr
of its natural history resembles that of cervical
intraepithelial neoplasia. Dysplasia and cervi-
ca| |rlraep|l|e||a| reop|as|a (ClN) are d|llererl
terms or names for the same condition—it is
a precursor to cervical cancer. ClN ray oe
mild, moderate or severe.
Kaposi’s sarcoma—A rare, malignant skin
luror l|al occurs |r sore Al03 pal|erls. ll
can be accompanied by fever, enlarged lymph
nodes and gastrointestinal problems.
Leiomyoma—A benign neoplasm derived from
smooth muscle.
leukemia—A form of cancer in which abnor-
mally growing white blood cells are scattered
throughout the body and bone marrow. They
can take over the marrow and prevent it from
making enough normal blood cells (white,
red and platelets), leaving the patient highly
susceptible to serious infections, anemia and
bleeding episodes. The cells can also spill into
l|e o|ood, |rl|lral|rç ard |rlerler|rç W|l| l|e
function of other organs. The four main types
ol |eu|er|a are: acute lympho blastic leuke-
mia (ALL), acute myeloid leukemia (AML),
chronic lymphocytic leukemia (CLL), and
chronic myeloid leukemia (CML). The acute
types have a rapid onset, and overwhelming
infection or blood loss can cause death. The
chronic forms progress much more slowly.
lung cancer—The leading cause of cancer
deaths in both men and women. There are
several types of lung cancer, the most common
being squamous cell carcinoma, small (oat)
cell carcinoma, adenocarcinoma and large cell
Medicines in Development Cancer 2012
131
Glossary
carcinoma. Each has a different growth pattern
and response to treatment. The squamous cell,
small cell and large cell types are all strongly
associated with tobacco abuse.
lymphoma—Cancers in which the cells of lym-
phoid tissue, found mainly in the lymph nodes
and spleen, multiply unchecked. Lymphomas
la|| |rlo lWo caleçor|es: lodç||r d|sease, c|ar-
acterized by a particular kind of abnormal cell,
and non-Hodgkin lymphomas, which vary in
their malignancy according to the nature and
activity of the abnormal cells. Mantle cell lym-
phoma is a type of non-Hodgkin lymphoma.
macroglobulinemia—A disorder in which
plasma cells produce an excessive quantity
of macroglobulins (large antibodies) that ac-
curu|ale |r l|e o|ood. ll resu|ls lror a çroup
of abnormal, cancerous lymphocytes and
plasma cells. Men are affected more often than
Worer, ard l|e averaçe açe al orsel |s ê5.
mastocytosis—A condition characterized by
|rl|lral|or ol rasl ce||s |rlo l|e l|ssues ol l|e
body. Mast cells are connective tissue cells
which release chemicals including histamine
that are very irritating and cause itching, swell-
|rç, ard lu|d |ea|açe lror ce||s.
medullary—Relating to the medulla (any soft
marrow-like structure, especially the innermost
part) or marrow.
melanoma—A cancer made up of pigmented
(usually brown-colored) skin cells anywhere in
the body.
mesothelioma—A tumor of the lining of the
lung and chest cavity (the pleura).
metastases/metastatic—Areas of secondary
cancer that have spread from the primary or
original cancer site.
mucositis—The swelling, irritation, and ulcer-
ation of the mucosal cells that line the digestive
tract. Mucositis can occur anywhere along the
d|çesl|ve lracl lror l|e roul| lo l|e arus. ll
can be a very troublesome and painful side
effect of chemotherapy.
multiple myeloma—A malignant condition of
middle to old age, characterized by the uncon-
trolled proliferation and disordered function of
plasma cells in the bone marrow. The condi-
tion, which makes the patient particularly prone
to infection, is rare, with about three new cases
annually per 100,000 population.
myeloablation—A severe form of myelosup-
pression, a condition in which bone marrow
activity is decreased, resulting in fewer red
o|ood ce||s, W||le o|ood ce||s, ard p|ale|els. ll |s
a side effect of some cancer treatments.
myelodysplastic syndromes (MDS)—Blood
disorders that ultimately are fatal. Patients
usually succumb to infections or bleeding. The
term “preleukemia” has been used to describe
these disorders.
neoadjuvant therapy—Chemotherapy, radia-
tion therapy, or hormone therapy given before
the primary or main treatment. Neo-adjuvant
therapy, like chemotherapy and radiation
therapy, is often given before surgery to reduce
the size of a tumor or to make surgery less
complicated.
neuroblastoma—A tumor of the adrenal
glands or sympathetic nervous system (the
part of the nervous system responsible for
certain automatic body functions, such as the
control of heart rate). Neuroblastomas are the
most common extracranial (outside the skull)
solid tumors of childhood.
osteosarcoma—Cancer of the bone that oc-
curs predominantly in adolescents and young
adu|ls. ll accourls lor 5 percerl ol carcer |r
children.
peritoneal—Relating to the peritoneum, the
membrane that lines the abdominal cavity and
covers most of the abdominal organs.
Phase 0—First-in-human trials conducted
in accordance with FDA’s 2006 guidance on
exp|oralory lrvesl|çal|ora| NeW 0ruç (lN0)
studies designed to speed up development of
promising drugs by establishing very early on
whether the agent behaves in human subjects
as was anticipated from preclinical studies.
Phase I—Safety testing and pharmacologi-
ca| prol||rç ol reW druçs |r sra|| ruroers ol
humans.
Phase II÷Ellecl|veress lesl|rç ard |derl|lca-
tion of side effects of new drugs in humans.
Phase III—Extensive clinical trials in humans
to verify effectiveness and monitor adverse
reactions of new drugs.
prolactinoma—A noncancerous pituitary
tumor that produces a hormone called prolac-
tin, which results in too much prolactin in the
blood.
refractory—Resistant to treatment or cure.
sarcoma—A malignant tumor that arises from
deep body tissues, such as muscle, bone or
lorous l|ssue.
T-cell—One of two main classes of white blood
cells called lymphocytes, which are important
lo l|e oody's d|sease-lç|l|rç |rrure sysler.
thrombocytopenia—A reduction in the
number of platelet cells in the blood, which
causes a tendency to bleed, especially from
the smaller blood vessels.
thymoma—Although rare, thymomas are the
most common tumor of the thymus, a small
organ located in the upper chest just below
the neck that produces certain types of white
blood cells (lymphocytes) before birth and
during childhood. Thymomas arise from thymic
epithelial cells, which make up the covering of
l|e l|yrus. up lo 10 percerl ol l|yroras are
invasive. They affect men and women equally
and are usually diagnosed between the ages
ol 10 ard ê0. T|yroras are urcorror |r
children.
unresectable—Unable to be removed (re-
sected) by surgery.
Medicines in Development Cancer 2012
132
Selected Facts about Cancer in the United States
‡ Carcer |s l|e secord |ead|rç cause ol deal| oy d|sease÷rear|y 1 ol every 1 deal|s÷|r l|e ur|led 3lales, exceeded or|y oy |earl d|sease.
‡ Ver |ave s||ç|l|y |ess l|ar a 1 |r 2 ||lel|re r|s| ol deve|op|rç carcer, lor Worer, l|e r|s| |s a ||ll|e rore l|ar 1 |r 3. Aooul ZZ percerl ol a||
carcers are d|açrosed |r peop|e açes 55 ard o|der.
‡ T||s year a|ore, rore l|ar 1.ê r||||or reW carcer cases are expecled lo oe d|açrosed, ard ar esl|raled 5ZZ,190 peop|e are expecled lo d|e ol
carcer. T|al's rore l|ar 1,500 peop|e a day.
‡ 3c|erl|lc ev|derce suççesls l|al aooul ore-l||rd ol l|e carcer deal|s expecled l||s year W||| oe re|aled lo overWe|ç|l or ooes|ly, p|ys|ca| |racl|v-
ity, and poor nutrition, and thus could be prevented.
‡ T|e Nal|ora| Carcer lrsl|lule esl|rales l|al rear|y 12 r||||or Arer|cars W|l| a ||slory ol carcer Were a||ve |r Jaruary 2008. T|e 5-year re|al|ve
surv|va| rale lor a|| carcers d|açrosed oelWeer 2001 ard 200Z |s êZ percerl, up lror 19 percerl |r l|e r|d-Z0s.
‡ Studies have shown that pain occurs in 30 percent of all cancer patients, regardless of the stage of the disease, and 90 percent of patients with
advanced cancer experience severe pain. Half of patients may be undertreated for cancer pain.
2
‡ The most common cause of cancer-related pain is from metastases to the bone. Up to 80 percent of cancer patients with bone metastases
exper|erce pa|r. T|e secord rosl corror cause ol carcer pa|r |s re|aled lo lurors |rl|lral|rç l|e rerve ard |o||oW v|scus. Turors rear reura|
structures may cause the most severe pain. The third most common cause of pain associated with cancer result from chemotherapy, radiation,
or surgery.
2

‡ Breakthrough pain—pain that occurs even when taking regular pain medication—is common in cancer patients. Breakthrough cancer pain
occurs |r 50 percerl lo 90 percerl ol orco|oçy |rpal|erl sell|rçs, 89 percerl ol |ore care ard |rpal|erl |osp|ce sell|rçs, ard 35 percerl ol
corrur|ly-oased orco|oçy pracl|ces. Peop|e W|l| orea|l|rouç| pa|r |ave a s|çr|lcarl|y ||ç|er rale ol |osp|la||zal|or l|ar l|ose W|l|oul orea|-
l|rouç| pa|r (3ê.9 percerl vs. 22.5 percerl, respecl|ve|y) ard draral|ca||y ||ç|er esl|raled arrua| cosls ol care (S1.Z r||||or corpared W|l|
S192,000).
3
‡ T|e Nal|ora| lrsl|lules ol lea|l| esl|rales overa|| cosls lor carcer |r 200Z al S22ê.8 o||||or: S103.8 o||||or lor d|recl red|ca| cosls (lola| ol a||
|ea|l| experd|lures) ard S123 o||||or lor |rd|recl rorla||ly cosls (cosl ol |osl producl|v|ly due lo preralure deal|).
Overview
1
Pain
Costs
1
Medicines in Development Cancer 2012
133
New Cancer Cases/Deaths
1
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
All Sites .................................................................................. 1,638,910 ..................................................................................... 5ZZ,190
Male ............................................................................. 818,1Z0 ..................................................................................... 301,820
Female ......................................................................... Z90,Z10 ..................................................................................... 2Z5,3Z0
Acute Lymphocytic Leukemia .......................................................... ê,050 ......................................................................................... 1,110
Male ................................................................................. 3,150 ............................................................................................ 820
Female ............................................................................. 2,600 ............................................................................................ 620
Acute Myeloid Leukemia ............................................................... 13,780 ....................................................................................... 10,200
Male ................................................................................. Z,350 ......................................................................................... 5,Z90
Female ............................................................................. ê,130 ......................................................................................... 1,110
Bladder Cancer .............................................................................. Z3,510 ....................................................................................... 11,880
Male ............................................................................... 55,ê00 ....................................................................................... 10,510
Female ........................................................................... 17,910 ......................................................................................... 1,3Z0
Bone Cancer (and joints) ................................................................. 2,890 ......................................................................................... 1,110
Male ................................................................................. 1,600 ............................................................................................ 790
Female ............................................................................. 1,290 ............................................................................................ 620
Brain Cancer (and other nervous system) ..................................... 22,910 ....................................................................................... 13,700
Male ............................................................................... 12,630 ......................................................................................... 7,720
Female ........................................................................... 10,280 ......................................................................................... 5,980
Breast Cancer .............................................................................. 229,060 ....................................................................................... 39,920
Male ................................................................................. 2,190 ............................................................................................ 110
Female ......................................................................... 226,870 ....................................................................................... 39,510
Cervical and Uterine Cancers ........................................................ 59,300 ....................................................................................... 12,230
Male ....................................................................................... — ...............................................................................................—
Female ........................................................................... 59,300 ....................................................................................... 12,230
Chronic Lymphocytic Leukemia ..................................................... 16,060 ......................................................................................... 1,580
Male ................................................................................. 9,190 ......................................................................................... 2,730
Female ............................................................................. ê,5Z0 ......................................................................................... 1,850
Chronic Myeloid Leukemia .............................................................. 5,130 ............................................................................................ 610
Male ................................................................................. 3,210 ............................................................................................ 370
Female ............................................................................. 2,220 ............................................................................................ 210
Colorectal Cancer ........................................................................ 113,1ê0 ....................................................................................... 51,ê90
Male ............................................................................... Z3,120 ....................................................................................... 2ê,1Z0
Female ........................................................................... Z0,010 ....................................................................................... 25,220
Selected Facts about Cancer in the United States
Medicines in Development Cancer 2012
134
Selected Facts about Cancer in the United States
Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
Esophageal Cancer ....................................................................... 1Z,1ê0 ....................................................................................... 15,0Z0
Male ............................................................................... 13,950 ....................................................................................... 12,010
Female ............................................................................. 3,510 ......................................................................................... 3,030
Kidney Cancer (and renal pelvis) .................................................. ê1,ZZ0 ....................................................................................... 13,5Z0
Male ............................................................................... 10,250 ......................................................................................... 8,ê50
Female ........................................................................... 21,520 ......................................................................................... 1,920
Leukemia (all types) ...................................................................... 1Z,150 ....................................................................................... 23,510
Male ............................................................................... 26,830 ....................................................................................... 13,500
Female ........................................................................... 20,320 ....................................................................................... 10,010
Liver Cancer .................................................................................. 28,720 ....................................................................................... 20,550
Male ............................................................................... 21,370 ....................................................................................... 13,980
Female ............................................................................. Z,350 ......................................................................................... ê,5Z0
Lung Cancer (and bronchus) ....................................................... 226,160 ..................................................................................... 1ê0,310
Male ..............................................................................11ê,1Z0 ....................................................................................... 8Z,Z50
Female ......................................................................... 109,690 ....................................................................................... Z2,590
Lymphoma (all types) .................................................................... 79,190 ....................................................................................... 20,130
Male ............................................................................... 13,120 ....................................................................................... 10,990
Female ........................................................................... 36,070 ......................................................................................... 9,110
Lymphoma (non-Hodgkin’s) ........................................................... 70,130 ....................................................................................... 18,910
Male ............................................................................... 38,160 ....................................................................................... 10,320
Female ........................................................................... 31,970 ......................................................................................... 8,620
Melanoma-Skin Cancer ................................................................. Zê,250 ......................................................................................... 9,180
Male ............................................................................... 11,250 ......................................................................................... 6,060
Female ........................................................................... 32,000 ......................................................................................... 3,120
Multiple Myeloma ........................................................................... 21,700 ....................................................................................... 10,710
Male ............................................................................... 12,190 ......................................................................................... 6,020
Female ............................................................................. 9,510 ......................................................................................... 1,ê90
Ovarian Cancer ............................................................................. 22,280 ....................................................................................... 15,500
Male ....................................................................................... — ...............................................................................................—
Female ........................................................................... 22,280 ....................................................................................... 15,500
Pancreatic Cancer ......................................................................... 13,920 ....................................................................................... 37,390
Male ............................................................................... 22,090 ....................................................................................... 18,850
Female ........................................................................... 21,830 ....................................................................................... 18,510
New Cancer Cases/Deaths
1
continued
Medicines in Development Cancer 2012
135
Selected Facts about Cancer in the United States
New Cancer Cases/Deaths
1
continued
Sources:
1. 0anoer Faors & F|gures 2012, American Cancer Society (www.cancer.org)
2. Remedy Health Media, LLC (www.healthcommunities.com)
3. American Pain Foundation (www.painfoundation.org)

Cancer Type Estimated 2012 New Cases Estimated 2012 Deaths
Prostate Cancer ........................................................................... 211,Z10 ....................................................................................... 28,170
Male ............................................................................. 211,Z10 ....................................................................................... 28,170
Female ................................................................................... — ...............................................................................................—
Stomach Cancer ............................................................................ 21,320 ....................................................................................... 10,510
Male ............................................................................... 13,020 ......................................................................................... 6,190
Female ............................................................................. 8,300 ......................................................................................... 1,350
The U.S. system of new drug approvals is
perhaps the most rigorous in the world.
ll la|es 10-15 years, or averaçe, lor ar
experimental drug to travel from lab to U.S.
patients, according to the Tufts Center for the
3ludy ol 0ruç 0eve|oprerl. 0r|y lve |r 5,000
compounds that enter preclinical testing make
|l lo |urar lesl|rç. Ard or|y ore ol l|ose lve
is approved for sale.
0r averaçe, |l cosls a corpary S1.2 o||||or,
including the cost of failures, to get one new
medicine from the laboratory to U.S. patients,
according to a 2007 study by the Tufts Center
for the Study of Drug Development.
0rce a reW corpourd |as oeer |derl|led |r
the laboratory, medicines are usually devel-
oped as lo||oWs:
Preclinical Testing. A pharmaceutical com-
pany conducts laboratory and animal studies
to show biological activity of the compound
against the targeted disease, and the com-
pound is evaluated for safety.
Investigational New Drug Application (IND).
After completing preclinical testing, a company
l|es ar lN0 W|l| l|e u.3. Food ard 0ruç
Administration (FDA) to begin to test the drug
|r peop|e. T|e lN0 s|oWs resu|ls ol prev|ous
exper|rerls, |oW, W|ere ard oy W|or l|e
reW slud|es W||| oe corducled, l|e c|er|ca|
slruclure ol l|e corpourd, |oW |l |s l|ouç|l
lo Wor| |r l|e oody, ary lox|c ellecls lourd |r
l|e ar|ra| slud|es, ard |oW l|e corpourd
is manufactured. All clinical trials must be
rev|eWed ard approved oy l|e lrsl|lul|ora|
Rev|eW 8oard (lR8) W|ere l|e lr|a|s W||| oe
conducted. Progress reports on clinical trials
must be submitted at least annually to FDA and
l|e lR8.
Clinical Trials, Phase I. These tests usually
involve about 20 to 100 healthy volunteers. The
lesls sludy a druç's salely prol|e, |rc|ud|rç l|e
safe dosage range. The studies also determine
how a drug is absorbed, distributed, metabo-
lized, and excreted as well as the duration of
its action.
Clinical Trials, Phase II. lr l||s p|ase,
corlro||ed lr|a|s ol approx|rale|y 100 lo 500
volunteer patients (people with the disease)
assess a drug’s effectiveness and determine
l|e ear|y s|de ellecl prol|e.
Clinical Trials, Phase III. This phase usually
|rvo|ves 1,000 lo 5,000 pal|erls |r c||r|cs ard
hospitals. Physicians monitor patients closely to
corlrr ellcacy ard |derl|ly adverse everls.
New Drug Application (NDA)/Biologic
License Application (BLA). Following the
completion of all three phases of clinical trials,
a corpary ara|yzes a|| ol l|e dala ard l|es ar
NDA or BLA with FDA if the data successfully
demonstrate both safety and effectiveness.
T|e app||cal|ors corla|r a|| ol l|e sc|erl|lc
information that the company has gathered.
Applications typically run 100,000 pages or
more.
Approval. Once FDA approves an NDA or
BLA, the new medicine becomes available
for physicians to prescribe. A company must
continue to submit periodic reports to FDA,
including any cases of adverse reactions and
appropriate quality-control records. For some
medicines, FDA requires additional trials
(P|ase lv) lo eva|uale |orç-lerr ellecls.
Discovering and developing safe and effective
reW red|c|res |s a |orç, d|llcu|l, ard expers|ve
process. PhRMA member companies invested
ar esl|raled S19.5 o||||or |r researc| ard
development in 2011.
The Drug Discovery, Development and Approval Process
Developing a new medicine takes an average of 10-15 years;
For every 5,000-10,000 compounds in the pipeline, only 1 is approved.
The Drug Development and Approval Process

Sign up to vote on this title
UsefulNot useful